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Summary 
National reports on the drug situation in Austria are drawn up annually for the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the Federal Ministry re-
sponsible for health affairs. They deal with the subject of illicit drugs. This report gives an 
overview of current developments regarding the political and legal framework, the epidemiol-
ogical situation and demand reduction interventions in the reporting period 2008/9. Every 
year specific issues are also highlighted; for this report, the themes of market and production 
of cannabis as well as treatment for older drug users have been selected. 
Summary and discussion of the most important trends 
In 2008 the Narcotic Substances Act (SMG) was amended in order to harmonise with EU 
legislation the Austrian provisions on use and handling of narcotic substances and precur-
sors. Under the amended act it has been admissible to grow cannabis for the purpose of ob-
taining active substances for the production of pharmaceuticals. In addition, the legal basis 
has been provided for using e-government functions to maintain the central narcotic sub-
stances database, for establishing nationwide substitution monitoring and for regulating the 
exchange of information in the context of coordinated, comprehensive treatment and coun-
selling routines for substitution patients. Several decrees were issued to control the sub-
stances of BZP, oripavine, Spice as well as smoking blends similar to Spice.  
In the Government Policy Statement of the new Federal Government, the theme of addiction 
is only mentioned with regard to the further development of the national strategy to prevent 
addiction and suicide, with special regard to risks for children and young people, and with re-
gard to strategies for healthy schools. According to the current political focuses, legal sub-
stances as well as forms of addiction that are not related to substances have played an in-
creasingly important role in prevention activities as well as in the services of drug help units. 
This is reflected in the fact that, in addition to the Federal Drug Forum, also an Alcohol Fo-
rum was established, which has already started to prepare a national alcohol prevention 
strategy. 
The main themes of drug policy discussions included measures to prevent drug-related 
deaths and, as also in previous years, opioid substitution treatment and the effects of the 
new decrees of 2007. Reports from the provinces, among other themes, document the struc-
tural changes that were necessary as a consequence of the new legal situation. In the report-
ing period, recommendations were drawn up that are to be integrated in amendments to the 
Narcotic Drugs Decree and the Oral Substitution Further Training Decree. 
A number of recent data assessing the current drug situation are available. Approximately 
one out of five people used cannabis at some point in life, with the highest shares (up to 
40%) found among young adults. The rates concerning other substances are considerably 
lower in the general population, i.e. between 2% (heroin) and 4% (ecstasy, amphetamines, 
cocaine) at most. Moreover, the rates covering current drug use (12-month prevalence) are 
even smaller, which shows that use of illicit substances is typically limited to experimental 
use and to a certain period in life. The prevalence rates obtained in new surveys are much 
smaller than in past years. Part of the results sowing strong declines with regard to lifetime 
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prevalence rates are in fact impossible, and methodologies should thus be discussed in more 
detail. In 2008, smoking of Spice was a relevant issue in the media coverage of psychoactive 
substance use, but it is unknown whether Spice, obtained in black markets or through the 
internet, is still used. According to reports on the party scene, pills sold as ecstasy increas-
ingly often contain (also) ingredients such as mCPP or PMA, which is a considerable health 
risk. Only 15% of drugs sold as speed actually contained only amphetamines. In addition, in-
stances of high-risk use of GBL, which converts into GHB in the body, were reported. 
The most recent prevalence estimates on problem drug use (in Austria, this primarily con-
cerns poly-drug use with opioids) relate to the year 2007 and indicate between 22 000 and 
33 000 problem drug users. 
The client year 2008 is the third year for which data from DOKLI, the nationwide documenta-
tion system of clients of Austrian drug help units, are available. In the treatment sector, 
opioids continue to predominate as primary drugs among problem drug users, while cocaine 
plays a marginal role only. Different to a number of other EU members, in Austria opioids are 
the substances most frequently involved in drug use relevant for treatment. People with can-
nabis as their primary drug are the second-largest group in the treatment system. It would be 
a point worth discussing whether this high share actually is the result of health problems or 
psychosocial problems caused by cannabis use or whether it rather reflects repressive poli-
cies regarding cannabis. Another question is whether the needs of this group of clients can 
always adequately be met in the existing drug help units. More detailed studies based on 
these results found in the context of the routine monitoring of DOKLI would be needed in or-
der to obtain further insight. 
The data quality of statistics on drug-related deaths has deteriorated because autopsies now 
tend to be performed less often in cases of suspected drug overdoses. This significantly re-
duces the epidemiological conclusiveness of the corresponding data. In order to maintain a 
high quality of this epidemiological key indicator, activities at several levels are imperative. 
Regarding prevalence rates of infectious diseases, again no data basis is available that 
would permit reliable statements on extents or trends. Great attention has been paid to psy-
chiatric comorbidity; the shares of drug users who also suffer from mental or behavioural dis-
orders continue to be high. 
Recent trends in the fields of prevention and drug help services show increasing regionalisa-
tion, e.g., in the form of control bodies at district level and local intervention plans. These 
plans are often drawn up in the context of community prevention but in part they also relate 
to services by drug help units. Technical standards are taken into account in all areas: for in-
stance, both prevention programmes to be implemented at nationwide level as well as guide-
lines for the treatment of benzodiazepine addiction are being prepared. The target groups of 
drug users with a background of immigration and their families have begun to play a more 
prominent role in the drug help sector, and existing services are being adapted in order to 
address this group. In the treatment sector, regional capacities still are insufficient, mainly 
due to rather high shares of clients undergoing compulsory health-related measures because 
of use of cannabis and also the fact that opioid substitution treatment has increasingly often 
been carried out at drug outpatient departments or drug counselling centres. Attempts to im-
prove the treatment of infectious diseases among drug users focus on the cooperation be-
tween the drug help sector and the corresponding medical care institutions. Activities to facili-
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tate coexistence without conflicts in public places – and thus to prevent drug-related crime – 
are being expanded, as are activities aimed at reintegration by means of occupation pro-
grammes. 
2008 saw a decline in police reports, in particular reports relating to cannabis, which the 
Federal Ministry of the Interior explains with investigations of drug dealing structures in order 
to smash drug gangs. This does not mean that drug use has gone down, however. 
Selected Issue: Market and Production of Cannabis 
According to the Federal Criminal Agency at the Federal Ministry of the Interior the produc-
tion of cannabis in Austria is insignificant compared to other countries. Cannabis products 
are primarily imported to Austria from the Netherlands, the Balkan countries, the Schengen 
Area, Morocco and Switzerland. Austria is of growing relevance as a country of transit for 
cannabis products from the Far East (India, Nepal) to Western Europe. According to 
BMI/.BK, cannabis products are sold all over Austria, but especially in and around cities in 
both public places or streets and bars known as places of drug dealing. The majority of sei-
zures concern herbal cannabis, although pronounced variations show in individual years with 
regard to both number of seizures and quantities seized. In 2008 92% of reports relating to 
cannabis were made because of violations of Section 27 of the SMG, which regulates illegal 
handling of drugs, 3% of cannabis reports concerned Section 28 of the SMG (preparation of 
narcotic drug trafficking), and 5% related to Section 28a (narcotic drug trafficking). 
Selected Issue: Treatment and Care for Older Drug Users 
There are some indications that the number of drug users aged 40 or older is rising. Analy-
ses of the DOKLI data of the client year 2008 have shown differences in patterns of use in 
different age groups. Regarding drug-related health problems, the situation of older clients 
has to be considered as substantially worse than that of younger clients. It should be taken 
into account that older drug users are underrepresented in the services that communicate 
data to DOKLI. As yet, the causes of this fact are a matter of speculation. There are no spe-
cific programmes for the target group of older drug users in the Austrian drug help system. 
The EU project SDD-Care is of key significance regarding the development of strategies for 
future assistance to, and care for, older drug users. 
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Introduction 
This is the 14th time that the REITOX Focal Point at GÖG/ÖBIG (Austrian Health Institute) 
presents its annual Report to the EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) and the Austrian Federal Ministry responsible for health affairs. The REITOX Fo-
cal Point is a central link in Austria’s data and information network of drug-related matters 
and closely cooperates with the relevant federal and provincial agencies in this field as well 
as addiction and drug help centres. 
This report deals with illicit drugs and serves both as a national report on the situation in Aus-
tria and as Austria’s contribution to describing the drug situation in the European Union (EU). 
Similar reports are submitted by the REITOX Focal Points in all EU member states and by 
the EU candidates, according to guidelines issued by the EMCDDA. These reports are es-
sential as a basis of the EMCDDA’s Annual report on the state of the drug problem in the 
European Union (latest publication: EMCDDA 2008).  
Part A of this report deals with new developments and trends with regard to the drug policy 
framework, the epidemiological situation and health-policy interventions aiming at demand 
reduction. It is based on previous reports (latest report: GÖG/ÖBIG 2008c) and refers to the 
reporting period from summer 2008 to summer 2009, while routine statistics refer to the year 
2007. In Part B of the report two selected issues are presented in more detail. In the present 
report the corresponding chapters deal with cannabis markets and production as well as 
treatment for older drug users. The Annex includes a number of additional tables with de-
tailed information and data. 
Every year the REITOX Focal Points also submit to the EMCDDA annual standard tables 
and structured questionnaires. These data and information have also been integrated in this 
report, with references to these sources given in the text. For an overview of all standard ta-
bles (= ST) and structured questionnaires (= SQ) please consult Annex C. 
This report is based on many different data and information communicated to GÖG/ÖBIG by 
various experts in the field of drugs. In this respect, the reports on the drug situation in the 
individual Austrian provinces drawn up by the Drug Coordination and Addiction Coordination 
Offices have been especially significant. In addition, a number of experts provided back-
ground information and specific data for individual chapters of this report (see Selected Is-
sues). We would like to express our gratitude for their cooperation. 
We are especially indebted to the members of the advisory working group of the REITOX 
Focal Point Austria, Mr Michael Dressel (Drug Coordinator of the City of Vienna and Provin-
cial Representative), Ms Irmgard Eisenbach-Stangl (member of the Scientific Committee of 
the EMCDDA), Mr Thomas Neubacher (Drug Coordinator of Vorarlberg and Provincial Rep-
resentative), Mr Franz Pietsch (Federal Drug Coordinator and head of the Federal Drug Co-
ordination, BMG), Mr Robert Scharinger (BMG) and Ms Johanna Schopper (head of the De-
partment of Drugs and Narcotic Substances at the BMG) for their helpful comments and in-
valuable input. 
  
  
 
Part A 
New Developments  
and Trends  
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1 Drug Policy: Legislation, Strategies and 
Economic Analysis 
The Narcotic Substances Act (SMG), which has been in force since 1998 and constitutes the 
main framework of Austria’s drug policy, was amended in December 2008. The SMG primar-
ily focuses on quantities and not on kinds of substance – with the exception of a special pro-
vision concerning cannabis and mushrooms containing psilocin, psilotin or psilocybin – and 
provides a wide range of alternatives to punishment. At the federal level the central actors in 
the field of drug policy include the Federal Drug Coordination and the Federal Drug Forum, 
which has the task to coordinate policies with the provinces (see Figure 1.1). Due to the fed-
eral structure of Austria’s health and social care system, the provinces play important roles 
with regard to the adoption and implementation of drug policy measures. All nine provinces 
have drawn up drug strategies or addiction plans and nominated Drug or Addiction Coordina-
tors.  
Drug policy measures are financed primarily by the Provincial Governments, the social insur-
ance funds and the Federal Government. The COFOG classification1, which is promoted by 
the EU, has not fully been implemented in Austria, and in the individual budgets expenditure 
related to drugs or addiction is hardly specified (see GÖG/ÖBIG 2007b). Therefore, no defi-
nite statements regarding expenditure in this field can be given for Austria. 
1.1 Legal framework  
In the reporting period, as announced last year (GÖG/ÖBIG 2008c), the Narcotic Substances 
Act (SMG) was amended. The primary aim of the amendment was to harmonise with EU leg-
islation the Austrian provisions on use and handling of narcotic substances and precursors, 
to permit growing cannabis for the purpose of obtaining active substances for the production 
of pharmaceuticals, to provide a legal basis for using e-government functions for maintaining 
the central narcotic substances database and to adopt provisions regulating nationwide 
opioid substitution monitoring and exchange of information in the context of coordinated, 
comprehensive treatment and counselling routines for substitution patients. The 2008 
amendment to the SMG (BGBl I 2008/143 v. 19.12.2008) includes the following provisions: 
• Section 6a of the SMG permits the growing of cannabis plants by the Austrian Agency for 
Health and Food Safety (AGES) in order to obtain a narcotic substance for the production 
of pharmaceuticals as well as for scientific purposes related to this field. The substances 
produced may only be made available to enterprises that are authorised to produce phar-
maceutical products and act as wholesalers to distribute them. 
                                                
1 COFOG, or Classification of Functions of Government (public expenditure broken down by areas of activity) comprises ten di-
visions, which are further divided into groups and classes. In Austria, only expenditure according to the 10 COFOG divisions, 
without groups and classes, is available. 
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• Under Section 8a of the SMG, physicians are obliged to report without delay to the district 
authorities, in their functions as health authorities, the beginning and end of opioid substi-
tution treatment. In the case of individual prescriptions of substitution substances, also the 
substance in question has to be specified. Any observations made in connection with the 
treatment, care or counselling of substitution patients may only be communicated to oth-
ers if the patient in question has expressly given their permission or if this is absolutely 
necessary in order to protect the patient’s health. If the patient’s prior permission cannot 
be obtained, the reasons for this have to be documented. 
• Section 24 of the SMG provides that the Ministry of Health maintain a narcotic substances 
registry to document violations of the SMG, and a substitution registry in order to prevent 
multiple treatment with substitution substances. In addition, all deaths that are causally 
linked to drug use have to be documented and analysed. This Section also includes de-
tailed regulations regarding who has to provide which kind of information. The facts that 
have to be reported and entered in the narcotic substances registry (Section 24a of the 
SMG) include the corresponding offence and its legal basis, substances or precursors 
seized as well as information on temporary discontinuation of penal action, dismissal of 
proceedings or convictions. In addition, also persons whose examination according to 
Section 12 of the SMG showed misuse of narcotic substances have to be registered. Data 
that are relevant for the substitution registry (Section 24b of the SMG) include the data 
specified in Section 8a as well as data on physicians providing treatment and the referring 
authority, the substitution substance of the first long-term prescription including dosage 
and any change of substance. Regarding drug-related deaths (Section 24c of the SMG) 
the day and place of death as well as when and where the deceased was found have to 
be reported, also the findings of the post-mortem examination, indications of drug over-
dose or other substances used, other evidence concerning the cause of death as well as 
the type and quantity of narcotic or other substances found. All data communicated may 
be used for statistical and scientific purposes but not for analyses related to individual 
persons. 
• Section 25 of the SMG deals with the organisation and maintenance of the narcotic sub-
stances registry and the substitution registry in the form of electronic registries of the Min-
istry of Health, as well as administration and use of the data of these registries. According 
to these provisions data, when used for statistical or scientific purposes, have to be trans-
ferred to a statistics registry and any direct or indirect link to individual persons has to be 
deleted. Online access to the data is only possible if certain conditions are met, and prior 
authorisation by decree by the Ministries of Health and Justice is required. It is also speci-
fied in which cases data of the narcotic substances registry have to be deleted immedi-
ately (e.g., after dismissal of proceedings), after one year (in cases of examination under 
Section 12 of the SMG) or after five years, at the latest. Data entered in the substitution 
registry have to be deleted immediately in case of death, or no later than six months after 
the end of treatment. 
In correspondence with the amendment to the SMG of 2008, also the Narcotic Drugs Decree 
and the Psychotropic Substances Decree had to be amended as they are related to the SMG 
(BGBl II 2008/480 v. 19. 12. 2008 and BGBl II 2008/481 v. 19. 12. 2008, respectively). 
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An amendment to the Oral Substitution Further Training Decree (BGBl II 2009/5 v. 
2. 1. 2009) extends the transition period before these provisions will enter into force (see 
GÖG/ÖBIG 2006). Physicians who are on the list of doctors entitled to carry out opioid sub-
stitution treatment on grounds of professional practice have to be deleted from the list unless 
they furnish the required proof of qualification by 31 December 2009. 
Changes in the legal framework during the reporting period also concern the control of new 
substances. After the psychoactive effect of the active substance of Spice became known, a 
Decree was adopted that prohibits putting into circulation, importing and delivering herbal 
smoking blends that contain JWH-018 (BGBl II 2009/6 v. 7. 1. 2009). Subsequently, also 
other psychoactive substances were detected in Spice and products similar to Spice, there-
fore it was necessary to expand the prohibition to include other substances with cannabi-
nomimetic effects2 as well (BGBl II 58/2009 v. 3.3.2009). Further legal steps are being con-
sidered. 
The amendments to the Narcotic Drugs Decree (BGBl II 2009/173 v. 15. 06. 2009) and the 
Narcotic Substances Limit Quantities Decree (BGBl II 2009/174 v. 16. 06. 2009) aim at in-
cluding also oripavine and BZP in the control structure of the SMG and consequently imple-
menting the corresponding decisions adopted at international level. As measuring methods 
have become more sensitive and also very small residual quantities of alkaloids may be de-
tected in decocainated extracts of coca leaves used as flavourings, the amendment to the 
Narcotic Drugs Decree also defines more precise maximum admissible residual amounts (a 
total of 1.25 ppm or 1.25 mg/l or mg/kg). 
As a consequence of the changes in the legal framework regarding opioid substitution treat-
ment (OST), which entered into force in March 2007 (see GÖG/ÖBIG 2007b), in spring 2008 
activities were started to give an overview, and to assess the effects, of this development 
(see Chapter 5.3). The resulting recommendations serve as a basis for modifications of the 
corresponding legal provisions. This matter has been under assessment since August 2009. 
1.2 National action plan, strategy, evaluation and 
coordination 
The main political and administrative framework has not changed in the reporting period (see 
SQ32). Autumn 2008 saw federal elections, and on 2 December 2008 the new Government 
was inaugurated. In the Government Policy Statement 2008–13 (Bundeskanzleramt 2008) 
the theme of addiction is only mentioned in the chapter on health. Under the heading of 
health promotion and prevention, a plan is outlined that aims at an advancement of the na-
tional strategy to prevent addiction and suicide, with special regard to risks for children and 
young people. This is an expansion of the national addiction and alcohol strategy planned so 
far, preparations for which were started in the reporting period in the context of the Alcohol 
Forum. The strategy for healthy schools will be further developed in line with the focus on 
                                                
2 Synthetic substances that imitate the effects of cannabis 
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children’s and young people’s health. This also includes the issues of psychological health 
and addiction. 
The Federal Drug Forum (see Figure 1.1) held two regular meetings in the reporting period 
(November 2008, April 2009). Among other themes, their agenda included legal questions 
relevant for the field of drugs (see Chapter 1.1), possible minimum standards for autopsy re-
ports as well as harm reduction measures, procedures regarding the national addiction and 
suicide prevention strategy as well as establishing cofinancing structures between federal 
and provincial authorities (see GÖG/ÖBIG 2008c). The working groups convoked by the 
Federal Drug Forum to draw up guidelines for a nationwide uniform implementation of Sec-
tion 12 of the SMG (see GÖG/ÖBIG 2008c) and to evaluate the legal framework of opioid 
substitution treatment (see Chapter 5) continued their activities in the reporting period. The 
new working group on annual reporting on activities regarding the Addiction Help Compass 
modified the Addiction Help Compass to meet the requirements connected with reporting. In 
addition, a new steering group was established, which deals with ways to reduce drug-
related deaths (see Chapter 7.1). 
In the provinces, the legal framework did not change in the reporting period, but new devel-
opments are to be expected. For instance, Upper Austria, based on the addiction strategy in 
force, is drawing up an addiction plan aimed at pointing out existing services and giving 
guidelines for medium-term developments in the field of addiction. In Styria a drug strategy 
was prepared, which will be adopted by the Provincial Government in autumn 2009. In the 
Tyrol, an analysis of social environments is carried out which, combined with past evalua-
tions of the current drug strategy, will form the basis for drawing up a new drug strategy, 
which will also take into account regional developments and special regional characteristics 
that have been identified as of summer 2009 in the context of information events at district 
level (Kern, personal communication). In Carinthia, a body of experts of the Addiction Advi-
sory Board of Carinthia prepared a list of demands that include an expansion of the provin-
cial Addiction Prevention Unit and youth welfare agencies, the establishment of a coordina-
tion office focusing on children of addicted parents, an expansion of professional addiction-
oriented services by increasing the staff of the Drug Coordination Office, the creation of spe-
cific occupational rehabilitation services and a drug department for inpatient acute treatment 
primarily of opioid addicts, as well as better involvement of the Addiction Advisory Board in 
discussions on addiction policy matters. 
In Lower Austria, drug advisory boards at local level have been established since 2008 (see 
GÖG/ÖBIG 2008c) to promote discussions of the theme of addiction. In the town of Mödling, 
as a result of these activities, a local action plan on addiction was drawn up (Hörhan, per-
sonal communication). A similar approach is pursued in the district of Vöcklabruck (Upper 
Austria), where a plan of measures to be taken was prepared (see Chapter 3.1). Although its 
main focus is placed on steps to prevent addiction, the theme of opioid substitution treatment 
is also included. 
  
Figure 1.1: Overview of the organisational structure of the drug sector in Austria 
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In order to expand universal and selective prevention in the province of Burgenland, a strat-
egy paper was drawn up (Hausleitner 2008). It lists the necessity to expand structures, co-
operation and networks as well as to increase resources, as prevalence rates of risky pat-
terns of behaviour such as drug use have risen. Therefore, it has been recommended to es-
tablish a special prevention institute that is in charge of all prevention measures, from plan-
ning and defining interventions to coordinating them with cooperation partners. The corre-
sponding measures will be carried out by several service providers. The strategy will be im-
plemented over the next few years. 
1.3 Economic analysis 
The financial regulations in the field of drugs did not see changes in the reporting period. For 
an overview of the present situation please consult SQ32. A point worth mentioning might be 
that after the change in substitution treatment regulations a number of provinces entered into 
negotiations, or concluded agreements, with the social insurance funds (see GÖG/ÖBIG 
2008c) in order to obtain remuneration for physicians providing opioid substitution treatment. 
The problem of remuneration in cases of patients referred to compulsory treatment has been 
a matter debated for several years already and has been an important issue also in the re-
porting period (see Chapter 1.2). However, solutions to this problem are not likely to be found 
in the near future. 
Regarding budgets, no detailed information is available, therefore no overview can be given. 
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2 Drug Use in the General Population and Specific 
Targeted Groups 
In 2004 and 2008 two representative studies focusing on alcohol, tobacco and drugs, fi-
nanced by the Ministry of Health, were carried out. These studies are the most important 
data sources available regarding drug use in the population. The drug parts of the question-
naires correspond to the guidelines of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). The data on school populations have been obtained from the ESPAD 
surveys (conducted as of 2003). In Vienna, the time series of surveys concerning drug use 
go back to the year 1993. In addition, regional surveys and studies have repeatedly been 
carried out for specific settings. Regarding drug use in youth scenes, data from counselling 
talks of the secondary prevention projects MDA basecamp and ChEck iT! are available. 
As to prevalence of drug use, a distinction is made between lifetime prevalence (drug use at 
some point in life), 12-months prevalence (drug use in the past year) and 30-day prevalence 
(drug use in the past month). Statements on current or frequent use of drugs can only be de-
rived from 12-month or 30-day prevalence rates. 
In Austria, experience of illicit drug use primarily concerns cannabis, with prevalence rates of 
approximately 30% to 40% among young adults. According to the majority of representative 
studies, experience of ecstasy, cocaine and amphetamines is found among approximately 
2% to 4% of the population, and experience of opioids is between around 1% and a maxi-
mum of 2%. In recent years, the range of substances taken in the context of experimental 
use has widened. In certain scenes and groups of young people, high prevalence rates for a 
variety of substances are found, including biogenic drugs as well as solvents and inhalants. 
2.1 Drug use in the general population 
2008 was the second time that a representative survey3 on prevalence and patterns of use of 
legal and illicit narcotic substances was carried out on behalf of the Federal Ministry of 
                                                
3 The questionnaire was prepared by the Ludwig Boltzmann Institute of Addiction Research and GÖG/ÖBIG, and the survey 
was conducted by the market research institute market by means of face-to-face interviews. After a briefing of the interviewers, 
the persons to be interviewed were selected by means of random sampling. The corresponding addresses were communi-
cated to the 593 interviewers involved in this project, who contacted the respondents and interviewed them. Different to the 
previous survey, in this research project two subsamples of the same size were distinguished: persons aged 15 to 24 and per-
sons over 24 years. In the target group of people aged 25 or older, according to the last-birthday method, the person in the 
household chosen for the interview was the one aged 25 or older with the most recent birthday. When choosing addresses for 
the sample subgroup aged 15 to 24, the first step was to verify if a person of this age group lived in the household. As a sec-
ond step (in households with more than one person of this age group) the method described above was used to schedule a 
meeting. Each address was contacted at least three times (exceptions: no person in the required age group in the household; 
interview already concluded or refusal to be interviewed). The participation rate was 34.4%, which is significantly higher than in 
2004. The field stage took place between 27 October and 1 December 2008. For 46% of interviews, phone checks were 
made. 73 questionnaires had to be eliminated, and 4 196 questionnaires could be analysed. Analysing and reporting will be 
carried out by the Ludwig Boltzmann Institute for Addiction Research at the end of 2009.  
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Health (BMG). The final report on this study and detailed analyses will not be available be-
fore the end of 2009 (Uhl et al. 2009, under preparation), but preliminary results can already 
be given (see Table A1 in Annex A resp. ST1). In the context of the survey on use, a total of 
4 196 people over 14 were interviewed with regard to their experience of use of legal as well 
as illicit psychoactive substances. 50% of respondents were in the age group from 15 to 24 
(oversampling of young people / young adults). In the analyses regarding overall population, 
this oversampling was balanced by means of weighting. 
In sum, the prevalence rates found in the 2008 survey were lower for almost all drugs com-
pared to the survey of 2004 (see Figure 2.1). Regarding cannabis, lifetime prevalence went 
down to nearly half the percentage of 2004. Such a decline in lifetime prevalence rates within 
a period of only four years is impossible. Other factors, e.g., stronger tendencies to deny use 
of illicit drugs or possibly methodological problems, must have been essential reasons for the 
low rates indicated. These results should be discussed in detail by the Austrian group of ex-
perts on population surveys of drug use. 
Figure 2.1: Lifetime and 12-month prevalence rates of illicit drug use among the general population, 
2004 and 2008 (percentages) 
 
Source: Uhl et al. 2005a and 2009, under preparation; representation by GÖG/ÖBIG 
The share of respondents indicating experience of alcohol (95%) or tobacco (67%) is mark-
edly higher than people admitting illicit drug use. 
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under one percent regarding all other substances (see Figure 2.1). This confirms the as-
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Recent data are again available from the Vienna drug survey4, which permits an analysis of 
long-term trends since 1993 (IFES 2009; see also Table A1 in Annex A and ST1). 
Compared to previous surveys, indications of drug use went down or remained at levels simi-
lar to the past, with the exception of opioids (see Figure 2.2). Regarding cannabis, after a 
continuous rise, rates of use went down again. Although the decline is considerably smaller 
here, this result shows an interesting parallel to the development of prevalence rates in the 
aforementioned nationwide population surveys, and should be discussed. 
In the age groups under 30 and between 30 and 40, a share of 20% reported experience of 
cannabis, compared to 22% in the group aged 40 to 50 and 25% in the group between 50 
and 60. In the group older than 60, only 3% indicated experience of cannabis. As a rule, life-
time prevalence rates are higher among men than among women (e.g., cannabis: 22% v. 
11%). To obtain a more comprehensive picture, also use in the past three years and in the 
past 30 days was studied: here the resulting prevalence rates are considerably lower com-
pared to lifetime use (e.g., cannabis: 5% v. 3%). 
Figure 2.2: Lifetime experience of illicit drugs among the population of Vienna from 1993 to 2009 
(percentages) 
 
 
 
Source: IFES 2009; representation by GÖG/ÖBIG 
                                                
4 The Vienna drug survey (IFES 2009) was conducted in February 2009 among a representative random sample of 600 people 
aged 15 or older, in the form of oral interviews. Such surveys of experience of use have been carried out with similar method-
ologies every two years since 1993, on behalf of the Vienna Addiction and Drug Coordination. 
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Smoking of Spice (see Chapter 10.3) was a relevant issue in the media coverage of psy-
choactive substance use for some time in 2008. Spice has meanwhile been prohibited (see 
Chapter 1), and it is unknown whether Spice, obtained in black markets or through the inter-
net, is still used. 
2.2 Drug use in the school and youth population 
In 2007 a school survey was carried out in Austria for the second time in the context of the 
ESPAD project5 (see ST2). A comprehensive analysis is not yet available and will be com-
pleted late in 2009. A few results on experience of use have already been communicated in 
the report of last year (GÖG/ÖBIG 2008c).  
2.3 Drug use among targeted groups 
In 2008 MDA basecamp, a secondary prevention project run in the Tyrol (see Chapters 3.2 
and 7.3), continued its survey6 on combined drug use in party settings, the primary area of 
activity of MDA basecamp (MDA basecamp 2008 and 2009). The lifetime prevalence rates 
found (cannabis: 94%; ecstasy: 72%; speed: 69%; cocaine: 66%; magic mushrooms: 64%; 
LSD: 45%) are very high in particular regarding the typical party drugs of speed, ecstasy and 
cocaine. The prevalence rates are higher among men than among women. 30% of respon-
dents said that they always took illicit substances at parties, and another 27% indicated fre-
quent drug use. 88% stated that a few or almost all of their friends used illicit substances at 
parties, and 71% said that they had already used two or more illicit substances, or alcohol 
and party drugs, simultaneously or within a short time. The most frequent combination is al-
cohol and cannabis, and if only illicit substances are considered, the combination of speed 
and ecstasy is named most often (among men, cannabis combined with ecstasy is found al-
most as frequently). This study shows that combined drug use is of great relevance among 
the audience of electronic music events, and highly significant correlations also show be-
tween a person’s own drug use and drug use among their friends, as well as illicit drug use at 
parties and combined drug use. 
The drugs mentioned in the context of the event services7 offered by ChEck iT! (see Chapter 
10.3) show that cannabis predominates in party settings, followed by ecstasy, speed and co-
caine. Cannabis was discussed in 47% of the talks, with ecstasy (36%) ranking second, and 
cocaine was an issue in 19% of the talks (VWS 2009a). 
                                                
5 In 2007 Austria (Strizek et al. 2009, under preparation) took part in the ESPAD study (European School Survey Project on Al-
cohol and other Drugs) the second time after 2003 (see Uhl et al. 2005b). In the 2007 survey a total of 277 classes with 5 959 
school students in the 9th and 10th grades were asked to complete questionnaires on experience of use. The results pre-
sented relate to  4 574 respondents of the age group between 15 and 16 years. The Austrian ESPAD study was funded by the 
Federal Ministry of Health, Family and Youth. 
6 In the context of this survey carried out as of 2007 with hardcopy and online questionnaires, a total of 565 people aged be-
tween 14 and 45 (24% of them women) were interviewed at parties or when visiting scene websites (MDA basecamp 2009). 
7 In 2008, the event services offered by ChEck iT! covered a total of 12 events, with 214 counselling talks. 
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3 Prevention 
According to the EMCDDA classification of prevention, this chapter has been divided into 
universal prevention, selective prevention and indicated prevention8. However, in practice the 
terms of primary and secondary prevention9 continue to be used to some extent as this clas-
sification is regarded to be less stigmatising. In Austria, the corresponding measures are 
primarily implemented at local and regional levels, in accordance with expert consensus. In 
this context, the provincial Addiction Prevention Units (see Chapter 1.1), the Addiction Pre-
vention Forums of Salzburg and Vienna as well as regional coordination and control bodies 
(Salzburg) play important roles. As a rule, the prevention measures are oriented towards 
long-term effectiveness and sustainability, which is aimed at primarily by means of training 
programmes for multipliers. In line with Austria’s comprehensive approach to addiction, many 
prevention measures are not aimed at specific substances but also encompass forms of ad-
diction that are not related to substances. In recent years, specific interventions concerning 
legal substances (alcohol and nicotine) as well as forms of addiction that are not related to 
substances (e.g., compulsive gambling) have become increasingly important. However, this 
report focuses on unspecific measures or interventions specifically aiming at illicit sub-
stances. 
In addition to a number of standard programmes carried out at nationwide level, in recent 
years also numerous regional activities have routinely been initiated and advanced (see Ta-
bles A23 and A24 in Annex A). Current prevention measures taken are described on the in-
dividual websites and in the annual reports and newsletters of the Addiction Prevention 
Units, the Ministry of Education (BMUKK), the GÖG/FGÖ and other relevant actors, as well 
as in previous reports on the drug situation and in the Best practice portal of the EMCDDA 
(see References). Furthermore, new strategies and approaches have continually been de-
veloped in order to optimise the quality of prevention activities and to take into account to a 
greater extent the specific needs of individual target groups and different settings. 
Other activities worth mentioning of the Addiction Prevention Units include network building 
and public relations work, (financial) support of prevention initiatives and organising further 
training events for experts, e.g., the expert meeting on the state of the art of prevention in 
Austria held by ARGE Suchtvorbeugung (Working Group for Addiction Prevention) in autumn 
2008 at Steinach/Brenner in the Tyrol, or the conference Männersüchte – Frauensüchte 
(Men’s Addictions – Women’s Addictions) on gender-related aspects of drug use, addiction
                                                
8 Universal prevention is aimed at large groups of the population (e.g. school communities, towns) that, independent of the in-
dividual situation, are equally likely to develop patterns of substance use. Selective prevention focuses on smaller groups that, 
due to biological, psychological, social or environmental risk factors – independent of the individual situation – are more likely 
to develop patterns of substance use than the general population (e.g., children of addicted parents). Indicated prevention 
addresses individual persons who already show early signs of substance use or problem patterns of behaviour that are asso-
ciated with drug use but do not yet meet the criteria for a diagnosis of dependence and for whom the risk of developing addic-
tive behaviour is thus particularly high. A requirement for indicated prevention is that medical experts have already diagnosed 
mental, conduct or behavioural disorders that are known to constitute risk factors regarding the development of addictive be-
haviour, e.g. attention deficit hyperactivity disorder (ADHD). 
9 Primary prevention aims at avoiding the development of a disease, in this case, an addiction disease, already before drug use 
or drug problems have arisen. Secondary prevention addresses drug users who definitely have problems, which have not yet 
become manifest to their full extent, however.  
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 and prevention, organised by the Addiction Prevention Institute of Linz, Upper Austria. In the 
reporting period, quality assurance was an important focal theme regarding prevention in 
Austria; it includes both technical standards and standardised interventions and pro-
grammes. For instance, new online feedback forms were prepared in Lower Austria to con-
tribute to quality assurance. The return rate was approx. 50%, and the work and services of 
the Addiction Prevention Unit were assessed very favourably (Fachstelle für Suchtvor-
beugung, Koordination und Beratung 2009). 
3.1 Universal prevention 
For an overview of Austria’s universal prevention activities and the general framework of pre-
vention please consult SQ22/25. Schools play an important role as settings of implementa-
tion. Here, prevention takes place on a statutory basis in the context of the educational prin-
ciple of health promotion10. It is recommended that prevention measures at schools involve 
all stakeholders of the school community as well as regional addiction experts. On this basis, 
training courses on addiction prevention and further training events are organised, (e.g., a 
conference on health promotion advancement in schools held by FGÖ in March 2009), 
teaching materials and projects are prepared and all stakeholders are offered practical assis-
tance in planning and implementing prevention activities. These activities are primarily aimed 
at awareness raising and health promotion approaches in the entire system and increasing 
life skills among students. In the older age groups, often patterns of use are also discussed. 
In the reporting period PLUS, a programme for the age group from 10 to 14 prepared by 
ARGE Suchtvorbeugung (Working Group on Addiction Prevention), with kontakt & co taking 
over coordinating functions (see GÖG/ÖBIG 2007b), was also tested in Salzburg and Styria, 
with promising results. As of autumn 2009 the programme’s pilot stage will include imple-
mentation with scientific monitoring in other provinces as well. PLUS combines fixed and 
variable modules that may be adapted to the specific needs of individual groups. In May 
2009 Akzente Salzburg, under the title of Herzens-Bilder (Images of the heart), organised an 
expert meeting dealing with the nationwide Eigenständig Werden (Become independent) 
education programme so that teachers working in this profession for a long time may get new 
impulses and additional motivation for implementing the programme (Rögl, personal commu-
nication). 
The list of standardised prevention measures and projects for schools available in Salzburg 
is now complete, and a feedback questionnaire has been prepared for a comprehensive 
documentation of prevention activities in schools settings (Drogenkoordination des Landes 
Salzburg 2009). In November 2008 the Vienna Institute of Addiction Prevention (ISP) organ-
ised an expert meeting on models, approaches and perspectives regarding prevention in 
schools: in addition to fundamental knowhow and quality criteria for up-to-date prevention on 
a scientific basis, the existing prevention services for schools in Vienna were made transpar-
ent (Sucht- und Drogenkoordination Wien 2009b). For this purpose also a list of projects of 
                                                
10 Health promotion, in accordance with the Ottawa Charter of the WHO, is understood as the process of enabling people to in-
crease control over, and to improve, their health, i.e. to reach a state of complete physical, mental and social well-being. 
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prevention activities in schools of Vienna was compiled. The tendency to use theatre educa-
tion in prevention contexts has continued: for instance, the reporting period saw a perform-
ance of the musical Helden – Von Sehnsucht und Zuversicht (Heroes: Of longing and confi-
dence) also in Carinthia (see GÖG/ÖBIG 2008c). Forum theatre methods have been applied 
more often; the models developed in this context so far primarily focus on alcohol, e.g., Mit 
Maß und Ziel – Es kotzt mich an (In metes and bounds: I’m fed up). 
In Upper Austria, a programme of long-term expert coaching for internal projects in voca-
tional schools was agreed upon with the Province School Board (Institut Suchtprävention 
2009a). The corresponding activities will include the communication of basic information by 
the Institute of Addiction Prevention as well as adoption of joint procedures and coaching 
services when addiction problems arise, assistance in the implementation of interventions 
and consulting with regard to teaching methods. In addition, a programme that trains voca-
tional school teachers to become addiction coordinators was drawn up. In Styria, as a re-
sponse to great interest on the part of the vocational schools, an advanced course was or-
ganised in cooperation with the University of Education (VIVID 2009). The project It’s my life 
was developed with the aim of promoting the psychological health of young people at voca-
tional schools in Carinthia, and in the school year 2008/9 it was tested at one school (Amt 
der Kärntner Landesregierung 2009). The students may choose one out of four focal themes 
(stress, interpersonal conflicts, self-confidence and patterns of consumption), which are then 
discussed with experts. The project will also integrate enterprises where trainees work and 
the parents of trainees, and at each school health promotion structures will be established 
with the assistance of a health circle and a steering group. 
The prevention activities targeting kindergartens and families were continued. They include 
further training programmes, provision of information materials and information events for 
parents. New interventions in this field are primarily aimed at advancing the implementation 
of prevention activities in families by giving concrete advice and enhancing parenting skills, 
also in connection with drug use. The first five pilot performances of Echt ... nichts für schwa-
che Nerven! (The Real thing ... Not for the faint of heart), a join-in theatre play for parents in 
Lower Austria (see GÖG/ÖBIG 2008c) have shown that the goal of encouraging parents to 
think about the themes presented has been met (Mellish, personal communication). What 
turned out to be particularly helpful was to combine the play with a four-hour workshop. New 
leaflets and/or booklets were prepared in Upper Austria (ABC der Suchtvorbeugung [Preven-
tion basics] addressing parents of primary school children), in Styria (Antworten geSucht [In 
dire need of answers] also addressing parents of primary school children and Was geht ab? 
[What’s missing?] for parents of young people) as well as in Vorarlberg (8 Sachen, die Erzie-
hung stark machen [8 Strong points of parenting]). Some of them are combined with series of 
lectures (in Vorarlberg: Kinder stark machen [Strengthening our children] 11) or seminars 
(Was geht ab? [What’s missing?] in Styria. VIVID succeeded in establishing a cooperation 
with the foster parent association of Styria and in this context organised courses on the 
theme of addiction. Akzente Salzburg, cooperating with the specialised addiction outpatient 
departments of Traunstein (Germany) and Bad Reichenhall (Germany) started a new IN-
                                                
11 www.supro.at (project description of 14 May 2009) 
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TERREG project12: FamilienBande – Was geht ab?! (Family ties: What’s missing?!; see Dro-
genkoordination des Landes Salzburg 2009). Its goals, in addition to those already men-
tioned, also include awareness raising among adults with regard to their roles as models, 
and developing risk awareness. The ‘parent tables’ are central elements of the project: here 
persons trained in prevention visit mothers and fathers at home to discuss parenting ques-
tions related to substance use; and they also approach this issue in computer games13. The 
course programme Hilfe, mein Kind pubertiert (Help, my child is going through puberty) is 
another element worth mentioning; it addresses parents of adolescents aged 10 to 16 and 
specifically targets parents who cannot easily be reached and motivated in other ways. So 
far, a number of intensive courses for parents have taken place, and as of autumn 2009 the 
implementation of the programme will be enhanced. 
The majority of prevention measures taken in the workplace aim at preventing trainees from 
developing patterns of addiction behaviour. Other interventions concentrate on preventing 
the development of addiction in everyday work, with the focus placed on alcohol. In Styria the 
current further training schemes for trainers and managers have now been complemented by 
courses for supervisors in the residence halls for trainees. 
The prevention activities targeting young people have not seen new interventions or trends, 
and the existing programmes have been continued. In this setting media education has 
tended to play an increasingly important role in the corresponding interventions, and also 
aims at combining the communication of prevention issues and media skills. The focus is 
typically placed on drinking, however (e.g. in the programmes prEvent and BilderRausch 
[The ecstasy of images] in Vienna, or Reflect and Act in Vorarlberg). A study on the role that 
detached youth social work plays for prevention (GÖG/ÖBIG 2009b) has shown that this type 
of social work may serve as a health-promoting structure and can be regarded as part of un-
specific prevention measures. Because of its special approaches and methods it has the po-
tential to counteract addiction and violence. This potential could be enhanced if additional 
measures were taken (such as further training programmes as well as better networks or co-
operation with experts in this field) and if the necessary framework for activities in this regard 
were created by granting sufficient resources and independence in practical approaches. 
The trend towards prevention activities at community level has continued. Apart from 
awareness raising among the general public, initiatives in this field also aim at defining and 
implementing concrete measures oriented towards the special situation of the region in ques-
tion. It is important that communities take steps themselves and adapt measures to their 
specific needs. In Upper Austria, Wir setzen Zeichen (We’re making a point) is an example of 
prevention at community level. A guideline for the implementation of such initiatives was pre-
pared, which describes the individual steps to be taken (Institut Suchtprävention 2008). In the 
district of Vöcklabruck (see GÖG/ÖBIG 2008c) a variety of further training events were or-
ganised until summer 2009; they were primarily oriented towards youth social work but also 
addressed parents, teachers, instructors of trainees, decision makers and other interested 
                                                
12 INTERREG is a Community initiative of the European Regional Development Fund (ERDF) to stimulate interregional coop-
eration in the European Union. 
13 www.familienbande.cc (30 July 2009) 
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parties14. In spring 2009 a regional set of measures was drawn up, which, in addition to ac-
tivities promoting prevention in schools and kindergartens, also includes measures of early 
detection and early intervention, lifestyle-oriented interventions as well as the expansion of 
detached youth social work and sparetime activities organised for children and young people. 
A follow-up project will be started in Wels, Upper Austria, in autumn 200915, and the first 
meeting of experts and interested private persons has already taken place in June 2009. 
Akzente Salzburg organised PräventionsFrühstück – Prävention, die aufweckt und schmeckt 
(Prevention breakfast: prevention that raises your spirit and tastes good), an informal ex-
perts’ event in which new projects and information may be communicated to a large number 
of networking partners, key actors and other multipliers (Rögl, personal communication). This 
event has taken place twice so far and in future it will be a permanent element in the reform 
strategy for the regionalisation of prevention in Salzburg. 
Other activities in the reporting period include the Peer Drive Clean project of the EU, which 
was started as a pilot project in Upper Austria in 200816. It is a peer project aimed at provid-
ing specific information for young people on the risks of drinking and drugs in road traffic. For 
this purpose, students aged between 18 and 24 are trained and assisted by the Institute of 
Addiction Prevention. The project system is that two peers cooperate to organise a 75-
minute lesson in the context of obligatory driving school courses. The good results of this ap-
proach underline that peers are in a better position to encourage exchange and reflection 
than teachers in conventional driving school settings. Further training courses on prevention 
basics were also organised for key actors of the Austrian army, and as a high share of peo-
ple tested positive for illicit substances, this approach has been intensified (Institut Sucht-
prävention 2009b)17.  
3.2 Selective prevention in at-risk groups and settings 
SQ26 gives an overview of selective prevention measures and the framework in which they 
take place. The activities to build networks for children in at-risk families have been con-
tinued. In Lower Austria, five goals of the networks were set: apart from further training, net-
work building and increased awareness raising and lifting the taboo on addiction in the public 
discussion, another point is to establish direct services for children in families with addiction 
problems (Mellish, personal communication). As of this year, Burgenland has organised a se-
ries of further training courses focusing on the theme of children in at-risk families and a 
seminar for the target groups of social education workers as well as child and youth welfare 
workers, on identifying, understanding and coping with difficult life conditions of children and 
young people (Hausleitner 2009). In Vorarlberg and Carinthia, a cooperation standard and 
guideline, respectively, were agreed upon by the youth welfare departments and drug help 
units, which will permit joint approaches to counselling and treatment on the basis of clearly 
defined competencies (ENCARE 2009a, 2009b). The eventual aim is to optimise the care 
                                                
14 www.wirsetzenzeichen.at (30 July 2009) 
15 www.praevention.at (news of 30 June 2009) 
16 www.praevention.at (project description of 30 July 2009) 
17 www.praevention.at (news of 26 Jan. 2009) 
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structures for children of addicted parents. On the one hand, the children may thus be sup-
ported in their development and it should be possible for them to live with their parents per-
manently, and on the other, the cooperation between parents and the drug help system is 
improved. In the Tyrol and Styria, a further training event for kindergarten teachers was or-
ganised, which provided information on addiction and the situation of children living in fami-
lies with addiction problems (ENCARE 2009a, 2009b). The participants were also advised on 
how to enter into talks with parents. In addition a leaflet for parents was prepared, in which 
needs of children are described and an appeal is made to the parents to make assistance 
and support available to their children. 
In addition to the aforementioned focus, in Austria prevention activities for specific target 
groups are primarily found in recreational settings, with the aim to communicate a critical 
approach to psychoactive substances (risk competence) as well as alternatives to substance 
use. In this context, the club and party scenes are relevant settings. In 2008 MDA basecamp, 
supported by the Provincial and Local Governments of the Tyrol, was able to expand its ser-
vices by integrating the new MDA basecamp flexteam approach (MDA basecamp 2009), 
which permits regular services provided by the team at events in the individual districts of the 
Tyrol. ChEck iT!, responding to incidents connected to Spice (see Chapters 2.1 and 10.3), 
prepared an information leaflet on Spice that addresses (psychological) parents of children 
and young people, and in January 2009 an information event was organised (VWS 2009a). 
In Vienna, peer activities in sparetime settings play a relevant role, but the corresponding 
project (Party Fit!) run by ISP is oriented towards alcohol (Sucht und Drogenkoordination 
Wien 2009a). 
Young first-time drug users have also been defined as a specific at-risk group, and meas-
ures in this field primarily aim at early detection and early intervention targeting young people 
who show risky patterns of use but no manifest addiction symptoms. A training course was 
organised, and further procedures to be pursued were defined, for FreD goes net, an early 
intervention project at EU level, which is coordinated and currently tested in Austria by the 
Institute of Addiction Prevention in Linz, Upper Austria (see GÖG/ÖBIG 2008). Young drug 
users (aged 14 to 21) reported to the police for the first or second time, after an orientation 
talk to decide upon eligibility, may attend a FreD course at an addition or drug counselling 
centre. The programme is supported by the police and health authorities as well as the public 
prosecutors’ offices. The Tyrol saw an expansion of the services of Walk About, a project fo-
cusing on experience-based approaches for the target group of young people between 14 
and 22 who have drug use problems (see Chapter 9.3). Initial results of the ViVA programme 
(see GÖG/ÖBIG 2008c) have shown that binding written agreements should be concluded 
with the centres where the programme is implemented (SUPRO 2009). The ProFi pro-
gramme (see GÖG/ÖBIG 2008c) could not be expanded to reach a greater number of peo-
ple as it was not possible to motivate young people to take part in a course voluntarily, with-
out the pressure of having to undergo compulsory health-related measures or similar obliga-
tions (SUPRO 2009). 
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Regarding the target group of immigrants, the Anababa – Ailem ve Ben film project of 
Vorarlberg mentioned in the report of last year (see GÖG/ÖBIG 2008c) was concluded with a 
premiere performance of the film18, which is now shown at prevention events for parents of 
Turkish background. In Vienna, the ISP institute cooperated with representatives of Municipal 
Department 17 (Integration and Diversity) and the Dialog association to establish the SUP-
MIG working group whose aim is to communicate prevention issues to people with a back-
ground of immigration (Sucht- und Drogenkoordination Wien 2009a). 
People with hearing disabilities are a new target group for whom the existing information 
services on prevention are unavailable or insufficient. Therefore the ISP of Vienna, in coop-
eration with the association equalizent, will prepare special information materials available on 
DVD and as a booklet (Sucht- und Drogenkoordination Wien 2009). 
3.3 Indicated prevention 
Indicated prevention in the sense of the EMCDDA definition (see Chapter 3) has not been 
implemented in Austria so far. The majority of measures addressing particular target groups 
are based on social factors in the sense of selective prevention. The majority of measures 
that are adopted in response to patterns of behaviour of individual persons are not based on 
an additional medical diagnosis but only on addictive or at-risk behaviour and behavioural 
disorders associated with addiction. However, this does not correspond to the EMCDDA’s 
definition of indicated prevention, for which a diagnosis by a physician is required. 
3.4 National and local media campaigns 
In Austria, in agreement with experts in this field, no media campaigns on illicit substances 
are launched. The only exception is a number of community-oriented projects in the context 
of public relations work which are announced through media campaigns (e.g., at Vöckla-
bruck, Upper Austria). 
 
                                                
18 www.supro.at (project description of 21 Jan. 2009) 
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4 Problem Drug Use 
The EMCDDA’s current definition of problem drug use is ‘injecting drug use or long-
duration/regular use of opioids, cocaine and/or amphetamines’19. However, recent discus-
sions at EU level aim at expanding this definition (e.g., to include problem use of cannabis as 
well). Austria’s definition of problem drug use largely corresponds to the one of the EM-
CDDA, but underlines that it is primarily patterns of use and not substances as such that are 
risky or safe. Problem drug use means that drug use is accompanied by physical, psycho-
logical or social problems. If exclusively legal problems have ensued the term problem drug 
use does not apply (see, e.g., GÖG/ÖBIG 2008d). 
As of 1993, the capture-recapture (CRC) method has been used for prevalence estimates in 
Austria (see Uhl et al. 2001). The data on which the estimates are based come from reports 
to the police related to opioids (see Chapter 9.1), the substitution registry (see Chapter 5.3) 
and drug-related deaths (see Chapter 6.3). In addition the DOKLI nationwide documentation 
system of clients of Austrian drug help centres provides information that is very helpful for an 
interpretation of the results obtained (see Chapter 5.3).  
Poly-drug use with opioids, which often are injected, has traditionally played a significant role 
in Austria. In the past decade the range of substances taken in the context of poly-drug use 
has widened. Injecting use of cocaine has also become more relevant in the street scene. 
However, the DOKLI data on patterns of use among clients of the drug counselling system 
show that opioids continue to predominate as primary drugs (see e.g., GÖG/ÖBIG 2009a). 
According to recent estimates, a prevalence rate of 22 000 up to a maximum of 33 000 prob-
lem opioid users, mostly in the context of multiple drug use, seems realistic for Austria. How-
ever, prevalence estimates of problem drug use are difficult to give as methodological prob-
lems arise due to the complexity of the subject, and the figures obtained are conclusive to a 
limited extent only. Thus any results given are rough approximations and have to be inter-
preted with caution. The prevalence rate of alcohol dependence, compared to illicit drugs, is 
estimated to be 5% of the population over 15 in Austria. This means that a total of 350 000 
people in Austria are to be regarded as alcoholics (Uhl et al. 2009). 
4.1 Prevalence and incidence estimates of PDU 
In Austria scientific estimates of the prevalence of problem drug use are only available for 
opioids and for poly-drug use with opioids. The most recent estimates relate to the year 
2007. Taking into account also other data sources it is safe to assume that the prevalence of 
problem drug use, after a rise until 2004, has slightly gone down again in recent years (for 
details see GÖG/ÖBIG 2008c). 
                                                
19 http://www.emcdda.europa.eu/themes/key-indicators/pdu (30 Sept. 2009) 
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The data from DOKLI, the nationwide documentation system of clients of Austrian drug help 
units, indicate that apart from persons showing patterns of (poly-)drug use with opioids, an-
other group also plays a major role in the treatment system, at least in the category of people 
undergoing long-term outpatient treatment: a share of 24% out of the total number of people 
starting long-term outpatient therapy in 2008 named cannabis as their only primary drug 
(compared to 4% of inpatients; see Chapter 5.3 and GÖG/ÖBIG 2009a). It would be a point 
worth discussing whether this high share actually is the result of health problems or psycho-
social problems caused by cannabis use (which would mean that this group should be taken 
into account when prevalence rates of problem drug use are studied) or whether it rather re-
flects repressive policies regarding cannabis use (see Chapter 11). Another question is 
whether the needs of this group of clients are adequately met in the existing drug help cen-
tres. More detailed studies based on these results found in the context of the routine monitor-
ing of DOKLI would be needed in order to obtain further insight. 
Apart from these two groups, i.e., clients showing (poly-drug) patterns of use with opioids 
and clients with only cannabis used as their primary drug, few other clients are found in the 
drug help system. 12% of clients in the outpatient sector, and also 12% in the inpatient sec-
tor, do not belong to either group (GÖG/ÖBIG 2009a). If cannabis is not taken into account, 
one may conclude that almost all people registered in the drug help system have opioid prob-
lems (in the context of poly-drug patterns of use). As exactly this group is covered by the 
CRC estimates, and assuming that, with regard to patterns of use, clients of drug help units 
are representative of all problem drug users, this means that the estimates obtained reflect 
almost all problem drug users in Austria. 
4.2 Data on problem drug use from non-treatment sources 
A recent multi-city study on patterns of use, which also includes data from Vienna (Eisen-
bach-Stangl 2009) gives both an analysis of available quantitative data and the results of 
qualitative interviews to describe drug use in Vienna20. Thus, the following typology is charac-
teristic of Vienna: 
Marginalised poly-drug users: this group primarily uses morphine, benzodiazepines and 
other psychopharmaceuticals as well as cannabis, and at times also heroin and cocaine. 
More than two out of three people of this marginalised group are undergoing drug-related 
treatment and care. This group is estimated to comprise between 7 500 and 14 000 people. 
Cocaine and heroin users: different to the above group, the drugs that are primarily used 
are heroin and cocaine or morphine (often combined), and at times cannabis and benzodi-
azepines. This marginalised group of approximately 280 to 1 000 people mostly remains out-
side the treatment system. 
                                                
20 A total of 14 semistructured interviews (12 face-to-face, 2 phone interviews) were held with stakeholders in the fields of drug 
policy, drug treatment, the police, street social work, opioid substitution treatment, pill testing, youth psychiatry and grow 
shops, and with one cannabis user. In addition interviews with 30 drug users that took place in the context of another project 
were included. 
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Cocaine snorters: among them, cocaine snorting predominates, and at times, also heroin or 
other drugs are used. This group of 30 000 to 40 000 people is primarily composed of so-
cially privileged persons whose income is sufficient to finance their drug use. They are hardly 
registered by the drug help system. 
Recreational drug users: this group (estimated to include around 5 000 people) is part of 
the party scene; the primary drug used is cannabis, and sometimes they also take ecstasy, 
amphetamines, cocaine, hypnotics, LSD and mushrooms. The group members are socially 
integrated and hardly turn to drug help centres. 
Cannabis smokers: they use cannabis as the only illicit drug, from daily to occasionally. 
This group comprises approximately 100 000 people who are socially integrated. 
The groups described above can clearly be distinguished from each other, with the exception 
of the group of cocaine and heroin users, which may overlap with the group of marginalised 
poly-drug users. 
If one compares the above groups to the groups of persons showing problem drug use with 
opioids in GÖG’s prevalence estimates it is obvious that the latter estimates only relate to the 
groups of marginalised poly-drug users as well as cocaine and heroin users. The estimated 
number of people in the respective groups of this study also largely corresponds to the re-
sults of the CRC estimates. No reliable estimates can be given regarding the number of peo-
ple in the other three groups who show problem patterns of use (health or social problems 
because of drug use). 
Salzburg provided analyses of patterns of use among persons examined according to Sec-
tion 12 of the SMG21 (Drogenkoordination des Landes Salzburg 2009). As in previous years, 
use of cannabis predominates in this group of persons (88% out of 367 examinations). 12% 
of examinations was related to use of cocaine or ecstasy or opioids, respectively, 6% to 
speed and 3% to hallucinogenic drugs. 72% of examinations was carried out because of use 
of one substance, 17% resulted from use of two substances (typically cannabis combined 
with opioids, cocaine or ecstasy) and 8% from three or more substances. For more details on 
persons showing patterns of problem drug use in the party scene and, in part, problem pat-
terns of recreational drug use, see Chapter 2.3. 
As in previous years, also in 2008 several reports mention high-risk use of substances with 
GBL ingredients, e.g., in scene locations in Vienna and St. Pölten (see Chapter 10.3). 
                                                
21 Persons who, because of a reasonable suspicion of drug abuse and who, after a report to the police, or information by a head 
of school, a military agency or driving licence authority, were medically examined with regard to the need for undergoing a 
health-related measure. 
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5 Drug-related Treatment: Treatment Demand and 
Treatment Availability 
Austria has an almost nationwide network of centres that provide drug-related counselling, 
care and treatment services22. A total of almost 200 specialised units provide inpatient and 
outpatient treatment or counselling related to addiction and illicit substances (investigations 
by GÖG/ÖBIG). Drug counselling, care and treatment services are provided both by special-
ised centres and in the context of the general health care system (e.g., psychiatric hospitals, 
psychosocial services, established physicians). Inpatient treatment is open to people from all 
over Austria and also from abroad. In quantitative terms, opioid substitution treatment (OST) 
has become the most important form of treatment in Austria, and efforts to improve it have 
continuously been made. 
Austria attributes great importance to the diversification of available treatment options. As a 
result, in the past decade the inpatient sector saw a development from long-term to short-
term treatment and generally to more flexibility with regard to possible kinds of treatment, for 
instance in the form of modular systems. Opioid substitution treatment may be obtained in 
inpatient settings, and withdrawal is also possible in outpatient departments. The goal of this 
development has been to take into account to a greater extent individual needs and the pa-
tients’ situation in life. This also means that a variety of substitution substances may be pre-
scribed. As the general aim is to maintain a comprehensive treatment and care network, 
most service providers also organise a variety of preparatory and aftercare measures as well 
as recreational and reintegration services (see Chapter 8.2) and also interventions for spe-
cific target groups (e.g. young people or persons with psychiatric comorbidity). For an over-
view of available drug help services please consult ST24, SQ27 and the Addiction Help 
Compass23, which is currently being revised. For detailed descriptions of available services 
please consult the websites as well as the annual reports and newsletters of the individual 
centres, ÖBIG’s previous reports and the Best practice portal of the EMCDDA (see Refer-
ences). 
The services provided in the fields of addiction counselling and treatment have also tended 
to be expanded to include legal drugs as well as forms of addiction not related to substances, 
and programmes to this effect have been started (e.g., nicotine-free programmes and coun-
selling for gambling addicts), which cannot be discussed in this report. 
Since 2006, data on clients of drug help units have been obtained from the DOKLI nation-
wide documentation system, which covers the majority of relevant centres providing drug-
related services in Austria. The data gathered include all questions defined by the EMCDDA, 
and in addition, data on infectious diseases (also according to EMCDDA guidelines) and 
ICD-10 codes are collected on a voluntary basis. The substitution registry, which has been
                                                
22 The maps showing the regional distribution of drug help centres and services are being revised and therefore not included in 
this report. 
23 http://suchthilfekompass.oebig.at  
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maintained at the Federal Ministry of Health since 1989, is a further data source worth men-
tioning. Regarding personal data of clients, only gender, age and province of residence are 
registered, however. 
5.1 Strategy/policy 
Drug treatment strategies and policies are defined in the drug or addiction strategies of the 
individual provinces and in the corresponding laws (see Chapter 1). The reporting period did 
not see relevant changes in this field, but a number of studies were drawn up and recom-
mendations for improvements of addiction treatment were made. For instance, according to 
an expert opinion drawn up in Carinthia, integrated care structures for addiction patients 
should be aimed at (Prehslauer, personal communication). In order to build the necessary 
addiction-related competencies in the health and care institutions concerned, a set of meas-
ures to this end is required (see Chapter 1.2). Another demand that has been identified is the 
need for specific therapy services for children and families with addicted parents. 
The majority of studies and suggestions have focused on opioid substitution treatment, how-
ever. In cooperation with the Provincial Commissions of Experts (see GÖG/ÖBIG 2008c), re-
ports on the effects of the new regulations for OST were drawn up in 2008, from which rec-
ommendations by the working group of the Federal Drug Forum were derived (see Chapter 
1.2). Recommendations in this field also came from the Quality Assurance Commission for 
Addiction Diseases at the Superior Public Health Council. The recommendations by the two 
commissions will form the basis for a further amendment in autumn 2009. 
Reports from the provinces confirm the effects mentioned already in previous years (see 
GÖG/ÖBIG 2008c), i.e., a reduction in the number of physicians providing opioid substitution 
treatment (Lower Austria, Upper Austria), insufficient treatment and care capacities in a 
number of provinces (Lower Austria, Upper Austria, Tyrol), rising numbers of clients in drug 
outpatient clinics, which results in long waiting times and bottlenecks regarding other drug 
help services (Upper Austria, Salzburg). It is also reported that a number of physicians who 
still provide opioid substitution treatment have refused to take part in additional further train-
ing programmes and therefore will not be eligible for OST after the end of the transition pe-
riod (Upper Austria). However, there are also provinces, e.g., Vienna and Vorarlberg, where 
no reduction in OST physicians has been registered. Several provinces report declining 
numbers of patients who are allowed to take substitution substances at home, paralleled by a 
rising number of patients who have to take these substances under supervision in pharma-
cies (Vienna, Styria). This does not seem to be the case in Upper Austria. The provinces 
have taken a variety of measures in order to ensure care structures that meet the corre-
sponding demand, for instance, financial incentives modelled after Vienna’s remuneration 
agreement between the Medical Association and the provincial health insurance fund: such 
agreements have either been concluded already (Upper Austria, Salzburg) or they are 
planned (Lower Austria). Another measure in this field is the decision not to publish the lists 
of physicians qualified for opioid substitution treatment, which have to be maintained accord-
ing to the Oral Substitution Further Training Decree (Upper Austria). Several provinces plan 
to build additional capacities especially for diagnosing and determination of maintenance 
doses. In both Upper Austria and Salzburg (see GÖG/ÖBIG 2008c) this will be performed by 
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specialised physicians who work at regional counselling centres (Sturm und Schwarzenbrun-
ner 2008). This plan has not (fully) been implemented in either province, however. Styria and 
the Tyrol consider the possibility to establish additional, or expand already existing, special-
ised outpatient departments (Ederer, personal communication; Ärztekammer Tirol 2008). 
In addition, a number of recommendations for improvement of the existing situation have 
been made: for instance, a reduction of training requirements (i.e., of the necessary number 
of training hours) and training obligations only for physicians in charge of deciding on main-
tenance doses, as well as ensuring diversified services (several substitution substances to 
choose from), services for drug patients with psychiatric comorbidity provided by established 
psychiatrists, or specialised care services at drug outpatient departments for patients whose 
treatment turns out to be difficult, and also inpatient and semi-inpatient treatment options for 
substitution patients. The issue of defining substances that should preferably be prescribed 
has also been discussed controversially (see GÖG/ÖBIG 2007). One of the problems men-
tioned is that undesirable psychological side-effects of methadone, different to physical intol-
erance, cannot be assessed objectively (Sturm und Schwarzenbrunner 2008). Another point 
of criticism concerns the lack of nationwide guidelines, e.g., regarding measures to be taken 
in difficult cases (Sturm und Schwarzenbrunner 2008). 
A number of studies on opioid substitution treatment in Austria deserve mention in this re-
gard. However, one has to bear in mind that the surveys on which they are based were con-
ducted before the legal framework was changed in 2007. A cross-sectional study24 by 
Springer et al. (2009) shows diverse aspects of assessments of available substitution sub-
stances by patients and physicians: while slow-release morphine is assessed as the best 
substance with regard to suppressing withdrawal symptoms, retention rates and patients’ 
preferences, buprenorphine is assessed more favourably as far as its small risk of abuse is 
concerned. On the whole, the assessments of slow-release morphine and buprenorphine are 
positive to similar extents, while methadone is assessed significantly less favourably. Metha-
done also ranks last in the assessments by patients. It cannot definitely be said to which ex-
tent this result may be explained by subjective expectations on the part of respondents 
and/or objective effects of the substances in question. However, a comparative study on 
substitution with slow-release morphine v. methadone25, carried out by Schweizer Haus 
Hadersdorf (SHH 2009), shows similar results: patients treated with slow-release morphine 
definitely felt better, stabilisation was easier and could be achieved faster. Different to treat-
ment with methadone, prolonged treatment also led to an improvement of psychopathologi-
cal behaviour and the patients’ current situation. Patients treated with slow-release morphine 
made significantly greater improvements regarding drug use as well as family situation/social 
                                                
24 In the context of this study carried out by the Ludwig-Boltzmann Institute of Addiction Research, cofinanced by the Ludwig 
Boltzmann Society, the Anton Proksch Institute and Mundipharma, 176 physicians were interviewed who provided substitu-
tion treatment to more than two, or four, substitution patients, respectively (in doctor’s offices or at drug help centres). Then 
the interviewees were asked to randomly select between 3 and 5 substitution patients and to complete patient questionnaires 
for them on the basis of case histories and interviews with the patients in question. Another questionnaire was filled in by the 
patients themselves. In sum, a documentation of 619 substitution patients was available. 
25 From October 2003 to December 2005, 48 persons were examined or interviewed, respectively. 23 of them obtained substitu-
tion therapy once more and were administered either methadone or slow-release morphines. Another 25 patients were pre-
scribed slow-release morphine because of an intolerance of methadone. 
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and psychological situation compared to methadone patients. The greatest differences 
showed with regard to overall stress tendencies and general mood. Similar results were also 
found after patients changed from methadone to slow-release morphine, but to smaller ex-
tents. Side effects such as nausea or constipation occurred slightly more often in patients 
taking methadone compared to slow-release morphine. 
According to Springer et al. (2009), the current dose taken does not seem to have an influ-
ence on the feeling of contentment of substitution patients, while people to whom substitution 
substances are dispensed once a week or less often, feel considerably more contented than 
others. Aeschbach Jachmann et al. (2008)26, however, state that the doses administered are 
of great importance for retention and good results of OST but that considerable potential for 
optimisation exists regarding determination of doses. 
Further analyses of the cross-sectional study (Springer und Uhl 2009) reveal that opioid sub-
stitution treatment takes considerably more time than the treatment of other patients as nu-
merous additional problems exist. 61% of both general practitioners and psychiatrists who 
carry out OST have provided this service for more than 10 years. Almost all of them deter-
mine maintenance doses and continue to treat their patients also afterwards. 84% of substi-
tution patients are treated in doctor’s offices or drug help units where more than 100 patients 
obtain substitution treatment. While only a small part of respondents generally refuse further 
training, a large number are against the 40-hour further training requirement and say that 
they will not undergo training to this extent. The cooperation with the public health officers is 
generally described as satisfactory. Although these results relate to the time before 2006, 
they partly correspond with reports from the provinces communicated in 2008. 
Another relevant issue in the field of opioid substitution treatment concerns benzodiazepines 
that are prescribed in addition to the substitution substance, and the problems arising from 
this practice (interaction, addiction potential). In Upper Austria, between 10% and 20% of 
substitution patients are also prescribed benzodiazepines (Sturm und Schwarzenbrunner 
2008). According to the study by Springer et al. (2009) this applies to 23% or 22%, respec-
tively, of patients taking methadone or slow-release morphines, and it seems to be related to 
taking high doses of the substitution substance (31% of patients). The study by Aeschbach 
Jachmann et al. (2008) found a rise in additional prescriptions of benzodiazepines in the pe-
riod analysed, but paralleled by a significant decline in the relationship of benzodiazepine 
prescriptions to opioid prescriptions. Still, in 2005 an average of 27% of patients were admin-
istered additional doses of benzodiazepines, which was found to be related to the type of 
substitution substance taken (the greatest number of benzodiazepine prescriptions con-
cerned patients taking slow-release morphines and the smallest number was found with re-
gard to patients taking buprenorphine). The study confirms that a certain part of OST patients 
actually need benzodiazepines, but the share of patients taking additional doses of benzodi-
azepines still seems too high, in particular with regard to the fact that many patients turn to 
                                                
26 The long-term prescriptions issued in the 3rd quarters of the years 2002 and 2005 and financed by the Vienna Health Insur-
ance Fund were analysed. In addition, general practitioners provided data on additional prescriptions of benzodiazepines. 
Those doctors who did not treat the required number of substitution patients (i.e., < 11 patients) were not included in the 
analysis. The data material thus comprised 21 145 prescriptions by 154 general practitioners. The data concerning the re-
maining 151 physicians were included in the analysis of prescription practices of individual persons. 
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another physician to get these prescriptions. Fischer27, in an interview concerning this study, 
found a correlation of this prescription practice with the number of substitution patients per 
doctor. In order to reduce additional prescriptions of benzodiazepines, Fischer recommends 
intensified further training of attending physicians as well as treatment in specialised psychi-
atric outpatient clinics of addiction patients suffering from additional psychiatric diseases 
(which is a typical reason for administering benzodiazepines). This would ensure correct di-
agnoses of these comorbidities, so that adequate forms of treatment could be started, and 
possible interactions between opioids and psychopharmaceuticals could be taken into ac-
count. Eventually, she also points out the need for transparent error management systems at 
the Medical Associations, as well as a restriction to a sensible number of substitution patients 
per physician – i.e., roughly 45 to 50 patients, according to Fischer. 
In 2008 Vienna’s Expert Commission on Opioid Substitution Treatment started to draw up 
guidelines for the treatment of benzodiazepine dependence (Sucht und Drogenkoordination 
Wien 2009). These guidelines focus on prescriptions to be issued and the resulting costs, as 
well as on further training programmes for physicians prescribing benzodiazepines. The Dia-
log association has already drawn up its own guidelines for treating benzodiazepine depend-
ence and now attempts to discuss this problem with each patient treated, and to achieve a 
reduction of benzodiazepine use (Dialog 2009b), either by outpatient reduction programmes 
or inpatient partial withdrawal. 
5.2 Treatment systems 
The capacities of Austria’s drug help system have continually been expanded but are insuffi-
cient nevertheless. This is reflected in waiting lists and in waiting times which, depending on 
treatment centre, may be up to six weeks for the first counselling talk, several months for 
admission to treatment and up to six months for inpatient withdrawal treatment. Pronounced 
regional differences show in this regard, however: for instance, the Addiction and Drug Coor-
dination of Vienna reports no waiting times for the province of Vienna. The reasons for insuf-
ficient capacities in the counselling centres have remained the same (see GÖG/ÖBIG 
2008c), and in the outpatient treatment departments, the results of changes in OST regula-
tions show (see Chapter 5.1). In the inpatient sector, lack of beds is the main reason for ca-
pacity problems. The Carina therapy department also reports strong demand for therapy 
places, which has led to waiting times of several months (Stiftung Maria Ebene 2009b). This 
in turn is supposed to have effects on the duration of treatment. 
In order to increase capacities in the individual areas, a number of new services were made 
available or planned in the reporting period. In Vorarlberg, it was decided to establish a de-
toxification department affiliated to the Lukasfeld therapy department (Neubacher, personal 
communication); implementation is scheduled for the next two years. The plan includes a 
withdrawal area separated from the rest of the unit, with seven beds primarily for young pa-
tients who want to undergo drug-free treatment (Wölfle und Haller 2008). It is also open to 
patients who need partial withdrawal or harm-reduction measures or for whom survival and 
                                                
27 www.drogensubstitution.at (14 May 2009) 
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minimisation of infection risks are primary goals. However, the Provincial Hospital of Rank-
weil will continue to treat those patients who suffer from intoxication or withdrawal symptoms 
that require supervision, from acute psychoses or disorientation, and those who shoe con-
siderable risk of self-harm or harm to others as well as severe physical comorbidity or sec-
ondary diseases that need intensive medical supervision. Since October 2008, as a conse-
quence of rebuilding works, withdrawal treatment at the Anton Proksch Institute (API) has 
been provided at a new location. This has already resulted in a slight increase of bed capaci-
ties, and diversified treatment approaches can be implemented (see GÖG/ÖBIG 2008c). In 
Lower Austria, API, Caritas of the Diocese of St. Pölten and the Association of Psychosocial 
Centres (PSZ) cooperated to establish additional addiction counselling units (Hörhan, per-
sonal communication). This means that by autumn 2009, the capacities will be at the planned 
levels in all districts. As of November 2008, the BIZ counselling centre of northern Styria has 
also taken over the functions of a specialised addiction outpatient clinic (Ederer, personal 
communication). This service has met with much interest, and after half a year already, wait-
ing lists had to be introduced. In order to increase capacities, supplementary financing was 
demanded, and a cooperation with the Provincial Sigmund Freud Neurology Hospital (LSF) 
of Graz is considered. The cooperation of the Drug Counselling Centre of the Province of 
Styria and the drug outpatient department of LSF was intensified: individual psychosocial 
counselling sessions have become an integral part of the admission procedure in the context 
of determining initial maintenance doses for opioid substitution treatment (Drogenberatung 
des Landes Steiermark 2009). 
In order to optimise preparatory care and aftercare services, the Walkabout therapy depart-
ment plans to establish a separate unit focusing on preparatory care and aftercare, located in 
the centre of Graz, which will open in autumn 2010 (Mahnert, personal communication). In 
2008 the Carina therapy department organised a meeting for former and current patients, 
which focused on life after treatment. Three groups, headed by facilitators, exchanged ex-
perience of the change from the protected treatment setting back to normal life (Stiftung 
Maria Ebene 2009a). The preparations for the event were integrated in the treatment proce-
dures, which provided an opportunity to deal with organisational difficulties and find solutions 
with the help of experts. 
A number of measures are aimed at optimising counselling and care services to orient them 
more specifically towards target groups and to address new groups of clients. For instance, 
the OIKOS counselling centre now offers services by medical specialists for adults with can-
nabis as their primary drug who live in or around Klagenfurt (Prehslauer, personal communi-
cation). This includes detailed diagnosing, monitoring of the patients’ development and 
treatment of drug problems as well as underlying psychiatric diseases. Young people con-
tinue to be referred to the outpatient department of child and youth neuropsychiatry. The Be-
yond the Line service for cocaine users in Vienna (see GÖG/ÖBIG 2008c and Chapter 7.3) 
takes into account that these clients usually are reluctant to meet other addicted people, 
therefore they are invited to the centre once a week outside the regular opening hours (Dia-
log 2009b). As many clients are highly agitated, a staff member is present in the waiting area 
to answer general questions and to facilitate discussions. Counselling as such takes place in 
individual settings, with the focus placed on finding short-term strategies for the next few 
days. Whenever demanded, also addiction acupuncture is available. Experience made so far 
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shows that acupuncture may be very helpful for initial treatment. Public relations activities for 
this special target group continue to be a challenge, however. As of the beginning of 2009 
Kontaktladen of Graz has run the 12-week KISS programme for control of drug use (Kon-
taktladen Graz 2009). In weekly sessions of 2 hours and 15 minutes, the participants are 
supported in setting their own goals and determining periods of time in which to change pat-
terns of use. The aim of this service is to find new ways to address addicted people, to sup-
port the clients in their willingness to change substance-related behaviour and to promote the 
course of treatment. The programme is based on the clients’ ability to control their drug use, 
which definitely exists in a certain share of drug addicts. 
In Vienna the working group on children and young people with drug problems addresses the 
target group of drug users under age; it focuses on counselling and care strategies during 
the transitional period from adolescence to adult life (Sucht und Drogenkoordination Wien 
2009b). Last year, special opening hours for young people were introduced (see GÖG/ÖBIG 
2008c), and in addition, the waiting area is now temporarily redesigned at these hours so that 
the specific demands of this group may be met more closely (Dialog 2009b). During this time, 
adults over 21 are admitted only if a meeting has been scheduled, and if necessary they 
have to wait in a separate area. On the other hand, young people may use the structures 
open to adults only in special cases of crisis. Both clients and staff members have given a 
very positive feedback regarding this new system. Since May 2009 the Z6 drug counselling 
centre of Innsbruck has also offered online counselling (Kern, personal communication). 
In Vienna a project on the optimisation of inpatient treatment of newborn babies of addicted 
mothers has been run; its goals include the reduction of the babies’ withdrawal phases and 
ensuring aftercare services for mothers and children (see Chapter 7.3). In Mödling (Lower 
Austria), the DESK pilot project (focusing on drugs and addiction problem of parents and 
children) was started in order to provide services for pregnant women who are addicted to 
alcohol, drugs or pharmaceuticals (Hörhan, personal communication). 
A diploma thesis on drug users with a background of immigration28 (Pajkovic 2008; see also 
Chapter 8.1) shows that this theme has not often been a subject of expert studies so far in 
Austria, and as a result, few services for this target group exist. In order to encourage ad-
dicted immigrants to turn to the drug help system more often, specific barriers that are en-
countered by both sides have to be eliminated and accessibility has to be enhanced. Typical 
barriers that have been identified in the centres include insufficient information on counselling 
centres, no staff available who speak the clients’ mother tongues, racism on the part of other 
addicted clients in the centres (and often the staff of the unit fail to intervene), resentment by 
staff towards this group of clients (more time and effort needed), exclusion because of na-
tionality and thus no eligibility for support, counselling and treatment structures oriented to-
wards middle classes, as well as the problem that immigrants are often thought to be drug 
dealers. The barriers that exist on the part of immigrant drug users are little knowledge of 
counselling and care services, fear of legal consequences, the view that addiction is a weak-
ness, prejudice by counsellors or the feeling that counsellors are not taking their side, lack of 
confidence in institutions, negative view of self-reflection and preference of alternative treat-
                                                
28 A literature research was carried out and problem-centred interviews were held with people of the target group. 
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ment approaches and healing methods practiced in the country of origin. As a response to 
this situation, the Dialog association has taken a first step and hired an ethnic Turk staff 
member (Dialog 2009b). In addition, a strategy that takes into account the problems men-
tioned will be drawn up. At the Hegelgasse office, a worker with a background of immigration 
helped prepare methodological inputs for services provided to immigrant families, which may 
be used by the entire staff. In 2009 Verein Wiener Sozialprojekte (VWS; Vienna Social Pro-
jects Association) hired a worker from Iran, and the new edition of the information booklet on 
addiction prepared by the wienXtra youth information service in cooperation with the Addic-
tion and Drug Coordination of Vienna also lists addiction-related services that are available in 
languages other than German. 
Regarding quality assurance in addiction treatment, apart from activities focusing on opioid 
substitution treatment (see Chapter 5.2) a number of other initiatives deserve mention: for in-
stance, in spring 2009 the Dialog association published a manual that describes Dialog’s 
quality management policy (Dialog 2009a). It documents Dialog’s guidelines and the general 
philosophy pursued as well as all processes of quality assurance and further development 
and also internal knowledge management (communication and documentation) as well as 
risk and error management. Uniform standards will be defined for the centres of the Addiction 
and Drug Coordination of Vienna in order to provide the basis for implementing case man-
agement procedures (Sucht- und Drogenkoordination Wien 2009b). In the inpatient sector, 
referral forms and a catalogue of available products have already been drawn up. In 2008 
Dialog implemented an assessment model, in which information on forms of drug use and 
the situation in life of the clients is gathered (Dialog 2009b). The results will be integrated in 
treatment planning in the sense of risk assessment regarding the future development of pat-
terns of use. 
In the reporting period the Ganslwirt centre evaluated its opioid substitution treatment ser-
vices (VWS 2009): the intended target group can be addressed to the desired extent and im-
provements were achieved in various respects. However, a problem area mentioned is that 
treatment is often ended very suddenly. As the fluctuation of staff in the outpatient clinic 
could be reduced, a better continuity of contacts to clients will be possible.  
A new evaluation of the Carina therapy department29, which is oriented towards drug-free 
treatment, showed a retention rate of 67% in 2008 and an average duration of treatment of 
approximately four months (Stiftung Maria Ebene 2009b). This confirms the trend towards 
shorter long-term treatment (see p. 25), and the results underline previous experience. The 
catamnestic interviews30 (clients treated in 2007) also primarily revealed positive develop-
ments (Stiftung Maria Ebene 2009c). However, an interesting fact is that in the opinion of re-
spondents, the treatment outcomes could be improved if the treatment periods were longer, if 
the therapists showed more understanding, if the treatment settings were addiction-free to 
greater extents and if the clients were better prepared for the time after treatment. 
                                                
29 In 2008 a total of 65 patients were treated (12 patients were admitted twice). 61 treatments were concluded in 2008, 41 of 
them with the desired result. Admission diagnosing took place 2 to 4 weeks after admission, and discharge diagnosing 4 to 2 
weeks before the completion of treatment. 29 persons filled in the questionnaire after completion of treatment. 
30 The catamnestic interviews took place one year after the end of therapy, by means of phone calls. 25 out of 54 people who 
had completed, or prematurely terminated, treatment in 2007 could be interviewed. 
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5.3 Characteristics of treated clients 
The client year 2008 is the third year for which data of the DOKLI nationwide documentation 
system of clients of Austrian drug help units are available31. 
The drug help centres in Austria that are covered by the DOKLI system communicated data 
on a total of 3 959 people who had started long-term outpatient treatment in 2008. For 
1 715 of them this was their first drug treatment in life. 1 352 patients started long-term inpa-
tient treatment, and for 168 clients this was their first long-term drug treatment. In addition 
to these persons undergoing drug treatment in a traditional sense, DOKLI also registered 
691 clients requiring assistance by low-threshold centres and 5 129 people receiving drug 
counselling in the form of short-term contacts. Generally speaking, the data gathered for 
2008 correspond to those of the two previous years. 
Figure 5.1: Number of people starting drug-specific treatment or assistance sessions in 2008, by age 
and type of service 
 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008; representation by GÖG/ÖBIG 
 
Approximately one out of five people undergoing treatment or receiving assistance are 
younger than 20 – with the exception of people treated in the context of inpatient settings, 
where their share is 11%. Between 47% (short-term contacts) and 60% (long-term inpatient 
treatment) of clients are in the age group from 20 to 29 years (see Figure 5.1, Table A17 in 
Annex A as well as ST3 and ST34). 
                                                
31 When interpreting the results, one has to bear in mind that, while double counts of clients of one centre can be excluded, due 
to the aggregate character of the data, double counts of clients who turned to several centres in 2008 cannot be avoided. The 
share of such cases of multiple treatment can only be guessed at. The report of Vienna’s BADO Basic Documentation gives a 
general idea of the magnitude of this aspect as in the case of BADO, double counts of clients who contacted several drug 
help centres during the reporting period can be detected by means of an identifier. In 2006, 14% of clients registered in BADO 
were provided services by more than one centre (11%: 2 centres; 3%: more than 2 centres – see GÖG/ÖBIG 2008a, IFES 
2007). However, as drug help centres are more easily accessible in Vienna due to the higher geographical density compared 
to rural areas, the share of double counts might be slightly smaller in the rest of Austria. 
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In all settings analysed, the share of women is between 22% and 31%. This roughly corre-
sponds to past experience (e.g. gender distribution regarding patients undergoing substitu-
tion treatment – see below – and drug-related deaths; GÖG/ÖBIG 2008b) and primarily 
seems to reflect the gender distribution in the group of problem users of illicit drugs. Gener-
ally speaking (with the exception of short-term contacts) the share of women in people re-
ceiving treatment tends to go down with rising age (see Figure 5.2 and Chapter 12.2).This 
situation also shows in the data on opioid substitution treatment and drug-related deaths and 
corresponds to experience reported by the majority of countries in the European Union (EM-
CDDA 2007). In addition, the documentation system reveals that women are younger at the 
time of first use of most substances and also start injecting drugs slightly earlier than men 
(see below). These data are in line with studies and analyses of recent years (EMCDDA 
2007, GÖG/ÖBIG 2007a, Haas 2005). 
Figure 5.2: Share of women in persons starting drug treatment or assistance sessions in 2008, 
by age and type of service 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008; representation by GÖG/ÖBIG 
In sum, approximately half of the clients are undergoing opioid substitution treatment when 
they turn to a drug help centre (except short-term contacts, for which this aspect is not 
documented). OST started in the course of clients’ contacts to the drug help centre has not 
been included. The share of opioid substitution patients is rising with age of clients (see 
Chapter 12.1).  
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In the field of conventional treatment (long-term outpatient or inpatient treatment), opioids 
predominate as primary drugs32. Cocaine is of marginal relevance as a primary drug (see 
Figure 5.3 and Table A21 in Annex A). This shows that in Austria, different to a number of 
other countries of the European Union, opioids (continue to) play an important role in the 
context of drug use relevant for treatment (see, e.g., EMCDDA 2007). Depending on the 
treatment setting, the share of cannabis as a primary drug is between 27% and 32%. How-
ever, this has to be qualified due to the fact that a very high percentage of persons are re-
ferred to compulsory treatment because of use of cannabis as their sole primary drug. For 
instance, this applies to 62% of clients undergoing long-term outpatient treatment (see also 
Chapter 4.1). 
Figure 5.3: People starting drug-related treatment or assistance sessions in 2008, by primary drug and 
type of service 
Note: Multiple answers were permitted 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008; 
representation by GÖG/ÖBIG 
In long-term inpatient and outpatient settings, women name opioids as primary drugs more 
frequently and cannabis less often than men. With rising age, opioids, cocaine and tranquil-
lisers/hypnotics are increasingly often indicated as primary drugs – with the exception of in-
                                                
32
 For compiling the DOKLI case history, clients are first asked which drugs they have ever taken. Then the drugs mentioned 
are classified according to current patterns of use, as primary drugs, additional drugs, drugs only taken in the context of ex-
perimental use and drugs not relevant for treatment. The primary drug is the drug which causes the greatest problems from 
the personal point of view of the client. Here, problems – on the basis of ICD 10 – are understood as psychosocial and health-
related problems and not solely legal problem situations. As a rule, the primary drug also is the drug because of which the cli-
ent has started the current treatment. If a client cannot decide which drug is their primary drug, several drugs may be named. 
Additional drugs are drugs which the client has used in addition to the primary drug in the past six months and which also 
constitute a problem for the client. Experimental drug use refers to intermittent use of the corresponding drug in the past six-
months without harmful use or manifest addiction problems. Drug use not relevant for treatment means that the drug in ques-
tion has occasionally been taken for more than half a year but no harmful use or manifest addiction problems show, or that 
the drug was used in the past but not during the six-month period preceding treatment (GÖG/ÖBIG 2009a). 
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patient treatment settings. Cannabis, on the other hand, is named less often by older clients 
in all settings (see Chapter 12.2). 
Figure 5.4: Age of first drug use (median) of persons starting long-term outpatient treatment in 2008, 
by substance and gender 
 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008; 
representation by GÖG-ÖBIG 
Further information on age of first use and predominant form of administration is available 
only for clients undergoing long-term outpatient and inpatient treatment. The median age of 
first use has shown to be between 17 and 20 years with regard to the majority of drugs. It is 
lower only in the case of alcohol and solvents/inhalants (14 years) and cannabis (15 years). 
A consistent tendency compared to the results for injecting drug use (see above) is that as a 
rule women are one year younger than men when they use drugs for the first time (see Fig-
ure 5.4 and Chapter 12.2). 
Persons undergoing long-term outpatient treatment most often name snorting (50%) as their 
preferred way of heroin use, followed by injecting use (40%; see Table A22). In inpatient set-
tings, the corresponding shares are 36% and 55%. This is an interesting result and was ana-
lysed in more detail in the context of the selected issue of last year’s DOKLI report 
(GÖG/ÖBIG 2008a). It showed that a considerable share of heroin users prefer snorting at 
the beginning of their drug career and turn to injecting use at a later stage, if at all (see Fig-
ure 5.5). For possible prevention approaches that might result from these findings please 
consult GÖG/ÖBIG 2008a. 23% of clients undergoing outpatient treatment and 44% of inpa-
tients primarily indicate injecting as their preferred form of cocaine use. The share of i.v. co-
caine users also increases with rising age of clients (see Figure 5.5). Amphetamines are 
snorted by about two out of three users, and one out of three indicate oral use.  
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Figure 5.5: Preferred form of use of heroin (n = 2235) and cocaine (n = 2 277) among people starting 
long-term outpatient treatment in 2008, by age (percentages) 
 
 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008; 
representation by GÖG/ÖBIG 
The selected issues chapter of this year’s DOKLI report (GÖG/ÖBIG 2009a) deals with older 
drug users. For results please consult Chapter 12.  
5.4 Trends of clients in treatment (including numbers) 
As DOKLI has been available since 2006 only, no statements on trends can yet be given. But 
time series going back over many years exist for opioid substitution treatment monitoring. 
The national monitoring of substitution treatment is performed by the Ministry of Health and 
based on the reports of attending doctors33. Although these reports are not always complete 
and frequently not provided in due time (see ÖBIG 2003), they still give a general impression 
of both quantitative developments and characteristics of clients (see ST3 and Figure 5.6).  
The problem of ghost cases34 was a significant deficit regarding data quality. In order to get 
this problem under control, the Ministry of Health started comprehensive correction routines 
in 2007, based on enquiries to attending doctors, and it may safely be assumed that the 
amendment to the Narcotic Drugs Decree (see GÖG/ÖBIG 2007b), which entered into force 
on 1 March 2007, has considerably improved reporting practices. Because of these correc-
tions and new developments, a number of differences compared to the figures given in pre-
vious years show. A considerable part of the rise in the number of treatments reported, and 
especially first treatments between 2006 and 2007, has probably been caused by the better 
coverage of cases. 
                                                
33
 As of 2009, the district authorities, in their function as health authorities, have been in charge of communicating data to the 
substitution registry. 
34
 If the end of treatment is not reported, the corresponding clients appear in the statistics as people currently undergoing treat-
ment also in the years after the actual end of treatment (= ghost cases) (for details see GÖG/ÖBIG 2006). 
64%
25%
84%
12%
54%
35%
76%
21%
36%
56%
63%
32%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Heroin snorting Injecting heroin use Cocaine snorting Injecting cocaine use
Under 20 20 to 29 years 30 or older
Chapter 5: Drug-related Treatment 
 38
Figure 5.6: Development of annual reports of persons currently undergoing opioid substitution 
treatment in Austria by first treatment and continued treatment, 1999–2008 
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Note: continued treatment means treatment started before the respective year or repeated treatment of persons already hav-
ing undergone substitution treatment in the past. First treatment means treatment of persons who have never been in 
substitution treatment before. Any differences to the figures given in previous years (GÖG/ÖBIG 2008) result from correc-
tions on the part of the BMG. 
Source: BMG, calculation and representation by GÖG/ÖBIG 
The growing acceptance of and readiness to undergo opioid substitution treatment is re-
flected in the annually rising number of persons reported as currently receiving OST (see 
Figure 5.6). 
As Figure 5.7 shows, the rise in first treatments in the last few years has primarily been ac-
counted for by the groups up to age 19 and between 20 and 24 years. 2007 is a massive out-
lier in this respect, with the number of persons treated nearly doubled in almost all age 
groups (which indicates better coverage). In 2008 the number of first treatments reported has 
gone down again, but continues to be above the first treatment figures of 2006.  
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Figure 5.7: First substitution treatment in life, by age, 1999–2008 
 
Source: BMG, calculation and representation by GÖG/ÖBIG 
An interpretation of this development cannot be given at present because it is impossible to 
estimate to which extent treatments that had been started earlier were subsequently reported 
in 2007 and 2008 and therefore incorrectly entered as first treatments in the substitution reg-
istry. In 2008, as in previous years, the share of women in first treatments was approximately 
one out of four. Further analyses according to age and province would not make sense here 
because of the change in coverage. A list of registered first treatments by province is given in 
Table A16 in Annex A.  
An analysis of the substances prescribed for first treatment also has to be made with caution, 
as part of the treatments, due to the reasons mentioned above, might incorrectly have been 
entered as first treatments. The share of slow-release morphines has further gone down 
compared to previous years and now amounts to 25% (2003: 47%). The prescription rates of 
methadone have remained roughly the same, and buprenorphine has been prescribed less 
often. It should be taken into account, however, that in 2008 Suboxone, a preparation com-
bining buprenorphine and naxolone, was included as a new substitution substance (present 
share: 10%; see Figure 5.8). Still, in previous years, the analyses of the DOKLI data show a 
different picture: according to DOKLI, slow-release morphines are prescribed most often 
(45% of long-term outpatient clients; 63% of clients receiving low-threshold assistance and 
61% of persons undergoing long-term inpatient treatment), followed by methadone (18% to 
27% of patients undergoing OST) and buprenorphine (only between 5% and 21%) 
(GÖG/ÖBIG 2009a). Buprenorphine is typically prescribed to younger clients. 
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Again, one has to bear in mind that a comparison of these data is possible to a limited extent 
only (see GÖG/ÖBIG 2007b).  
Figure 5.8: Development regarding kind of substitution substance used for first treatment 
1999–2008, percentages 
 
Source: BMG, calculations by GÖG/ÖBIG; representation by GÖG/ÖBIG 
For a rough estimate of all people undergoing drug-related treatment in Austria, the data 
from substitution monitoring and from DOKLI may be combined. In 2008 a total of 1 751 
people turned to drug help units covered by DOKLI to receive inpatient treatment, 9 102 
people underwent long-term outpatient treatment (GÖG/ÖBIG 2009a), and 11 119 people 
were registered as patients undergoing OST in 2008 (see Figure 5.7). In order to obtain total 
numbers, the following assumptions or parameters are considered: 
• In the DOKLI system, multiple counts of clients cannot be excluded. But based on the 
BADO system of Vienna, a correction factor may be calculated. In the BADO system, the 
share of clients receiving care in several drug help centres is 14% (IFES 2007). 
• DOKLI does not cover all drug help units: 71% of inpatient treatment centres and 93% of 
outpatient centres use DOKLI for case documentation (ST34).  
• The overlap between DOKLI and substitution monitoring may be estimated on the basis 
of the DOKLI item referring to the start of opioid substitution treatment (42% of drug out-
patients and 50% of drug inpatients were undergoing OST when they turned to the drug 
help centres). 
Based on these assumptions and parameters, it is estimated that long-term drug-related ca-
res services were provided to approximately 17 000 people in Austria in 2008. 
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6 Health Correlates and Consequences 
Infectious diseases are relevant in particular because of the risk of transmission due to inject-
ing drug use. The available data in this context are based on non-representative samples 
from the treatment sector or low-threshold centres. While the HIV prevalence rate still was 
around 20% in the early 1990s, it has remained at a low level since then (0% to 2%). The 
prevalence rate of hepatitis B was lower than 20% in the reporting year. Hepatitis C-Ab 
prevalence has remained around 50%. Regarding hepatitis C, the prevalence rates relating 
to HVC antibody (HCV-Ab) and HCV-RNA tests have been documented separately by a few 
drug treatment units. This is of interest as it is primarily positive testing for HCV based on 
PCR tests that indicates a chronic development of HCV. 
Psychiatric comorbidity in the context of drug addiction continues to be a focal theme in Aus-
tria. Although no routine data have been collected in this field, many data and reports from 
the treatment sector are available. These data indicate high prevalence rates of psychiatric 
comorbidity (dual diagnoses) among problem drug users. 
In Austria, the Ministry of Health has collected data on drug-related deaths since 1989. In the 
case of directly drug-related deaths, a causal connection between death and drug use may 
safely be assumed, i.e., the patients in question died as a result of acute intoxication (over-
dose). The data of the annual statistics and analysis are based on the reporting obligations 
under Section 24c of the Narcotic Substances Act, according to which the following informa-
tion has to be communicated to the Ministry of Health immediately: the Federal Ministry of 
the Interior (BMI) has to provide information on any police reports related to suspected drug 
offences, and the forensic medicine institutions, the public health authorities and hospitals 
have to report the results of post-mortem examinations or autopsies performed as well as 
any chemical and toxicological tests carried out on this occasion. If no post-mortem examina-
tion or autopsy has taken place, the Ministry of Health obtains the confirmation-of-death cer-
tificates that are documented at Statistics Austria. However, a considerable decline has 
shown regarding the number of cases in which post-mortem examinations including toxico-
logical tests are performed because of suspected drug overdoses in order to verify this sus-
picion and analyse the substances involved. For instance, in 2008, 32 cases occurred where 
the confirmation-of-death certificates indicated narcotic drug intoxications but no autopsy or 
post-mortem examination was ordered by the courts or the public health police, respectively. 
As a result, these cases could not be verified as cases of overdoses including narcotic drugs, 
thus, it is not sure whether they are in fact drug-related deaths or not. The number of deaths 
suspected to involve drug use that have not been examined in further detailed tripled in the 
past year, which affects the conclusiveness of the statistics and also makes it difficult to 
compare the corresponding data with those of previous years. In Vienna, as a consequence 
of the amendment to the Vienna Death and Funeral Act of 2007, the number of suspicious 
deaths in which no post-mortem examinations and toxicological tests were performed even 
grew by 400% (GÖG/ÖBIG 2008c). For the year 2008, it is thus impossible to give an exact 
number of persons whose death is proven to be connected with narcotic drug overdoses. 
Consequently, no time series and comparisons between provinces can be included.
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Nevertheless, the statistics still provide a number of data on patterns of use, gender distribu-
tion and average age of people who died of narcotic drug intoxication, which is of relevance 
for health policies. The problem of the reduced quality of epidemiological data and ways to 
improve the current situation has already been a topic of discussion in health policy contexts. 
It would be desirable from the point of view of health policy to perform autopsies in all cases 
of suspected drug-related death, because complete statistics that provide conclusive infor-
mation are essential as a basis of decision-making and prevention measures. 
6.1 Drug-related infectious diseases 
The data on drug-related infectious diseases that are given in Standard Table 9 (ST9) in-
clude national as well as subnational samples from low-threshold centres and inpatient 
treatment units. The corresponding prevalence rates are summarised in Table 6.1. The data 
of the reporting year indicate hepatitis B (HVB) rates ranging from 2% to 19%. The drug-help 
units again report low HIV prevalence rates between 0% and 2% (2007: 0% to 4%). The 
HVC antibody (HCV-Ab) prevalence rates of 2008 range from 22% to 60%, with the Lukas-
feld therapy department reporting a deviating prevalence rate of 22% (2007: 20%) also this 
year. A well-founded interpretation of this difference cannot be made. Thus, the trend already 
observed in previous years of HCV-Ab prevalence rates around 50% has continued (see 
GÖG/ÖBIG 2007b; GÖG/ÖBIG 2008c). 
Regarding HCV-RNA, a chronic development of the disease shows in a high share of pa-
tients testing positive for HCV-Ab. Because of the great differences of HCV-RNA prevalence 
rates that are reported, i.e., between 38% (Anton Proksch Institute) and 75% (Lukasfeld), 
these data cannot be used as a basis for deriving general statements on chronic develop-
ments of hepatitis C infections (see Table 6.1). Regarding HCV genotypes, neither national 
data nor information by individual centres is available for the reporting year35.  
                                                
35 For details on individual drug-related infectious diseases and HCV-RNA prevalence rates see also ST9. 
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Table 6.1: Data on hepatitis B, hepatitis C-Ab, hepatitis C-RNA and HIV infection rates in 2008 
Data source HBV rate HCV-Ab rate1 HCV-RNA rate6 HIV rate 
Lukasfeld therapy department   2% (1/5)2 22% (12/55) 75% (9/12) 0% (0/55) 
Long-term therapy department at Anton Proksch Institute 
(API) 
19% (13/67)2 60% (44/67) 38% (10/26) 1% (1/67) 
Low-threshold centre Ganslwirt 8% (7/89 )3 43% (27/63) not documented 2% (2/108) 
Caritas Marienambulanz outpatient department 13% (19/121)4 60% (72/121) 67% (48/72) 0% (0/121) 
DOKLI5 19% (58/306) 47% (165/350) 66% (94/143) 1% (3/317) 
Drug-related deaths (intoxications) in 2008 n.a. 8 n.a. n.a. n.a. 
1 These prevalence rates relate to persons in whom HCV antibodies were found (HVC-Ab) and not to HCV-PCR tests, which 
permit a direct detection of the virus. 
2 This percentage relates to persons in whom antibodies to hepatitis B were found and whose medical history did not indicate 
hepatitis B vaccinations. 
3 This percentage relates to persons in whom antibodies (anti-HBc Ab, anti-HBe Ab, anti-HBs Ab) or HBs antigens were found 
and who had not yet received hepatitis B vaccinations (isolated anti HBs Ab positive tests; data obtained from Ganslwirt’s vac-
cination project). 
4 Positive test results only refer to HBV-cAb positive and HBV-sAb positive results. In the reporting year, no HBV-sAg positive 
cases were found. 
5 These data refer to injecting drug users who started drug treatment in 2008; information on their infection status was obtained 
either by status testing or based on the case history. 
6 Only 100 and 108, respectively, out of a total number of 175 expert opinions on directly drug-related deaths explicitly men-
tioned the presence or absence of HCV Ab and HIV. In the remaining cases it is not clear whether no tests for the relevant in-
fections were carried out or whether the results were negative and thus not mentioned in the expert opinion. The two percent-
ages given therefore indicate maximum and minimum levels of HCV-Ab and HIV prevalence rates. 
7 The HCV-RNA rate relates to persons with positive HCV-Ab test results. 
8 n.a. = no data available 
Sources: Duspara, Stolz-Gombocz, Haltmayer, Anderwald, Bauer, personal communications; 
GÖG/ÖBIG 2009a; see also ST9; representation by GÖG/ÖBIG 
Generally speaking, the prevalence rates reported are comparable to a limited extent only 
because of differences in data collection methods by the individual centres (routine examina-
tions v. voluntary test services offered), and lack of representative data sources. A compari-
son of available HBV, HCV-Ab and HIV prevalence rates covering the period from 2005 to 
2008 (see Figures 6.1, 6.2 and 6.3) shows how difficult it is to derive reliable statements on 
changes and trends regarding the at-risk group of drug users. 
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Figure 6.1: Hepatitis C-Ab prevalence rates in Austria; 2004–2008 
 
1 Not all expert opinions on directly drug-related deaths (DRD) explicitly mention the presence or absence of HDV-Ab infections. 
In the remaining cases, it is not clear whether the infection status was not tested, or not mentioned because of negative test-
ing. The two percentages given thus represent the upper and lower limits of HCV-Ab prevalence rates. 
Source: ST9, calculation and representation by GÖG/ÖBIG 
Figure 6.2: Hepatitis B prevalence rates in Austria; 2004–2008 
 
Source: ST9, calculation and representation by GÖG/ÖBIG 
Figure 6.3: HIV prevalence rates in Austria, 2004–2008 
1 Not all expert opinions on directly drug-related deaths (DRD) explicitly mention the presence or absence of HIV infections. In 
the remaining cases, it is not clear whether the infection status was not tested, or not mentioned because of negative testing. 
The two percentages given thus represent the upper and lower limits of HIV prevalence rates. 
Source: ST9, calculation and representation by GÖG/ÖBIG 
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In 2008 a total of 1 048 hepatitis C infections relative to the general population were re-
ported. The hospital discharge statistics alone list 212 patients with acute viral hepatitis C in-
fections and 915 patients suffering from chronic viral hepatitis. In 2008, chronic viral hepatitis 
C was indicated as the main cause of death of 250 people, and one person died of acute vi-
ral hepatitis C. 763 cases of hepatitis B were reported in Austria. According to the hospital 
discharge statistics, various types of hepatitis B were diagnosed in a total of 317 patients, 
and in 24 cases, hepatitis B was indicated as the main cause of death. 138 hepatitis A infec-
tions were reported, 95 patients suffering from this infection were listed in the hospital dis-
charge statistics and no hepatitis A infection was documented in the cause of death statistics 
(see BMG 2009b; BMG 2009c; Statistik Austria 2009a; Statistik Austria 2009b). 
Due to the aggregate character of the above data, they cannot be linked, and thus, preva-
lence and incidence rates of hepatitis in the general population cannot be derived from these 
statistics. In addition, although hepatitis infections have to be reported, at least regarding 
HCV a reporting bias is likely (Strauss et al. 2003). Early in 2009 an electronic epidemiologi-
cal reporting system (EMS) was introduced in Austria in order to improve reporting quality: 
now monthly statistics on reports are provided, broken down by infectious disease and prov-
ince. Due to lack of information on routes of infection it is not possible, however, to identify 
potential at-risk groups such as injecting drug users. 
The reports from the long-term national AIDS statistics show that injecting use is the second-
most risky situation (16 reports) after heterosexual contacts (n = 25) and before homosexual 
contacts (n = 12). In 2008, 10 cases were filed as ‘other/unknown’, and in two cases, the vi-
rus was transmitted by transfusion. The statistics on AIDS deaths by risk situation and year 
show that half out of a total of 18 deaths listed were related to injecting drug use (BMG 
2009a; see Table A3 in Annex A). 
Data on other drug-related infections are available only for tuberculosis (TB). No person out 
of 101 for whom tuberculosis entries are given in the corresponding DOKLI data set had 
positive TB diagnoses. Three clients indicated TB infections when the case history was com-
piled. These figures confirm that TB still does not constitute a problem in Austria. The data 
on TB vaccination rates are based on a sample of 239 people. This year’s data confirm the 
low vaccination coverage regarding TB: it was 5% in 2008, and 8% in 2007 (see Chapter 5.3; 
GÖG/ÖBIG 2008a; GÖG/ÖBIG 2009a). 
The DOKLI data set on hepatitis A vaccinations includes 420 people, and regarding hepatitis 
B vaccinations, a sample of 569 people. The resulting vaccination coverage of 28% for 
hepatitis A and 31% for hepatitis B is in fact small. However, among people under 20, higher 
vaccination rates have been registered than in the other age groups (see GÖG/ÖBIG 
2009a). This HBV vaccination coverage is similar to the rates communicated by the inpatient 
departments of Lukasfeld (27%) and API (34%) but not by the Marienambulanz low-threshold 
outpatient clinic (10%; see ST9). The figures reported generally reflect previous vaccinations 
rather than the actual status of immunisation (GÖG/ÖBIG 2009a). 
In the context of an anonymous standardised survey carried out at Caritas drug help units in 
Innsbruck, within one week a total of 62 drug users were asked for information on previous 
HIV and HCV diagnoses or HAV/ABV vaccinations. This also included questions concerning 
patterns of drug use as well as behaviour-related data on syringe use and safer sex. At 
present the results of the survey are analysed (Schäfer, personal communication). 
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6.2 Other drug-related health correlates and consequences 
The Carina therapy department at Maria Ebene Foundation provided systematic diagnoses 
regarding psychiatric comorbidity according to ICD 10, which reveal that almost all pa-
tients suffer from one or several personality disorders. Affective disorders were found in 18% 
of patients, while the share of neurotic, stress or somatoform disorders among total diagno-
ses was small. Only 4% of patients had diagnoses of anxiety disorders (see Table 6.2; 
Stiftung Maria Ebene 2009b). 
Table 6.2: Psychiatric comorbidity by ICD-10 diagnose, Maria Ebene Foundation, patient year 2008 
ICD 10 chapter Block Code Percent 
Disorders of adult per-
sonality and behaviour 
(F60–F69) 
Specific personality disorders (PDs) 
(F60. –) 
Paranoid PD (F60.0) 7% (6/88) 
  Dissocial PD (F60.2) 11% (10/88) 
  Emotionally unstable PD (F60.3) 28% (25/88) 
  Histrionic PD (F60.4) 11% (10/88) 
  Anxious (avoidant) PD (F60.6) 9% (8/88) 
  Dependent (asthenic) PD (F60.7) 7% (6/88) 
  Other specific PDs (F60.8) 8% (7/88) 
 Mixed and other personality disorders 
(F61. –) Paranoid PD (F61.0) 17% (15/88) 
Mood (affective) 
disorders (F30–F39) 
Recurrent depressive disorder (F33. –)  16% (12/77) 
 Persistent mood (affective) disorders 
(F34. –) 
 3% (2/77) 
Neurotic, stress-related 
and somatoform 
disorders (F40–F48) 
Phobic anxiety disorders (F40. –) Social phobias (F40.1) 3% (2/77) 
 Other anxiety disorders (F41. –) Mixed anxiety and depressive disorder (F41.2) 1% (1/77) 
Source: Stiftung Maria Ebene 2009, calculation and representation by GÖG/ÖBIG 
Significant gender differences in the psychiatric diagnoses show with regard to eating disor-
ders (women: 42%; men: 6%). When the diagnoses were made, particular attention was paid 
to complex post-traumatic stress disorders, i.e. serious diseases as a reaction to stress, 
which were found in 39% of all patients – and in 69% of women. This means that more than 
two out of three women treated have experienced traumatic situations. Taking into account 
the corresponding ICD-10 diagnoses, this trauma frequently results from experience of sex-
ual and/or physical violence suffered over a long time (see Stiftung Maria Ebene 2009b). 
The DOKLI data also provide information on psychiatric comorbidity (see Chapter 5.3). In 
159 out of 239 people (66%) for whom at least one ICD-10 diagnosis not related to addiction 
was entered, a mental and behavioural disorder was found. The diagnoses range from affec-
tive disorders (e.g., depression), personality and behavioural disorders to neurotic, stress 
and somatoform disorders. On the other hand, Grüner Kreis states that in the reporting year 
38% out of 102 patients suffering from psychiatric multimorbidity had diagnoses of schizo-
phrenia as well as schizotypal and delusional disorders. At the Carina therapy department, 
this type of comorbidity is found in only 4% of patients. Grüner Kreis diagnosed personality 
and behavioural disorders in 33%, and affective disorders in 32%, of patients with comorbid-
ity (see GÖG/ÖBIG 2009a, Grüner Kreis 2009, Stiftung Maria Ebene 2009b). The results of 
the retrospective study on the prevalence of personality disorders at the API long-term ther-
apy department at Mödling, Lower Austria, still have not been published (see GÖG/ÖBIG 
2008c). 
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Need for crisis intervention among clients was reported primarily by low-threshold centres. 
For instance Substanz (Upper Austria) reports 46 acute crisis interventions in the reporting 
year (2007: 16 interventions), i.e., cases in which clients needed spontaneous help immedi-
ately. This concerned issues such as support of relatives after a person’s death, trauma be-
cause of violence in the drug scene, losing one’s home or crisis in the partnership. In 2008, 
four persons used the psychotherapeutic crisis intervention service more than 50 times 
(Substanz 2009). The statistics of the low-threshold centres in Vienna reveal that mental 
health, after accommodation and drug use, ranks third in the list of themes addressed in 
counselling talks. The number of crisis interventions (n = 371) more than doubled compared 
to the year before (n = 157; VWS 2009a). 
Apart from psychiatric comorbidity and the health consequences of the infectious diseases 
discussed above, also somatic diseases and damage resulting from the chronic effects of 
toxins or the precarious life conditions of injecting drug users deserve mention. 
In the reporting year, the low-threshold centres of Vienna reported 97 instances of life-saving 
measures taken, which is a slight decline compared to the year before (n = 109). According 
to statistics of Vienna’s ambulance service, in 2008 the number of patients with suspected 
overdoses of illicit substances was 897 in Vienna. This corresponds to 0.5% of total patients 
in this period. The increase that shows compared to the year before (n = 586) results from a 
modification in the documentation of ambulance data (Sucht- und Drogenkoordination Wien 
2009; VWS 2009a).  
Regarding comorbidity of pregnant drug users, only information on specific interventions are 
available (see Chapter 7.3). Statements on the prevalence of psychiatric or physical comor-
bidity cannot be made because the sample in question is not representative, among other 
reasons. These data can only be regarded as a description of the frequency of incidents. 
Therefore interpretations in a political, legal, economic or social context cannot be given ei-
ther. 
6.3 Drug-related deaths and mortality of drug users 
Regarding drug-related deaths, a distinction is made between deaths directly caused by drug 
use and indirectly related deaths (for details on methodology see GÖG/ÖBIG 2009c).  
Based on autopsy findings, a total of 169 directly drug-related deaths could be verified. This 
figure has to be regarded as the lower limit, however. In fact, if one also includes suspicious 
cases that were reported and for which only confirmation-of-death certificates (based on an 
external examination of the body) are available, between 169 and 201 deaths might directly 
be drug-related. For this reason, it cannot be assessed whether the number of deaths has 
gone down or risen compared to last year (175), and no statements on trends can be given. 
In 12% of cases of drug-related death, the toxicological analyses revealed only illicit sub-
stances (one drug or a combination of several drugs). In addition, psychoactive substances 
were also found in 54% of cases, in 9% alcohol was detected as well, and in 25%, both sub-
stances, i.e., alcohol and psychoactive drugs. As in previous years, poly-drug intoxications 
with opioids clearly predominate (97% of intoxications with known substances. The share of 
persons who had exclusively taken opioids (approx. 8%) remained at a level similar to the 
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year before (2006: 16%; 2007: 6%). Patterns of poly-drug use, where the effects of different 
substances may be potentiating and thus are difficult to control, continue to be widespread 
and constitute serious health hazards (see Chapter 4). 
 
Figure 6.4: Age distribution of directly drug-related deaths in Austria, 1998–2008; percentages 
 
Source: GÖG/ÖBIG 2009c; representation b GÖG/ÖBIG 
The grouped median36 of the age at death was 25.7 years in 2008: the age median of the re-
porting year thus again is at a level similar as in previous years, after a rise in age had shown 
for the first time in 2007 (2005: 25.9; 2006: 24.6; 2007: 28.3). The share of persons under 20 
(13%) was within the range of previous years (2005: 15%; 2006: 20%; 2007: 14%; see Fig-
ure 6.4). The share of persons between 20 and 24 years was 27%, which corresponds to the 
average of the last few years (2004: 22%; 2005: 25%; 2006: 26%; 2007: 26%). The share of 
women in directly drug-related deaths, i.e., 21%, is in line with the long-term average. 
 
                                                
36
 Grouped median means that 50% of cases are above this figure and 50% are below this figure. 
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7 Responses to Health Correlates and 
Consequences 
In Austria the responses to health correlates and consequences include a wide range of in-
terventions. The relevant measures focus on drug-related infectious diseases, in particular 
low-threshold assistance aimed at harm reduction. For instance, syringe exchange, hepatitis 
vaccinations and information on safer use/safer sex are typical services performed by low-
threshold centres and outreach services (street social work)37. Treatment of health conse-
quences is primarily provided by the general health-care system (e.g. emergency physicians, 
psychiatrists), and to an increasing extent also in the context of consulting hours of physi-
cians/specialists in low-threshold centres. In the past year, also the themes of diagnosing 
and treating hepatitis C, as well as comorbidity, were of particular relevance. The available 
information and data primarily come from the annual reports of individual units and the Drug 
and Addiction Coordination Offices of the provinces. 
7.1 Prevention of drug-related emergencies and reduction 
of drug-related deaths 
At present, the steering group of the Austrian Federal Drug Forum (BDF) that was convoked 
in February 2009 is preparing a special meeting of the BDF to discuss possible interventions 
to reduce drug deaths. The goal of the meeting is to draw up a comprehensive national strat-
egy paper on the prevention of drug-related deaths. Specific initiatives focusing on drug-
related emergencies and deaths are mainly pursued in the low-threshold drug help sector, by 
individual centres, and in some cases also at provincial level. In Vienna a study on drug-
related deaths is being conducted in order to increase the quality of knowhow on risk factors 
and to derive interventions aimed at harm reduction and prevention of deaths (Sucht- und 
Drogenkoordination 2009b).  
In 2008 the CONTACT hospital connection service for drug addicts in Vienna was called in 
386 cases to provide assistance (2007: 346). A total of 1 026 contacts during stays in hospi-
tal and 1 279 contacts after release from hospital were registered (Sucht- und Drogenkoordi-
nation Wien 2009a; see also Chapter 7.3). 
In the low-threshold sector, first aid still plays a predominant role. This theme is presented in 
information material or at events as well as in inhouse magazines (e.g., at the ‘theme bistro’ 
of streetwork/VWS). Clients of Komfüdro (Tyrol) may also train practical first aid measures in 
a group setting. In the reporting year Komfüdro again organised an obligatory first-aid train-
ing course for its staff. This ensures quick responses to (drug) emergencies that occur in the 
centre, and the knowledge obtained may be passed on to clients (see VWS 2009a; Kom-
füdro 2009). 
                                                
37 http://suchthilfekompass.oebig.at  
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7.2 Prevention and treatment of drug-related infectious 
diseases 
Preventing infections continues to play an important role in low-threshold centres and out-
reach work: here the exchange and sale of syringes is especially important. In addition to 
the established programmes for the exchange and sale of syringes that are run at provincial 
level, in Austria it is also possible to buy syringes and needles in pharmacies and vending 
machines. In the reporting year a vending machine was installed also in Dornbirn (Vorarl-
berg). Vorarlberg now has a total of seven vending machines, the safer sets for which are 
prepared by do it yourself, a low-threshold contact point, in the context of an occupation pro-
ject (do it yourself 2009). Salzburg has taken steps to implement low-threshold services for 
drug users. At present, syringes can only be bought at two vending machines or at the of-
fices of the AIDS Hilfe centre (Drogenkoordination des Landes Salzburg 2009).  
Figure 7.1: Syringe exchange at the Substanz centre (Upper Austria), 2004–2008  
 
Source: Substanz 2009; representation by GÖG/ÖBIG 
All data on syringe exchange by province that were systematically collected relate to the re-
porting year 2007 (see ST10; GÖG/ÖBIG 2008c). For this reporting year, only a few data 
from individual units are available, which again indicate high levels of, or strong rises in, sy-
ringe sales and syringe exchange. The trend of past years hat thus continued. For instance, 
at the Substanz low threshold centre of Upper Austria 92 138 sets were exchanged. If one 
adds the syringes exchanged and sold at the café as well as sales in the prevention vending 
machine, a total of 98 406 sets were distributed (see Figure 7.1; Substanz 2009). The ser-
vices for injecting drug users, in addition to making syringes available, continue to include the 
provision of sterile injection equipment (e.g., spoons), alcohol pads, medical filters and disin-
fectants. 
In spite of high return rates of over 95% drug users have repeatedly been reported to leave 
behind equipment in public places. The VWS centres attempt to contribute to awareness-
raising in this regard, both by individual talks and in the form of postcards, which have been 
distributed since early in 2009 (VWS 2009a).  
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Safer use and safer sex continue to be essential issues that are addressed in the context of 
outreach drug social work, usually on the occasion of syringe exchange. No significant de-
velopments compared to the previous year have taken place here. In 2008 the drug help 
units of Vienna published a guidebook for drug users that deals with the subjects of injecting 
drug use and its risks, alternatives to i.v. use, as well as information on individual substances 
and safer sex (VWS 2009b). In 2008 Komfüdro (Tyrol) again placed the focus of its work on 
safer use and hepatitis C prevention. In the context of a peer education project, a workshop 
on safer use and hepatitis was organised in cooperation with selected clients. Because of the 
positive feedback, a continuation of this initiative has been planned. Komfüdro’s activities of 
preventing infections, which address not only drug users, are also taken into account in the 
sanitary inspections of the individual centres. In this context daily work routines at the centre 
are tested with regard to sanitary standards (Komfüdro 2009). 
Hepatitis vaccination projects are further essential interventions to prevent and treat drug-
related infectious diseases. They are organised at regional level or as initiatives by individual 
centres. In most cases the offer of vaccination is combined with cost-free HIV and viral hepa-
titis testing. For instance, in 2008 the Ganslwirt low-threshold centre (Vienna) registered 123 
and Kontaktladen (Graz) 58 HAV/HBV vaccinations, and do it yourself (Vorarlberg) reported 
six hepatitis vaccinations. 
Treating infectious diseases in drug users has become increasingly important in the whole 
country. A prerequisite for successful treatment is that multiprofessional networks exist which 
link drug help institutions and providers of medical care. For instance, in Vienna drug patients 
who suffer from hepatitis B or C may also obtain treatment in all gastrointestinal outpatient 
departments of the individual hospitals. Other provinces have also taken steps to create a 
basis for effective treatment or to increase the quality of treatment for this difficult group of 
patients. For this purpose the drug help centres and the medical sector cooperate in the con-
text of quality circles38. This goal was also on the agenda of the fifth expert meeting on hepa-
titis C39, which took place in Vienna in June 2009. Regarding HIV treatment, the cooperation 
with the pulmonology and dermatology outpatient and inpatient departments of Vienna’s 
hospitals has been intensified (see GÖG/ÖBIG 2008c; Sucht- und Drogenkoordination 
2009b). 
Drug consumption rooms continue to be an issue in Austria. In February 2009 a meeting 
held in Innsbruck focused on new ways in drug policy and an international comparison of 
consumption rooms. In addition to an exchange of international experience, themes related 
to consumption rooms and safety as well as low-threshold approaches were presented and 
discussed, also with regard to their relevance for Austria. The plan of 2007 to establish a 
drug treatment point in Graz is also oriented towards this aspect. The original plan has 
meanwhile been revised and is about to be presented to the Ministry of Health. The new plan 
takes into account recommendations by the Federal Government such as comprehensive 
evaluation routines, as well as decisions in favour of support for this approach on the part of 
the Local Government of Graz and the Regional Parliament of Styria. After its revision, the 
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plan will be discussed by the Federal Drug Coordination (of the Federal Ministries of Justice 
and the Interior, headed by the Federal Ministry of Health) and the Federal Drug Forum 
(Zeder, personal communication). In the context of Vienna’s drug monitoring, the acceptance 
of consumption rooms among the general population was surveyed: in 2009, only 34% said 
that this was a sensible step, 22% were neither against nor in favour of consumption rooms, 
and 41% rejected the idea. However, distributing sterile syringes to drug users is accepted 
by 68% of the population. Still, it is interesting so see that the acceptance of consumption 
rooms, i.e. 34%, has been the best result so far. Since 1997, acceptance rates have been 
between 20% and 31% (IFES 2009). 
7.3 Responses to other health correlates and 
consequences 
Services with regard to psychiatric comorbidity are still part of the activities of the agencies 
providing drug help services. The services delivered by the individual centres hardly differ 
from those reported in previous years (see GÖG/ÖBIG 2007b, GÖG/ÖBIG 2008c). In the re-
porting year, Grüner Kreis established mobile long-term care services for patients showing 
psychiatric comorbidity. The patients’ individual needs are specifically taken into account to 
achieve their best possible occupational and social reintegration (Grüner Kreis 2009). The 
drug outpatient clinic (ASK) of Vienna expanded its multiprofessional diagnosing services: 
now also psychiatric comorbidities such as trauma, abuse or schizophrenia as well as addic-
tion-related infectious diseases can be considered more specifically. Patients and their rela-
tives obtain consulting in these fields and if necessary they may also receive treatment 
(Sucht- und Drogenkoordination Wien 2009b). Addiction and psychiatric comorbidity continue 
to be relevant issues at events organised for staff of drug help centres (see GÖG/ÖBIG 
2008c; Hörhan, personal communication).  
Interventions and measures that aim at the general state of health of drug users are inte-
grated in all treatment and care fields covered by the drug help network, with different fo-
cuses depending on the setting in question. In particular in the low-threshold field, the corre-
sponding services also include dressing of wounds, health information, hygiene practices, 
etc. At the Ganslwirt centre, because of its specific group of clients, emergency services 
such as crisis intervention and observation play important roles. As a rule, the theme of 
health and disease predominates in this setting. In addition, general practitioners or medical 
specialists provide consultation services in low-threshold centres. The services include verifi-
cation of the current infection status, vaccinations, urinalysis and pregnancy tests, as well as 
medical counselling and treatment (see VWS 2009a; Kontaktladen 2009; Substanz 2009).  
The Beyond the line project addresses the group of cocaine users, who are often socially in-
tegrated but cannot easily be reached (see Chapter 5.2). This group is characterised by high 
psychiatric comorbidity rates (anxiety disorders, depressive disorders) and specific health 
problems (proneness to tachycardia, persistent arterial hypertension). The available services 
include medical (physical and psychopathological) examination as well as psychosocial 
counselling. If necessary, also acute concomitant diseases are treated or patients are re-
ferred to further specialist examination and treatment (Dialog 2009). 
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Special health promotion services addressing women continue to be an integral part of the 
work of the low-threshold centres (see GÖG/ÖBIG 2008c). The corresponding services in-
clude counselling and support regarding problems that specifically concern women (e.g. 
prostitution to finance drug use, experience of violence), which usually occur in a clearly de-
fined setting. For instance, women’s cafés take place at regular intervals in the restructured 
contact points of streetwork/VWS (Vienna) and also Substanz (Upper Austria). A number of 
centres (e.g., Kontaktladen, Ganslwirt) also provide gynaecological consultation, often in co-
operation with medical specialists. Comprehensive services for pregnant drug users and their 
children are another focus of activities. At first, this problem area was primarily approached 
from a medical point of view, but meanwhile also other professions and institutions have 
been integrated in the care structure. In Vienna, the hospitals cooperate with the social work 
team of General Hospital Vienna, the CONTACT hospital connection service and eventually 
also with the Youth and Family Offices of the City of Vienna to respond to this cross-sectional 
issue. The goal here is to create a care network in which optimised services are provided to 
parents and children during the inpatient withdrawal treatment phase for the child, to intensify 
the bond between mother and child and to deliver subsequent outpatient services after the 
discharge from hospital. The counselling units provide regular care services for addicted 
mothers, which is a requirement defined by the Youth and Family Offices. These care ser-
vices include a variety of measures and treatment interventions for the child to monitor and 
promote their development. The services for mothers focus on the comprehensive theme of 
living with a child. The multi-agency care approach described above is based on regular net-
work meetings in which the structure of services and cooperation are further optimised (see 
Chapter 5.2; Sucht- und Drogenkoordination 2009b; Dialog 2009). 
MDA basecamp reports that 59% of all online enquiries were about counselling and assis-
tance in the sense of support and stress relief, and 21% of enquiries asked for medical in-
formation. Already in 2007, it showed that rising numbers of enquiries concerned opioids, 
and this trend has continued in the reporting year (21%). 24% of enquiries were related to 
cannabis (see Chapter 4.2; MDA basecamp 2009). 
The issue of nursing services for addicted patients is getting increasingly important. As of au-
tumn 2009 API will organise a training course on nursing addicted patients, which includes 
the communication of basic knowhow on addiction as well as care interventions in cases of 
detoxification and withdrawal, basic principles for responses to addicted patients, orientation 
towards health and resources in addiction care and care services for patients suffering from 
borderline personality disorder and psychiatric comorbidity.40 In the last few years the CON-
TACT hospital connection service (Vienna) has also held further training programmes and 
individual talks for hospital staff in Vienna, which deal with the specific care situation of pa-
tients suffering from addiction (see GÖG/ÖBIG 2008c). 
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8 Social Correlates and Social Reintegration 
The main sources for this chapter are the nationwide documentation system of clients of 
Austrian drug help centres (DOKLI), annual reports of addiction help centres and similar insti-
tutions as well as information issued by the Addiction and Drug Coordinations in the prov-
inces.  
As in previous years, the most pressing social problems of drug users are homelessness, 
unemployment and debts; this is mainly true of severely addicted users in the street drug 
scene. 
Interventions for social (re-)integration of (former) drug addicts are directed at both clients af-
ter drug-free treatment and people who are currently using drugs. In Austria, interventions of 
this kind have traditionally been of major importance, especially in the areas of housing, work 
and (further) education and training. To some extent they are part of the chain of therapy and 
integrated in the corresponding treatment modules. The various interventions, some of them 
low-threshold in kind, are available after treatment or as a part of drug assistance. Creating 
networks of drug-specific organisations in order to provide better service to clients has be-
come more and more important. 
8.1 Social exclusion and drug use 
Among the clients of 2008 registered in the Austrian DOKLI system (see Chapter 5.3), the 
share of people with jobs continues to be smallest in the group undergoing inpatient treat-
ment (2008: 13%; 2007: 10%). Here, the percentage of persons who indicate that they are 
unemployed is also highest (2008: 44%; 2007: 49; 2006: 45%). Especially among clients of 
long-term outpatient care, the share of women who have jobs is significantly smaller com-
pared to men (28% of women and 36% of men). While smaller shares of women state that 
they are jobless, recipients of welfare assistance are found more often among women than 
among men (see Table A18 in Annex A). An average of 48% of clients of low-threshold cen-
tres whose data are covered by DOKLI said they had stable accommodation (2007: 51%), 
compared to approximately 90% out of the group of people receiving long-term services (see 
Table A20 in Annex A). Regarding educational level, around two thirds of clients of Austrian 
drug help centres aged 19 or older said that their highest degree was a compulsory school 
leaving certificate. Around one out of five women and one out of four men said they had 
completed an apprenticeship. However, the share of women is higher in the categories refer-
ring to completion of vocational intermediate secondary school as well as general education 
and vocational education upper secondary schools (GÖG/ÖBIG 2009a). 
The social situation of the clients of drug help services in Austria definitely continues to be 
worse than that of the general population (as to housing, education, employment and in-
come). However, it should by no means be concluded from this that drug problems arise 
mainly in the group of socially disadvantaged people. All it shows is that this group will more 
Chapter 8: Social Correlates and Social Reintegration 
 55
readily turn to the drug help service system than people who (still) have their own social and 
financial resources (see Chapter 5.3). 
The diploma thesis by Pajkovic (2008)41 provides information on drug use and persons at risk 
of using drugs in socially disadvantaged or excluded groups. It is shown that immigrants are 
facing major stress factors such as identity crises, limited participation rights and inferior 
conditions with regard to housing, work and education. Therefore especially teenagers and 
young adults are exposed to substantial risks with regard to drug use. At the drug help cen-
tres, there are specific barriers caused on the one hand by inhibitions on the part of the cli-
ents themselves, on the other by restricted accessibility on the part of the centres (see also 
Chapter 5.2).  
At the Vienna Job Exchange (WBB) a remarkable rise of active referrals by Public Employ-
ment Service counsellors was registered in 2008. Compared to 2007, also the number of 
young people counselled by the competent Public Employment Service unit has tripled (from 
slightly more than 40 to 138). With few exceptions, the main reason for counselling was drug 
problems. In this group the share of women was 58%, compared to a 27% share of women 
among all clients of WBB. Half of the clients had been unemployed for more than two years, 
and more than two thirds were counselled mainly because of drugs (Wiener BerufsBörse 
2009).  
8.2 Social reintegration 
In the context of training and employment, since the beginning of 2009 the Public Employ-
ment Service has facilitated access to socio-economic enterprises for people with addiction 
problems also if they are not long-term unemployed. Especially for clients undergoing inpa-
tient treatment this makes it easier to access the secondary labour market directly, with the 
aim of eventually achieving the transfer to the regular labour market (Sucht- und Dro-
genkoordination Wien 2009b). The possible (re-)integration into the job market has proven 
especially difficult for older drug users (see also Chapter 12.3). 
Since January 2008 an overall plan for the reintegration of persons with addiction problems 
has been implemented in Vienna, with the aim of providing demand-oriented care to problem 
drug users and to improve the cooperation between relevant actors. According to this plan, 
clients are referred to the Diagnoses Institute to have their (in)ability to work diagnosed. Cli-
ents are referred by the Labour Training and Rehabilitation Centre (BBRZ) as part of an EU-
supported project for the reintegration of drug patients into the job market. The diagnosing 
procedure of the clients concerned consists of several parts focusing on social work, psycho-
logical and specific medical aspects, which are combined in an addiction-related report and a 
recommendation regarding follow-up treatment.  
However, Spirig et al. (2009) state that many of the drug users concerned are not entitled to 
receive unemployment benefits because of repeated interruptions in their career or a non-
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existent employment record. This problem is further aggravated by Public Employment Ser-
vice policies with regard to assessing job fitness. In Austria the financial needs of (long-term) 
unemployed people are covered by unemployment benefits or unemployment assistance. As 
a precondition for being entitled to obtain unemployment benefits or long-term unemployment 
assistance, clients must be willing and able to work, i.e., they should be ‘at the disposition of 
the labour market’ and take on jobs that are regarded as acceptable. Spirig et al. (2009) have 
observed that at the Public Employment Service Vienna, drug users tend to be classified as 
unable to work. As a consequence they are excluded from unemployment benefits and can 
only obtain welfare assistance. In the case of older drug users, even if they receive welfare 
assistance it is not guaranteed that their needs are met (e.g. regarding full coverage of care 
services). 
In 2008 the socio-economic enterprise gabarage was able to initiate Corporate Social Re-
sponsibility (CSR) cooperation with major Austrian enterprises such as Fernwärme Wien, 
Fest, TILAK or Knauf. Between 2006 and 2008 revenues were increased by 66%, to EUR 
120 649, which clearly reflects the success of gabarage (Sucht- und Drogenkoordination 
Wien 2009b).  
As a result of continuous and excessive use of narcotic substances, cognitive capabilities are 
often impaired; therefore, the association Dialog (in Vienna) initiated cognitive training pro-
grammes. As a part of the project Standfest (steadfast, see GÖG/ÖBIG 2008c) Dialog organ-
ises a four-week social competence training programme with the aim of giving clients a daily 
structure and an opportunity to make contact in a group setting as an incentive to try some-
thing new. Especially the newly established and ongoing courses of memory training under 
the slogan Use it or lose it as well as the recreation group and the health group respond to 
actual needs (Dialog 2009). 
In Vorarlberg, Caritas runs the project Startbahn (Departure Gate) – a low-threshold pro-
gramme for young people between 15 and 25, in which 14 young clients can work as day la-
bourers and are paid a wage at the end of each working day. The high number of young 
people who are referred to trainee places, jobs in businesses and on the job training through 
this project is very promising. Also run by Caritas, the project Kompass provides coaching to 
people looking for work, with the aim of integrating them in the first labour market. In 2008, 
the project had 167 clients (Caritas Vorarlberg 2009). 
In Graz the project Offline, providing occupation for drug patients, was started in 2009. This 
project of the private foundation Santner Privatstiftung is run by Caritas of the diocese of 
Graz-Seckau on behalf of the foundation and provides individually designed, low-threshold 
work places for long-term unemployed drug patients. It aims at supporting clients to regain 
social competences that are of relevance in the labour market, such as reliability, punctuality, 
etc., as well as a sustainable stability of their condition. The project’s working hours take into 
account the drug use patterns of the participants, who must be legally employable and have 
at least a work permit. Clients of Aloisianum may participate following a phase of stabilisa-
tion, as well as clients of Kontaktladen and individuals with drug problems who, independent 
of these two centres, show interest in the project upon their own initiative (Caritas Diözese 
Graz-Seckau 2009).  
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In Lower Austria a joint project of the Addiction Coordination and the Public Employment 
Service of Lower Austria is being developed in order to improve the position of former drug 
patients in the labour market (Hörhan, personal communication). 
In 2008 the association Grüner Kreis started a new programme for training during treatment, 
providing training courses for future catering experts at the seminar hotel Grüner Kreis at 
Mönichkirchen. This is a well-established and recognised training course organised in coop-
eration of the association Grüner Kreis with the International College of Tourism and Man-
agement (ITM), the Hotel Management School Semmering and the Public Employment Ser-
vice of Lower Austria. The programme runs parallel to treatment and aims at providing job 
qualifications for the patients to increase their opportunities for re-entering the job market. In 
2008 nine clients completed the training course (Grüner Kreis 2009a). 
A catamnestic survey42 (among clients of 2007; see also Chapter 5.2) at the Carina therapy 
department showed that one year after completing treatment, 56% of the respondents said 
they held regular jobs. The employment quota before treatment had merely been 12%. There 
is a broad range of occupations, including positions that require qualification (Stiftung Maria 
Ebene 2009c). 
According to the DOKLI report (GÖG/ÖBIG 2009a) and as mentioned under 8.1, nearly half 
of the clients of low-threshold centres live in an unstable housing situation43, which gives 
housing programmes special significance. In Vienna, SDW and Wiener Wohnen GmbH 
have continued the liaison service Konnex. In autumn 2008 the services of Konnex were ex-
panded to the entire area of housing assistance for the homeless in Vienna by means of 
specific events and responses to individual requests. Following a positive evaluation of the 
performance of Konnex, the service started regular operation (Sucht- und Drogenkoordina-
tion Wien 2009a and 2009b; see also GÖG/ÖBIG 2008c).  
At Caritas in Vorarlberg, addiction-specific work and assistance to the homeless have been 
combined since 2008 in order to create a joint pool of ideas and efforts. According to statis-
tics of the emergency sleeping facility run by Caritas of Vorarlberg, a decline in the number of 
clients has been registered, which is attributed to the successful prevention approach fol-
lowed there. In many cases it was possible to secure sustainable housing by means of out-
patient assistance (Caritas Vorarlberg 2009). 
In Klagenfurt the emergency sleeping facility Eggerheim run by Caritas of Carinthia is avail-
able also for drug patients. In 2008, 14 clients slept there, the total number of overnight stays 
being 2 618. Another 7 clients, who were not able to live alone, stayed in the care unit all 
year round, spending a total of 2 562 nights. The facility was increasingly often frequented by 
young adults showing challenging behaviour and signs of neglect (Kärntner Caritasverband 
2009). 
                                                
42 The catamnestic interviews took place one year after the end of treatment, by means of phone calls. 25 out of 54 people who 
successfully completed treatment or discontinued treatment in 2007 were interviewed. 
43 On the other hand, in the group of persons receving long-term care 90% say that their housing situation is stable. However, 
when interpreting the statements about the housing situation, it should be noted that ‘stable’ does not necessarily mean that 
the housing situation involves no problems whatsoever (e.g., problems may exist if clients still live in their parents’ household 
for want of an alternative on account of their drug problems). 
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9 Drug-related Crime, Prevention of Drug-related 
Crime, and Prison 
The data for the present chapter were provided by the Federal Ministry of Justice and the 
court criminal statistics maintained by Statistics Austria. Other sources of information include 
a research project run by the Federal Ministry of Justice, on opioid substitution treatment in 
prison, the annual reports of drug help units and communications by the Addiction and Drug 
Coordination in the Provinces. Last year’s report (GÖG/ÖBIG 2008c) contains a detailed 
presentation of the amendment to the Narcotic Substances Act which entered into force on 
1 January 2008, and all the resulting changes.  
As explained in previous years and also stressed by the responsible Ministry of the Interior 
(BMI 2009), the data concerning reports of offences permit only limited conclusions regarding 
the development of illicit drug use and misuse, because they primarily reflect the intensity 
and focus of police measures in this field. 
In 2008 there was a marked decline in the number of reported violations of the Narcotic Sub-
stances Act (SMG) compared to the previous year. Regarding offences against the SMG, 
there was a strong decline of convictions based on misdemeanours (Section 27) compared 
to last year. The number of convictions for felonies (Section 28) is only slightly lower than in 
2007. In this context it should be noted that in the present report, the term felony is used for 
all violations of Section 28 and Section 28a of the SMG, whereas offences against Sec-
tion 27 of the SMG are referred to as misdemeanours. 
9.1 Drug-related crime 
In 2008, the number of reported violations of the Narcotic Substances Act (SMG) was 20 043 
(2007: 24.166; see also Table A4 in Annex A and ST11), which represents a major decline 
compared to the two previous years. A total of 19 080 reports related to narcotic drugs (2007: 
22 929), the rest to psychotropic substances. Regarding type of report (see Figure 9.1), there 
was a substantial decrease of reported violations in 2008 compared to 2007 regarding both 
misdemeanours (illicit handling of narcotic substances – Section 27 of the SMG) and felonies 
(preparation of trafficking – Section 28 of the SMG and trafficking – Section 28a of the SMG). 
This means that in the reporting year, the number of reported misdemeanours and felonies 
went down by approximately 20% compared to the previous year (see Chapter 1.1).  
In terms of substances involved (see Table A6 in Annex A and ST11), compared to the pre-
vious year there was a general decline in the number of reported violations, which was espe-
cially strong in the case of cannabis (see Figure 9.2). Detailed information on reported viola-
tions in the context of cannabis is presented in Chapter 11 of this report. 
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Figure 9.1: Development of reports of violation of the Narcotic Substances Act, by misdemeanours 
and felonies in Austria, 1998–2008 
 
Note: The difference to the total number of reports results from reports that are not assignable. 
Source: BMI/.BK, representation by GÖG/ÖBIG 
At provincial level, compared to the previous year the number of reported offences shows the 
same trend as the nationwide situation: in almost all provinces the number of reports regard-
ing almost all substances decreased in the reporting year. Exceptions are minor increases in 
Burgenland regarding cocaine, in Salzburg and the Tyrol in the context of psychotropic sub-
stances and in Vorarlberg regarding heroin and opiates (see Table A7 in Annex A).  
In 2008, a total of 20 043 reports led to 2 490 arrests (2007: 3 195) in connection with nar-
cotic drug investigations; however, regarding arrests no detailed information (type of offence, 
substances involved, etc.) can be given.  
According to BMI/.BK the decline in the number of reported violations referred to above is 
due to investigations of structures, which led to the targeted smashing of drug rings, with 
similar amounts seized as in the previous years and a simultaneous decrease in the number 
of seizures. One also has to bear in mind that part of the police force were assigned to tasks 
in the context of events of the European Football Championship 2008 that took place in Aus-
tria.  
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Figure 9.2: Development of reports of violation of the Narcotic Substances Act by type of substance, 
1999–2008 
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Source: BMI/.BK; representation by GÖG/ÖBIG 
Figure 9.3 below as well as Table A8 in Annex A with data provided by the court criminal sta-
tistics show the development of the number of convictions under Sections 27 and 28 of the 
Narcotic Substances Act over the past ten years. Compared to previous years a significant 
decline of the total number of convictions (n = 4 291) according to the SMG was registered in 
2008. The number of prison sentences without probation (n = 1 247) declined to a similar ex-
tent. The continued decrease in the total number of convictions relating to the SMG has re-
sulted in a decline of the share of these convictions in the total number of convictions in 
2008. While each of the offences have decreased in number, the share of misdemeanours 
(Section 27 of the SMG) continues to be much higher (2 899 cases) than that of felonies 
(Section 28 of the SMG, 1 332 cases). However, the share of felonies in the total number of 
convictions related to the SMG, which had been 26% in 2007, rose to 31% in 2008. 
Table A10 in Annex A gives an overview of convictions according to age and basis of convic-
tion. Here the comparison to 2007 shows a general downward trend of the numbers for 
young people and adults in 2008, in line with the development described above. However, 
more adults were punished with fines and prison sentences with probation in connection with 
felonies. The number of adults is also higher with regard to other forms of punishment in 
connection with misdemeanours. 
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Figure 9.3: Convictions according to Sections 27 and 28 of the Narcotic Substances Act in Austria, 
from 1999 to 2008 
Until 2007: Section 28 of the SMG = trafficking, possession, etc, of large quantities of narcotic drugs (commercial trafficking) 
Section 27 of the SMG = trafficking, possession, etc., of small quantities of narcotic drugs 
 
As of 2008: Section 27 of the SMG = illicit handling of narcotic drugs 
Section 28 of the SMG = preparation of trafficking of narcotic drugs  
Section 28a SMG = trafficking of narcotic drugs 
Note: These figures only refer to the leading offence, i.e., the offence with the highest range of punishment, therefore not  
all convictions under the SMG are covered.  
Source: Statistics Austria (court criminal statistics); representation by GÖG/ÖBIG 
71% of all convictions resulted in prison sentences (2007: 67%; 2006: 66%), with a share of 
prison sentences suspended on probation of 45% out of the total number of prison sentences 
(2007: 47%; 2006: 44%), which is a slight decrease compared to the previous year. The 
share of young people sentenced to imprisonment was 3.1% (2007: 3.4%), and for 2.1% the 
prison sentence was suspended on probation (2007: 2.2 %).  
Detailed statistical data on convictions in Austria were presented in Chapter 11 of last year’s 
report (GÖG/ÖBIG 2008c). A comparison of the development of reported offences, convic-
tions and implementation of alternatives to punishment as provided by law is included in 
Chapter 9.3 of the present report. 
As yet, neither data nor surveys on offences committed in connection with drug acquisition 
and related offences are available. 
9.2 Prevention of drug-related crime 
 
In addition to a number of individual initiatives in the context of prevention at the level of 
provinces and drug-help units, interventions for raising the general feeling of security and 
ease in the public sphere are gaining in importance. One example is the project SAM 9, 
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which was presented in detail in last year’s report and submitted to an external evaluation by 
Institut für Konfliktforschung (Conflict Research Institute), with positive results (see 
GÖG/ÖBIG 2008c). 
In connection with the redesign of Karlsplatz square in Vienna, scheduled for 2010, a work-
ing group for developing future perspectives and approaches to drug-related problems at 
Karlsplatz was established. Its task is to prepare proposals for improvement in the sense of 
taking the pressure off the public sphere at Karlsplatz and a better integration of the clients 
into the addiction and drug help system in Vienna (Sucht- und Drogenkoordination Wien 
2009b).  
In October 2008 the City of Vienna and Verein Wiener Sozialprojekte (Vienna Social Projects 
Association) issued an information leaflet for the promotion of peaceful co-existence in the 
public sphere. It is aimed at people who move in the public sphere frequently and are not 
quite sure what is permitted there and what is not. This may result in conflicts among differ-
ent population groups in the public sphere. The leaflet provides information on rights and du-
ties in the public sphere; it has been published in nine languages in addition to German; the 
title of the English version is "The Dos and Don’ts" / Guidelines for People in Public (VWS 
2009a). 
In autumn 2008 the European Centre for Social Welfare Policy and Research on behalf of 
the Vienna Addiction and Drug Coordination Unit launched a social research study on drug 
patients in the public sphere. It is designed to provide a well-based investigation of the ques-
tion whether drug patients who move in the public sphere have access to the Vienna addic-
tion and drug help system and whether it is necessary to devise new interventions in this 
context. The study is due to be completed in autumn 2009 (Sucht- und Drogenkoordination 
Wien 2009b). 
9.3 Interventions in the criminal justice system 
In Austria the application of alternatives to punishment, especially suspension of sentence in 
the context of the principle of Therapy Instead of Punishment, is regulated by law. 
Regarding implementation of the legal framework, information on the application of statutory 
alternatives to punishment is available (for more details see ÖBIG 2004). In addition to con-
victions (see Chapter 9.1), data regarding temporary (probationary) waivers of reports (Sec-
tion 35 of the SMG) and proceedings dismissed (Section 37 of the SMG) are presented in 
Figure 9.4 and in Table A10 in Annex A.  
As the figure shows there has been a decrease in the number of waivers of reports since 
2005 and of proceedings dismissed since 2006. Only for cannabis, following a decline be-
tween 2005 and 2007, the number of waivers of reports increased. Table A9 in Annex A con-
tains further information on final convictions according to the Austrian Narcotic Substances 
Act in 2008, based on type of conviction, gender and age group. 
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Figure.9.4: Development of statutory alternatives to punishment applied in Austria from 1999 to 2008 
 
 
 
Until 2007: Section 35 SMG = temporary waiving of reports by the public prosecutors 
Section 35 (4) SMG = temporary waiving of reports in the case of small quantities of cannabis for per-
sonal use 
Section 37 SMG = temporary dismissal of proceedings by the courts 
 
As of 2008: Section 35 SMG = temporary discontinuation of penal action by the public prosecutors  
Section 35 (4) SMG = temporary waiving of reports in the case of small quantities of cannabis for per-
sonal use 
Section 37 SMG = temporary dismissal of proceedings by the courts 
Note: Data on Section 39 SMG (suspension of sentence – therapy instead of punishment) are not available at pre-
sent. 
Source: BMG, representation and calculation by GÖG/ÖBIG 
There is still a lack of reliable data on suspension of sentences according to the Therapy In-
stead of Punishment model (Section 39 of the SMG). Such figures would represent an impor-
tant source of information on the actual implementation of the model.  
A comparison of trends regarding reports of offences, convictions and application of alterna-
tives to punishment shows interesting results. Based on an index taken as 100% in 1998, 
i.e., in the year when the SMG entered into force, Figure 9.5 reveals that in the period of 
analysis between 1999 and 2005 the shares of convictions went up most significantly. As of 
2007 reports and convictions declined to similar extents, contrasted by a slight rise in the im-
plementation of alternatives to punishment. 
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Figure 9.5: Comparison of index-related development of reported drug offences, convictions and 
application of statutory alternatives to punishment in Austria from 1999 to 2008 
 
Note: Calculations are based on the year 1998, when the Narcotic Drugs Act was replaced by the Narcotic Sub-
stances Act. 
Sources: BMI/.BK, Statistics Austria, BMGFJ, calculation and representation by GÖG/ÖBIG 
Since 2008 young people have had the option to take part in the project Walk About at the 
drug counselling centre Z6 in order to fulfil court conditions imposed. Walk About is a secon-
dary addiction prevention project for young people between 14 and 22 who already show no-
ticeable drug use habits. In the course of the project, an activity of at least three day duration 
is planned, realised and reflected with a group of four to six adolescents. This process makes 
it possible to build intensive contact to the young people concerned on a basis of trust, and to 
involve their circle of friends. The project promotes drug-free experience, alternative patterns 
of action, it reveals group processes and encourages self-perception, self-esteem and self-
reflection. The preconditions for taking part in the Walk About project, which is applied as an 
alternative to the usual health-related interventions, are a stable living situation and the vol-
untary decision of the client to opt for this kind of intervention. It is also necessary that clients 
are not addicted and psychologically healthy. The total duration of this health-related inter-
vention should be between four and six months, with at least five contacts (including the 3-
day activity referred to above; Kern, personal communication, Z6 2008).  
In the Festschrift celebrating its tenth anniversary, Schweizer Haus Hadersdorf reports that 
due to the policy of making opioid substitution treatment available also in inpatient settings, a 
great number of clients came to Schweizer Haus Hadersdorf upon a court order according to 
Section 39 of the SMG pertaining to the Therapy Instead of Punishment model. In this area 
drug especially patients are found who formerly had no possibility of inpatient opioid substitu-
tion treatment. Therefore, today more than three out of four patients have the costs of their 
treatment covered by the State (upon court order) (Schweizer Haus Hadersdorf 2009). 
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9.4 Drug use and problem drug use in prisons 
The existing information on drug use in prisons was presented in detail in the Key Issue 
chapter on drug use in prison in the 2001 report (ÖBIG 2001). Since then, no significant 
changes have taken place. 
9.5 Responses to drug-related health issues in prisons 
In Austria, interventions regarding drug-related health issues in prison include especially 
opioid substitution treatment, prisons with drug-free zones and, to a lesser extent, harm re-
duction activities. In the latter context, however, no specific measures regarding infectious 
diseases have been taken so far (see Chapter 6.1). 
A survey supervised by Gegenhuber et al. (2008)44 gives an overview of the Austrian penal 
system, after a project phase during which prisoners and staff of only three prisons in the Vi-
enna area were interviewed. The survey was aimed at investigating the effects of opioid sub-
stitution treatment on drug-addicted prisoners and on the prison as an administrative unit in 
the Austrian penal system, from the perspective of those concerned and involved. At the 
same time, the intention was to reveal common as well as differing aspects of opioid substi-
tution treatment in the participating prisons. 
Prisoners were interviewed in groups of ten to twelve; while they filled in anonymous ques-
tionnaires individually, the interviewer was available for questions that might come up. The 
criteria for inclusion of respondents in the survey were a minimum age of 18, serving a prison 
sentence or pre-trial imprisonment as well as participation in an opioid substitution treatment 
programme. A sufficient knowledge of German was also required. At the time of the inter-
views, 654 prisoners were undergoing opioid substitution treatment, 183 (28%) of whom par-
ticipated in the survey.  
The results of the study show great differences between staff and prisoners and between the 
participating prisons. Compared to staff, in most cases the prisoners definitely have a more 
positive view of the effects of opioid substitution treatment. In general, prisoners consider 
maintenance programmes to be an effective means to limit drug use and drug trafficking in 
prisons, as they reduce health risk factors related to injecting use or sharing of injection 
equipment. 
The staff members that were interviewed stated to have registered noticeable changes re-
garding auto-aggressive behaviour and an improvement of the physical and psychological 
condition of the prisoners. Slightly more than one fifth of the interviewed staff said that their 
general working situation had improved since opioid substitution treatment had been intro-
duced. 
One of the remarkable aspects of the survey is the high share of prisoners sentenced to a 
period of more than ten years (more than one out of five respondents). The total share of in-
jecting use that was indicated was almost 90%, which is extraordinarily high. One fourth of 
                                                
44
 Following a research project that took place between 2005 and 2007 at European level, on behalf of the Federal Ministry of 
Justice (BMJ) 123 prison staff (about one third of which were women) and 183 male prisoners were interviewed between 
November 2007 and January 2008 (Gegenhuber et al. 2008).  
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the respondents started opioid substitution treatment during their present term of imprison-
ment; more than three out of four respondents state that access to such treatment had been 
easy. However, they said that when they were last undergoing substitution treatment before 
their imprisonment they had had more influence on the choice of substance than in prison 
(84% vs. 44%). 
Differences between prisons were noticed mainly regarding two issues. One the one hand, 
the choice of substitution substance is regulated differently in the participating prisons, which 
may lead to problems if prisoners are transferred to another prison. At the time of the survey, 
methadone was used in all participating prisons, while buprenorphine was administered addi-
tionally in eleven out of sixteen prisons and slow-release morphines in thirteen prisons. 
Three prisons used methadone only. On the other hand, the possibilities of taking up an oc-
cupation while in prison differed greatly, as prisoners undergoing substitution treatment in 
some cases are excluded from certain activities. 
A general overview of opioid substitution treatment in prisons is provided by a statistical sur-
vey by the BMJ, according to which in 2007, 772 prisoners in Austrian prisons were undergo-
ing opioid substitution treatment. Based on an estimated total number of 9 000 prisoners in 
Austria, this is a share of 8.6% (Kahl, personal communication). 
Drug-free zones have existed in Austrian prisons since 1995 and have continuously been 
expanded (ÖBIG 1997). The treatment of drug-addicted prisoners is also highlighted in a 
publication by the Federal Ministry of Justice, which is outlined in greater detail in the report 
of 2005 (ÖBIG 2005). 
SQ 23/29 contains further information regarding drug-related harm reduction and prevention, 
treatment of patients with infectious diseases in prison and prevention of overdosing after re-
lease from prison, which, however, is hardly pursued at present, if at all. Large-scale HCV 
tests are conducted among prisoners starting their imprisonment period, whereas individual 
counselling regarding infectious diseases in prison only takes place to a limited extent. The 
same applies to practical advice and training in connection with safer use. In Austria there 
are no syringe exchange programmes in prisons. Nevertheless training programmes for 
health promotion with regard to syringe exchange are run for the prison staff. There is no in-
formation material available on how to respond to drug-related emergencies in prisons. At 
the time of release from prison, HCV tests are carried out only very rarely.  
The fourth European conference on health promotion in prisons, which took place in April 
2009 in Vienna, focused on promotion and maintenance of health for prisoners as well as 
staff (Gesundheitsförderung in Haft 2009). 
In Graz clients of Kontaktladen continue to be counselled also in case of imprisonment; spe-
cial attention is attributed to the issue of health promotion in prison. A booklet on this subject 
(Haftinfos des Kontaktladens; see GÖG/ÖBIG 2008c) was presented to the public on the oc-
casion of a theme-specific event in 2009. The event was aimed at creating a basis of com-
munication between all relevant stakeholders in order to develop interventions in the sense 
of health promotion in prisons for the benefit of drug users and also for staff, based on a 
broad consensus (Kontaktladen 2009). 
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9.6 Reintegration of drug users after release from prison 
There is no information available that relates specifically to the reintegration of drug users af-
ter release from prison. Most reintegration measures for drug users are also open to former 
prisoners. 
 
  68
10 Drug markets 
The substance most frequently seized in Austria is cannabis, followed by cocaine and heroin. 
However, quantities seized are no valid indicators of the availability of a substance in Austria, 
as Austria often is not the final destination of these drugs but a transit country, and because 
these figures also reflect the intensity of police activities. Regarding potency and concentra-
tion of the substances available in Austria, experience of recent years has shown consider-
able variations. This applies to both substances used by the traditional street scene (opioids 
and cocaine) and also new synthetic drugs (ecstasy and amphetamines). The fact that actual 
ingredients and potency are often unknown constitutes a considerable risk factor for drug us-
ers.  
Information about the availability of illicit drugs can be derived from some questions of the 
ESPAD surveys (Strizek et al. 2009, under preparation) and the General Population Survey 
2008 (Uhl et al. 2009, under preparation) (see Chapter 2.1). Data on seizures referenced in 
this chapter were provided by the Federal Ministry of the Interior / Federal Criminal Agency 
(BMI/.BK), the data on price and purity were collected by ChEck iT! and BMI/.BK. 
10.1 Availability and supply 
Table 10.1 gives details on the responses to the question of the ESPAD survey on how diffi-
cult it would be for the respondents to have access to various enumerated legal and illicit 
substances if they wanted them. While 80% of the young people found it rather easy or very 
easy to get alcohol (wine/sparkling wine: 80%, hard liquor: 56%), the corresponding share for 
illicit drugs is slightly over one third (35 %) in the case of cannabis. Both ecstasy and am-
phetamines were considered to be available rather easily or very easily by 20% (Strizek et al. 
2009, under preparation).  
Table 10.1: Assessment of the difficulty to have access to various psychoactive substances  
Difficulty to have 
access to the 
substance in 
question 
Substance 
Cannabis Ecstasy Ampheta-mines 
Tranquillisers/ 
sedatives Cigarettes
Wine/ 
Sparkling 
wine 
Hard liquor 
impossible 17 % 28 % 23 % 28 % 2 % 3 % 6 % 
very difficult 13 % 18 % 17 % 20 % 2 % 2 % 10 % 
rather difficult 15 % 14 % 16 % 16 % 3 % 8 % 19 % 
rather easy 24 % 13 % 16 % 10 % 28 % 26 % 30 % 
very easy 11 % 8 % 8 % 4 % 57 % 54 % 26 % 
don’t know 21 % 20 % 20 % 23 % 9 % 7 % 10 % 
Source: Strizek et al. 2009, under preparation; representation by GÖG/ÖBIG 
According to the results of the general population survey of 2008 (Uhl et al. 2009, under 
preparation) 2.7% of the Austrian population was unexpectedly offered illicit drugs for free by 
strangers. 4.5% stated that they had been unexpectedly offered drugs for free by acquaint-
ances. Regarding unexpected offers to purchase drugs, the figures are 3.7% (strangers) and 
2.3% (acquaintances). Austria does not play a significant role as a country where illicit drugs
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 are produced. While cocaine reaches Austria primarily by air and by sea from South Amer-
ica, for heroin the route over the Balkans (Turkey, Bulgaria, Serbia, Croatia, Slovenia, Aus-
tria) is the dominant trafficking route. Cannabis products are imported from various countries 
and regions such as the Netherlands, the Balkan countries and Morocco; and to a small, but 
increasing extent, they are home grown in Austria. Amphetamines and derivatives are mainly 
imported from the Netherlands (BMI 2009). 
10.2 Seizures 
According to the Federal Ministry of the Interior (BMI) in 2008 the number of seizures slightly 
decreased for all drugs compared to the previous year (see Figure 10.1 and Table A12 in 
Annex A). The BMI also states that the decline in the number of reported violations of the 
Narcotic Substances Act in 2008 does not reflect a reversed trend in the area of drug-related 
offences, but is rather rooted in the focus of police activities, which was mainly on investiga-
tions of structures (see Chapter 9.1). 
Figure 10.1: Number of seizures of narcotic drugs in Austria, 1999–2008 
 
 
 
Source: BMI/.BK 2009, representation by GÖG/ÖBIG  
Compared to the total number of reports to the police there was no significant change in the 
amounts of narcotic substances seized (see Table A13 in Annex A and ST13). At the BMI 
registry for precursor substances, 247 investigated cases were reported; in the course of 12 
seizures, 22 kilograms of precursor substances were seized. In 2008 three small drug labo-
ratories were dismantled in Austria, all of which were kitchen laboratories used by the opera-
tors to produce methamphetamine for their own use. 
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10.3 Price/purity 
In the context of the ChEck iT! project (see Chapter 2.3), which tests the purity and ingredi-
ents of substances bought as ecstasy or speed during events of the party and clubbing 
scene, in 2008, 146 samples bought as ecstasy (pills) and 99 samples purchased under the 
name of speed were analysed during a total of seven music events (goa, techno, electronic) 
in the provinces of Burgenland, Lower Austria and Vienna (VWS 2009a).  
The percentage of pills bought as ecstasy that did not contain psychotropic substances other 
than MDMA, MDE or MDA was 63%, which is approximately at the level of the previous year 
and lower than the years before that (70% to 90%). In more than one fourth of the cases 
(26%) users had to be warned urgently not to take the pills they had bought under the name 
of ecstasy, the main reason being that MDMA had been replaced by non-controlled ben-
zylpiperazine derivatives, as had already been the case the year before. 26 of the tested pills 
(17%) contained meta-chlorophenylpiperazine (mCPP). Compared to MDMA, mCPP has a 
reduced psychoactive effect, but causes rather unpleasant side-effects such as headaches, 
nausea, kidney pain, nervousness, heavy breathing, fatigue and a hangover of several days. 
In addition, simultaneous use of MDMA may lead to convulsion. In 15 of the 26 pills contain-
ing mCPP, also metoclopramide was found, an anti-emetic (agent used to treat nausea and 
vomiting), which supposedly was added to suppress side-effects of mCPP such as nausea. 
Metoclopramide may interact with many substances and in some cases accelerate their ef-
fects, while it slows down the users’ reactions. Again, in 2008 the pharmaceutical buflomedil 
was detected in pills sold as ecstasy. This substance is used for the treatment of peripheral 
vascular disorders (VWS 2009a; see also GÖG/ÖBIG 2008). 
In July 2009 ecstasy pills containing PMA were detected for the first time since 2001. Com-
pared to MDMA, PMA (para-methoxyamphetamine) has a retarded effect, which entails the 
danger that more pills are used in order to achieve the desired effect. The resulting accumu-
lation of the active ingredient may lead to death. The Austrian nationwide information and 
early warning system located at GÖG/ÖBIG informed all relevant organisations, hospitals 
and experts of this problem. The early warning system of the EMCDDA issued the warning 
all over Europe. A warning was also broadcasted by the Austrian radio and television net-
work and published in numerous print media.  
A mere 15% of the substances bought as speed and analysed by ChEck iT! contained am-
phetamine only, whereas 27% was a mixture of amphetamine and caffeine and in 36% of the 
cases, amphetamine was mixed with other pharmacologically active substances (see Tables 
A14 and A15 in Annex A and ST15). 11% of these samples were classified as posing a seri-
ous threat to health (VWS 2009a). 
Autumn 2008 saw a public discussion about reports of a sudden rise in the use of an incense 
blend under the name of Spice that was legally available at that time. According to instruc-
tions on the packages the various Spice products were intended for use as fragrant incense 
for air freshening in rooms and by no means for smoking. However, the psychoactive effect 
of smoking this blend was propagated over the internet. At first, experts had no explanation 
for the effects of the Spice products, which users described as similar to cannabis. By the 
end of 2008 and beginning of 2009, several cannabinomimetic ingredients (CP-47,497, JWH-
018, HU-210) had eventually been detected in Spice products (see Chapter 2.1). 
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In spring 2009 several adolescents had to be taken to hospital after using gamma-
butyrolactone (GBL). According to information by the emergency department of the General 
Hospital Vienna, incidents involving GBL have repeatedly been registered in Vienna 
(Frossard, personal communication). Following the prohibition of gamma-hydroxybutyric acid 
(GHB) users have purchased GBL instead, which is legally available, e.g., as a wheel rim 
cleaner for cars. 
Information by the Ministry of the Interior on the purity and prices of various drugs sold at 
street level is given in Table 10.2 (see also ST14 and ST16). As in previous years, a consid-
erable variation of the potency of drugs sold at street level was noted. The data referring to 
ecstasy, amphetamines and cocaine are generally consistent with the figures registered by 
ChEck iT! (Nagy, personal communication). 
Table 10.2: Purity and price (EUR per gram*/pill**) of various drugs sold in the street in 2008 
  Herbal cannabis * 
Cannabis
resin* 
Brown 
heroin* 
White 
heroin* Cocaine* 
Ampheta-
mines* Ecstasy** LSD** 
Pu
rit
y 
Minimum 0.04 % 0.5 % 0.1 % – 0.7 % 0.5 % 3.5 % – 
Maximum 50 % 47 % 71 % – 96 % 66 % 100 % – 
Typical 7 % 8 % 9 % – 27 % 5 % 28 % – 
Pr
ic
e 
Minimum 9 8 60 – 60 15 5 30 
Maximum 10 10 80 – 90 20 10 35 
Typical 10 9 80 – 70 20 10 30 
Note: These data are based on information by undercover police agents. For the individual drugs, between 40 and 368 purity 
analyses were carried out.  
Source: BMI/.BK, representation by GÖG/ÖBIG 
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11 Cannabis markets and production 
In Austria, cannabis is the illicit substance that is most frequently used. This chapter, based 
on available data of the Federal Criminal Agency at the Federal Ministry of the Interior 
(BMI/.BK), gives an overview of cannabis production and cannabis markets in Austria. The 
Federal Ministry of the Interior (BMI) communicated the respective figures to GÖG/ÖBIG; 
most of these figures can also be found in the annual reports on drug-related crime issued by 
the BMI. 
11.1 Markets 
Scientific reports on medical (self-)experimentation with cannabis go back as far as the mid 
19th century (e.g., Schroff 1857). There are a few historical reports that mention cannabis 
cultivation and use in Austria, but production has not played a significant role in Austria at 
least as of the early 20th century (Springer, personal communication). Under Sections 27, 28 
and 28a of the Narcotic Substances Act (SMG) it is forbidden in Austria to grow cannabis 
plants for the purpose of obtaining narcotic drugs. The sale of young cannabis plants that do 
not yet contain THC (cuttings) and also of seeds may be classified as aiding and abetting a 
criminal act (i.e., the production of a narcotic drug) or as an attempt to commit an offence, 
which is punishable according to Sections 12 or 15, respectively, of the Criminal Code (BGBl 
1974/60). As of 2009, under an amendment to the SMG (BGBl I 2008/143) the Austrian 
Agency for Health and Food Safety (AGES), or a subsidiary company founded for this pur-
pose, has been permitted to grow cannabis plants in order to obtain pharmaceuticals as well 
as for scientific purposes related to this field (see Chapter 1.1.) 
There are grow shops that sell both cannabis plants and any equipment needed for growing 
cannabis. At present, only few grow are shops left where seeds and/or cuttings may be ob-
tained. The typical range of products of grow shops includes equipment for growing and 
smoking cannabis and, in most cases, a great variety of legal ethnobotanical products, 
mostly psychoactive plants or plant products from all over the world. In 2005 approximately 
60 grow shops existed in Austria, and as many as 20 of them in Vienna (BMI 2006); more re-
cent figures are not available, but the number of shops is not likely to have changed signifi-
cantly. 
In the past, cannabis was usually imported to Austria, but according to the Federal Criminal 
Agency at the Federal Ministry of the Interior (BMI/.BK) in recent years a rise in cannabis 
production in Austria, by means of indoor and outdoor cultivation, has been registered, with a 
yield of good quality. The cannabis produced in this way is not only used by the growers 
themselves and their friends but increasingly often it is also sold for profit. In 2008, illicit pro-
fessional indoor cultivation was practiced not only by Austrian nationals but also nationals of 
a number of foreign countries. However, according to BMI/.BK, the scope of cannabis pro-
duction in Austria still is insignificant compared to other countries. The figures on cannabis 
seizures by the police indicate that greater amounts of herbal cannabis than resin are pro-
duced and brought into circulation in Austria. No conclusive figures on market shares of indi-
vidual products are available for Austria, however. Although several seizures of  
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cannabis revealed with very high THC contents, according to BMI/.BK, sinsemilla, i.e., spe-
cially grown unpollinated buds of female plants with above-average THC contents, does not 
play a relevant role in Austria. 
Data by BMI/.BK indicate that organised groups manage the import and eventually the street 
sale of cannabis products in Austria. Cannabis is primarily imported from the Netherlands, 
the Balkan countries, the Schengen Area, Morocco and Switzerland. Austria also is of grow-
ing relevance as a country of transit for cannabis products from the Far East (India, Nepal) to 
Western Europe. According to BMI/.BK, cannabis products are sold all over Austria, but es-
pecially in and around cities in both public places or streets and bars known as places of 
drug dealing. In addition to Austrian dealers, also groups of dealers composed of third-
generation ethnic Turks or Yugoslavs of Austrian nationality, citizens of the countries of for-
mer Yugoslavia, west African states and – in particular in the areas of Innsbruck, Graz and 
Vienna – organised north African groups are involved in cannabis trade. While some dealers 
or groups seem to specialise in cannabis, other dealers or groups also sell other substances. 
Regarding market shares of the individual groups, no information is available. It is not known 
to which extent the cannabis used in Austria is self-grown or shared among friends or 
bought. Obviously, the quantities of cannabis purchased strongly differ according to individ-
ual user. 
Tables 11.1 and 11.2 give wholesale and street prices of herbal cannabis and resin. In sum, 
the prices of cannabis products seem to have risen in the last few years. The data on prices 
are based on undercover investigations by the police, i.e. they reflect the prices for which 
dealers offered cannabis to undercover police agents. In the past, these prices were gath-
ered every three months, and now once or twice a year, by the Drug Crime Office of the 
Federal Criminal Agency. Police reports on drug offences and routine surveys are additional 
helpful data sources. 
Table 11.1: Wholesale prices of cannabis products; comparison 2004–2008 (prices in euro per kg) 
Product 2004 2005 2006 2007 2008 
Cannabis resin  2 000–2 500  2 000–2 500  1 500–2 500  2 000–3 500  3 500–4 500 
Herbal cannabis  700–1 000  700–1 000  700–1 000  2 500–3 500  4 000–5 000 
Herbal cannabis produced in the EU  300–600  300–600  300–600  2 500–3 500  4 000–6 000 
Source: BMI/.BK, representation by GÖG/ÖBIG 
Table 11.2: Street prices of cannabis products; comparison 2004–2008 (prices in euros per g) 
Product 2004 2005 2006 2007 2008 
Cannabis resin  7–8  7–8  6– 8  8–10  8–10 
Herbal cannabis  3–4  3–4  3 –4  9–10  9–10 
Herbal cannabis produced in the EU  3–4  3–4  3–4  9–10  9–10 
Source: BMI/.BK, representation by GÖG/ÖBIG 
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11.2 Seizures 
According to information by BMI/.BK, drug offences are prosecuted in Austria independent of 
the type of substance involved. The corresponding activities aimed at supply reduction con-
centrate on combating street crime on the one hand and investigations of structures on the 
other. In addition, a number of focal areas have been defined: enhancement of international 
cooperation (partnerships for security), participation in international projects (e.g., through In-
terpol and Europol), intensified use of criminal analysis, national and international coopera-
tion with justice and customs authorities, prevention, increased skimming off of profits gained 
from offences, strategies against money laundering and nationwide surveillance of trade in 
drug precursor substances in the context of the Drug Precursor Reporting Agency. 
Figures 11.1 and 11.2 give the numbers, types and quantities of cannabis products seized 
between 2005 and 2008. As mentioned in Chapter 11.1, the majority of seizures concerns 
herbal cannabis, although pronounced variations show depending on the year of observa-
tion. 
Figure 11.1: Number of seizures of cannabis products from 2005 to 2008 
Source: BMI/.BK 2008; representation by GÖG/ÖBIG 
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Figure 11.2: Seizures of cannabis products from 2005 to 2008; grams 
 
Note: In correspondence with the United Nations Office on Drugs and Crime (UNODC), quantities are given in grams 
 
Source: BMI/.BK 2008; representation by GÖG/ÖBIG 
Table 11.3 gives seizures in 2008 by number of cases, type of cannabis and weight. What 
deserves mention is that 92% of seizures of herbal cannabis, and 97% of seizures of resin, 
concern weights between 0 and 150 grams. In terms of absolute quantities, 70% of resin sei-
zures and 65% of herb seizures related to quantities under 5 grams. These figures indicate 
that the majority of cannabis seized was intended for personal use. Correspondingly, the sta-
tistics on police reports described in Chapter 11.3 show a similar picture: 92% of reports re-
lating to cannabis were made because of violations of Section 27 of the SMG, which regu-
lates illicit handling of drugs but not large-scale, professional trafficking. 
Table 11.3: Seizures of cannabis products in 2008 
  Herbal cannabis Cannabis resin Cannabis plants Concentrated cannabis 
Weight Number of cases Number of cases Number of cases Number of cases 
0–150 g 3 145 (92%) 1 363 (97%) 132 (57%) 8 (100%) 
150g–1 kg 183 (5%) 28 (2%) 59 (26%) 0 
1 kg–50 kg 82 (2%) 19 (1%) 39 (17%) 0 
> 50 kg 0 (0%) 0 (0%) 0 (0%) 0 
Total 3 410 (100%) 1 410 (100%) 230 (100%) 8 (100%) 
Source: BMI/.BK 2008; representation by GÖG/ÖBIG 
A list compiled by BMI/.BK (see Table 11.4) gives the presumed countries of origin of the 
cannabis products seized, the last country of transit before the products entered Austria and 
the countries that were supposed to be the planned destinations. A breakdown by percent-
ages is not available, however. As described in Chapter 11.1 and illustrated in the corre-
sponding table, Austria has meanwhile also become relevant as a country of origin of herbal 
cannabis. An overview of available information on the organisational structures of interna-
tional trade to and through Austria is also given in Chapter 11.1. 
0
200.000
400.000
600.000
800.000
1.000.000
1.200.000
1.400.000
1.600.000
2005 2006 2007 2008
Se
iz
ur
es
 o
f C
an
na
bi
s p
ro
du
ct
s (
gr
am
s)
Year
Herbal cannabis Resin Concentrated cannabis Cannabis plants
Chapter 11: Cannabis markets and production 
79 
Below, seizures of cannabis grown in Austria are discussed in more detail. In 2006, a total of 
236 kg of cannabis plants were seized in Austria in the context of 204 police raids. 2007 saw 
seizures of 224 kg at 200 raids, and 2008, 178 kg at 230 raids (see Figures 11.1 and 11.2). 
As there are no international guidelines that define, for instance, what size a patch where 
cannabis is cultivated must have to be regarded as a plantation, no official statistics on the 
number of plantations or indoor and outdoor growing exist. The corresponding figures have 
been registered by BMI/.BK but they are not published as no comparison at international 
level can be made. The annual report of BMI/.BK (2007) provides some information; e.g., an 
indoor plantation of a size of 4000 m² was detected in Upper Austria and 4 500 cannabis 
plants were seized. In Vienna, an indoor cannabis cultivation area of 450 m² was found and 
239 kg of cannabis plants was seized, and in Lower Austria an outdoor area with 102 kg of 
cannabis plants was detected. However, if one adds the weight of the cannabis plants ob-
tained at these large seizures it shows that this figure is higher than the aforementioned total 
number of 224 kg of cannabis plants found in 200 seizures. According to BMI/.BK this results 
from a problem of registration: because there are no guidelines that specify when the plants 
have to be weighed and whether plant parts that have already been dried are to be entered 
as plants or as herbal cannabis, therefore these large seizures are not directly reflected in 
the statistics of BMI/.BK but as entries in the categories of plants and herbal cannabis 
(Mader, personal communication). 
  
Table 11.4: Origin of cannabis products seized from 2004 to 2008 
    2004     2005     2006     2007     2008   
  
Presumed 
country of 
origin 
Last country 
of transit 
Presumed 
country of 
destination 
Presumed 
country of 
origin 
Last country 
of transit 
Presumed 
country of 
destination 
Presumed 
country of 
origin 
Last country 
of transit 
Presumed 
country of 
destination 
Presumed 
country of 
origin 
Last 
country 
of transit
Presumed 
country of 
destination 
Presumed 
country of 
origin 
Last 
country of 
transit 
Presumed 
country of 
destination 
Herbal Albania Croatia Austria Albania Croatia Austria Albania Croatia Austria Austria Croatia Austria Austria Germany Austria 
cannabis 
Bosnia and 
Herzegovina Germany Germany 
Bosnia and 
Herzegovina Germany Germany 
Bosnia and 
Herzegovina Germany Germany 
Bosnia and 
Herzegovina Slovenia Germany Netherlands     
  Bulgaria Hungary  Italy Bulgaria Hungary Italy Bulgaria Hungary Italy Switzerland     Switzerland     
  Germany Netherlands Switzerland Croatia Netherlands Switzerland Croatia Netherlands Switzerland            
  Croatia Slovenia   Germany Slovenia   Germany Slovenia               
  Netherlands     Netherlands     Netherlands                 
  Switzerland     Switzerland     Switzerland                 
  Spain     
Serbia and 
Montenegro     
Serbia and 
Montenegro                 
  
former  
Yugoslavia     Spain     Spain                 
Resin 
Bosnia and 
Herzegovina Croatia Austria 
Bosnia and 
Herzegovina Croatia Austria 
Bosnia and 
Herzegovina Croatia Austria Morocco Belgium Austria India France Austria 
  Germany France Czech Rep. Germany Germany Czech R. Germany Germany Czech Rep. Nepal France Germany Morocco Spain Germany 
  Morocco Germany Germany Morocco Hungary Germany Morocco Hungary Germany   UK Italy     Italy 
  Nepal Slovenia Italy Nepal Netherlands Italy Nepal Netherlands Italy     Switzerland       
  Netherlands   Switzerland Netherlands Slovenia Switzerland Netherlands Slovenia Switzerland             
  Switzerland     Switzerland     Switzerland                 
  Spain     
Serbia and 
Montenegro     
Serbia and 
Montenegro                 
  
former  
Yugoslavia     Spain     Spain                 
 
Source: BMI/.BK 2008, representation by GÖG/ÖBIG 
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11.3 Offences 
In the provisions of the Narcotic Substances Act (SMG) the offences of purchase, posses-
sion, production, transport, import, export, passing on and making available to others of nar-
cotic substances are not listed in separate sections but are covered by one single section. 
Consequently, the statistics on police reports and on convictions are organised according to 
section, and a breakdown by production, trafficking and retail dealing cannot be made. The 
table below only covers Austria’s statistics on police reports because this permits a break-
down by substance and thus data on offences related to cannabis are available (see Table 
11.5). 
The decline in reports in 2008 compared to 2006 and 2007 does not necessarily mean that 
trafficking or use of cannabis has gone down, however (see Chapter 9.1). 
Table 11.5: Reports relating to Sections 27–29 from 2006 to 2008 
Year Product Sect. 27 SMG Sect. 28 SMG Sect. 28a SMG Sect. 29 SMG TOTAL
2006 Herbal cannabis 11 565 1 226  0 12 791
 Resin 5 281 632  0 5 913
 Concentrated cannabis 7 9  0 16
 Cannabis plants 218 83  0 301
 2006 Cannabis total 17 071 1 950  0 19 021
2007 Herbal cannabis 12 271 1 181  0 13 452
 Resin 4 708 575  1 5 284
 Concentrated cannabis 20 7  0 27
 Cannabis plants 230 70  0 300
 2007 Cannabis total 17 229 1 833  1 19 063
2008 Herbal cannabis 10 014 276 530   10 820
 Resin 3 497 109 264   3 870
  Concentrated cannabis 16 2 5   23
  Cannabis plants 275 44 31   350
  2008 Cannabis total 13 802 431 830   15 063
2006 and 2007:  
Section 27 SMG = trafficking, possession, etc., of small quantities of narcotic drugs 
Section 28 SMG = trafficking, possession, etc., of large quantities of narcotic drugs 
Section 29 SMG = public propaganda for drug abuse 
As of 2008: 
Section 28 SMG = preparation of narcotic drug trafficking  
Section 28a SMG = narcotic drug trafficking 
Source: BMI/.BK 2008; representation by GÖG/ÖBIG 
If the reports are studied with regard to shares accounted for by the individual SMG sections 
(Figure 11.3) it shows that, as described in the previous chapter, in 2008 the majority of re-
ports relating to cannabis concerned violations of Section 27 of the SMG (illegal handling of 
drugs) and only a small part concerned Section 28 (preparation for drug trafficking) or Sec-
tion 28a (drug trafficking) of the SMG. This means that in terms of quantities, it is primarily 
cannabis users who are apprehended and reported. 
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Figure 11.3: Distribution of reports relating to cannabis by section of the Narcotic Substances Act 
(SMG), in 2008 (n = 15 063) 
 
 
Source: BMI/.BK 2008; representation by GÖG/ÖBIG 
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12 Treatment and Care for Older Drug Users 
In the context of the following chapter, older drug users are defined as persons aged 40 
years and older who use at least one illicit substance. The presented results are based on 
data provided by the uniform reporting system on clients of drug help services (DOKLI), data 
on opioid substitution treatment and drug-related deaths as well as findings of the EU project 
SDD-Care (Senior Drug Dependents and Care Structures) referring to the situation in Aus-
tria; the analysis focuses on opioid users. Wherever the size of the available sample allows, 
a distinction is made according to age groups of 39 or younger, between 40 and 49, between 
50 and 59, and 60 and older. The focus of data interpretation is on the comparison of users 
older than 40 with users younger than 40. It should be noted that the share of drug users 
over 60 is very low, so that any data for this age group can only be interpreted with great 
caution. 
In Austria drug use as a modern phenomenon started in the mid-1960s. Under the assump-
tion that problem drug use begins at age 18, the first generation of drug patients are those 
born between 1952 and 1957 (see GÖG/ÖBIG 2009a). 
12.1 Age trends in drug users in and out of treatment 
There are several indications of a rising trend in the number of older drug users in Austria. 
Looking at data from the national substitution register, the number of drug users in substitu-
tion treatment aged 40 and older is observed to have doubled over the past few years (see 
Table 12.1, Chapter 5.3).  
Table 12.1: Number of persons in opioid substitution treatment as reported to the Ministry of Health 
between 2001 and 2008, by age group 
Year 
Age (years) 
39 and younger  40–49 50–59 60+ 
% %* % %* % %* % % * 
2001 77.3 81.5 21.0 17.0 1.7 1.4 0.1 0.0 
2002 75.1 80.0 22.9 18.3 1.9 1.6 0.1 0.1 
2003 73.3 79.0 23.9 18.8 2.6 2.0 0.2 0.2 
2004 71.2 77.6 25.1 19.7 3.5 2.5 0.2 0.2 
2005 70.3 77.4 25.3 19.4 4.1 2.9 0.2 0.2 
2006 70.1 77.6 24.6 18.9 5.0 3.4 0.2 0.2 
2007 71.3 78.0 22.9 17.9 5.5 3.9 0.3 0.2 
2008 70.8 78.3 22.4 17.1 6.4 4.4 0.3 0.2 
* after ghost-case corrections  
Source: BMG; calculations and representation by GÖG/ÖBIG 
For example, in 2001, 47 clients aged between 50 and 59 were undergoing opioid substitu-
tion treatment (taking into account ghost-case corrections – for a definition see GÖG/ÖBIG 
2008c, GÖG/ÖBIG 2009, under preparation), and by 2008 the number of clients in this age 
category had risen to 314. However, it should be noted that the available data are incomplete 
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and can therefore be used for an assessment of the age development of drug users to a 
rather limited extent only (GÖG/ÖBIG 2006 und 2007b). 
As to directly drug-related deaths the share of drug users aged 40 and older was 7.3% in 
1995 (ÖBIG 2005), it rose over the following years and reached 17.4% in 2000. By 2007 the 
number of deaths in this age group had fallen again, to 14.3%. No assessment of future 
trends can be made at this point (see Chapter 6.3). 
In their survey included in the SDD-Care project, Eisenbach-Stangl and Reidl (2009) 
come to the conclusion that the number of older drug users will rise (their focus is on users 
aged 35 and older). Age-stratified analyses based on prevalence estimates have shown that 
problem drug use including opioids has increased in this age group (2001: 28%; 2007: 33%). 
At CONTACT (Vienna) the number of clients aged 40 and older rose continually over the 
past few years. Until 2002 the number of older drug users had remained at 10% over a long 
period, but in recent years, the number of clients in this age group has increased to 28% in 
2008 (Sucht- und Drogenkoordination Wien 2009b). Organisations in the drug help sys-
tem of other provinces have also reported a rise in clients over 40 years of age (Dro-
genkoordination des Landes Salzburg 2009, B.I.T. 2008). 
Individual surveys conducted at national level enumerate the relevant factors regarding the 
rising number of older drug users but give no detailed analysis of the situation. Attention is 
drawn to the fact that ageing plays a key role in present society (strong effects of the baby-
boomer generation born between 1946 and 1964). In addition, services by the drug help sys-
tem and opioid substitution treatment programmes contribute to the rising number of older 
drug users that has been registered. Regarding age structure of drug users, a number of 
contextual factors should be taken into account, such as the historical development of drug 
use in a country. Other factors are differences in mobility which are influenced by patterns of 
use, or the accessibility of the drug help system, to name but a few (GÖG/ÖBIG 2009a). 
12.2 Drug use, health and social characteristics of current 
older drug users  
Based on the DOKLI data (see Chapter 5.3) a number of parameters have been selected to 
compare age cohorts in an attempt to find evidence of specific characteristics and needs of 
older clients of the Austrian drug help system. For the following analyses, the basic popula-
tion used was all clients who were in long-term inpatient or outpatient treatment in 2008. Fur-
thermore, where deemed significant, a comparison is made between clients using opioids as 
a their primary drug (for a definition see Chapter 5.3) and the total population of clients. 
In 2008, 86% of clients needing drug-related assistance were less than 40 years old (see 
Figure 12.1). 11% of the clients were aged between 40 and 49, 2% were aged between 50 
and 59, and a mere 31 persons were 60 or older. 
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Figure 12.1: Number of people who required drug treatment or assistance in 2008, by age and type of 
service 
Source: GÖG/ÖBIG 2009a, DOKLI, DOKLI analysis of client year 2008; representation by GÖG/ÖBIG 
The duration of treatment in the age groups below 40 years was less than four months in 
approximately half of the cases (see Table A25 in Annex A). In the age group between 40 
and 49, about one fourth of the clients were assisted for four to six months; among this age 
group, for 17% the duration of drug assistance was between 13 and 24 months and for 13%, 
between 25 and 36 months. As a general trend, clients aged 40 and older showed a longer 
period of treatment than the younger age cohorts. Data on the duration of treatment should 
be interpreted with great caution, as for a reliable assessment the coming client years will 
have to be taken into consideration (for details see GÖG/ÖBIG 2009a). 
In all age groups, the clients’ main impulse for contacting a drug help unit was their own 
initiative (see Table A26 in Annex A). For slightly more than half of the clients aged 40 and 
older with opioids as their primary drug this is the main incentive to undergo long-term inpa-
tient or outpatient treatment (between 39% and 49% of clients younger than 40). In general, 
the influence of family and friends has been observed to decrease with age, whereas the 
significance of the clients’ own initiative rises with age. In all age groups (with the exception 
of clients younger than 19) a court order or obligation in the context of a health-related 
measure for drug users was indicated as the second-most frequent main impulse for contact-
ing a drug help centre. Furthermore, the age analysis shows that among drug users aged 40 
or older the general practitioner tends to give the main impulse for contacting a drug help unit 
in a greater number of cases than in younger cohorts. On the basis of a total population of all 
person who were in long-term inpatient or outpatient assistance during 2008, the same 
trends as for the clients with opioids as primary drug may be observed, with only slight differ-
ences in the distribution of percentages. However, the influence of family was registered to 
rise again in the age group of users over 60 (see Table A27 in Annex A). 
Data analyses by Eisenbach-Stangl and Reidl (2009) as well as analyses of the DOKLI data 
for the client year 2008 indicate that drug users in different age groups show different pat-
terns of drug use. Analyses based on the primary drug of use reveal that apart from the fact 
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that the share of opioids rises and the share of cannabis decreases with age, there are no 
major differences between the age cohorts (see Figure 12.2). It is interesting to note that, in 
the age group between 50 and 59, this trend is reversed (i.e., a slight decrease in the share 
of opioids, and a slight increase in the share of cannabis as a primary drug is observed in the 
group between 50 and 59). 
Figure 12.2: Persons who required inpatient or outpatient treatment or assistance in 2008, 
by primary drug (according to EMCDDA) and age group (percentages) 
Note: As only four persons were 60 years and older, this age group is not represented in the graph. 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008; representation by GÖG/ÖBIG 
Among persons aged 40 or older in long-term outpatient or inpatient settings using opioids as 
primary drug, injecting is named most frequently as the predominant form of administra-
tion of heroin (about 70%), followed by snorting (between 17% and 22%). By contrast, 
snorting is indicated most often in the group of clients younger than 30 (between 46% and 
56%). Like the older cohorts, clients in the age group between 30 and 39 again indicate in-
jecting as their predominant form of heroin use (see Table A28 in Annex A). Regarding the 
predominant form of using cocaine, snorting is most frequent in all age groups, followed by 
injecting (see Table A30 in Annex A). As a general trend it has been observed that the share 
of persons who indicate that they inject heroin or cocaine continually rises with age. In the 
age group between 50 and 59, the share of intravenous cocaine users is slightly lower. 
Snorting as a predominant form of heroin use declines with age, and until the age of 59 in the 
case of cocaine. Based on a total population of all persons who were in long-term inpatient or 
outpatient treatment or assistance, parallel trends have been registered for heroin and co-
caine use (see Tables A29 and A31 in Annex A). Moreover, there is evidence that in the 
course of their drugs career clients change their mode of use from snorting to injecting (see 
GÖG/ÖBIG 2008a, Chapter 5.3). 
With regard to the median age of first use it has been found that the age of first use was 
higher for older drug users than for younger ones (see Figure 12.3). The median age of first 
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use of cannabis was between 14 and 16 in all age groups (see Table A32 in Annex A). 
Based on a total population of all person who were in long-term inpatient or outpatient treat-
ment, only slight differences in the median age of first use are noticeable; in the age group 
between 50 and 59, the age of first use of cocaine was slightly higher (24.5 years; see Table 
A33 in Annex A). The question whether older drug users actually started using drugs at a 
higher age (age effect) or whether the results are distorted because of the sample (sample 
effect) and whether older drug users remember the facts correctly (memory effect), is a topic 
for discussion. 
Figure 12.3: Age at first use (median) of persons with opioids as their primary drug, who were clients 
in long-term outpatient or inpatient treatment in 2008, by age group 
 
Note: As less than 20 persons were 60 years and older, this age group is not represented in the graph. 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Below, selected indicators describing sociodemographic aspects and the social situation 
reveal specific characteristics of older drug users who take opioids as their primary drug in 
long-term outpatient and inpatient treatment (see Table 12.2). The majority of drug users 
aged 40 and older is men, the share of women clients in this age group is approximately one 
fifth. In general, the share of women clients decreases with age (see Chapter 5.3). Regarding 
the highest degree of school education that drug users have obtained, the level of educa-
tion tends to rise with age. It is debatable whether this is due to an age cohort effect (better 
quality of education in the generations of older opioid users), a selection effect (better edu-
cated opioid users survive for a longer period; see also Eisenbach-Stangl and Reidl 2009) or 
further education and training programmes (degrees are completed at a later stage). The 
high share of drug users younger than 19 who do not have a compulsory school-leaving cer-
tificate or higher education cannot be interpreted, as this group is still in the process of 
school education or training. 
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Table 12.2: Clients with opioids as their primary drug undergoing long-term outpatient or inpatient 
treatment and selected sociodemographic and social indicators, by age, 2008 
Variables 
Age (years) 
younger than 19
(n = 449) 
between 20 
and 29 
(n = 3 212) 
between 30 
and 39 
(n = 1 384) 
between 40 
and 49 
(n = 699) 
between 50 
and 59 
(n = 142) 
Women 49% 31% 25% 22% 23% 
Treatment based on court order 19% 24% 18% 14% 15% 
Living in Vienna 27% 37% 40% 34% 19% 
Gainfully employed 29% 27% 26% 23% 21% 
Unemployed 28% 42% 38% 29% 14% 
Receiving welfare assistance 7% 12% 12% 14% 18% 
Doing military service / alternative service / on 
parents leave / retired 1% 4% 10% 23% 37% 
No compulsory school degree 14% 6% 4% 3% 1% 
No higher degree of education except compulsory 
school leaving certificate 76% 60% 58% 59% 48% 
Stable housing situation 94% 91% 90% 92% 94% 
Living alone 12% 23% 34% 43% 45% 
Note: As less than 20 persons were 60 years and older, this age group is not represented here.  
Source: GÖG/ÖBIG 2009a, DOKLI analysis client year 2008; representation by GÖG/ÖBIG 
As to the housing situation a high share in all age groups indicate stability (e.g., clients 
have their own apartment). The share of persons living alone rises continually with age and 
is 45% among the age group between 50 and 59. Based on the available data it is not evi-
dent whether this is a sign of isolation. An interesting aspect is that the percentage of drug 
users living in Vienna has risen among the younger age groups and is declining among drug 
users aged 40 and older. Vienna seems to be less attractive as a place to live for older drug 
users; it is not clear whether this is also a trend in the general population or whether there 
are other determining factors. Results on the means of subsistence show that the category 
indicating retirement has sharply risen among older drug users. Still, the extremely low per-
centage of employed drug users may be interpreted as indicating problems regarding inte-
gration into the labour market, especially for older drug users. Older drug users receive so-
cial benefits more frequently than drug users younger than 40. Based on a total population of 
all persons who were undergoing long-term inpatient or outpatient treatment, most of the dif-
ferences between age groups described above are similar or somewhat less marked (see 
Table A34 in Annex A). 
The CONTACT hospital connection service (Vienna) has found differences between older 
and younger clients which coincide with the analyses of DOKLI data described above. Ex-
amples for factors that distinguish older from younger clients are: social exclusion (especially 
among men); inability to live alone; no access to medical, addiction-related and social ser-
vices because of bad physical or psychological condition and resulting limitations of mobility; 
lack of future perspectives; few or no opportunities to enter the job market; no daily structure; 
few options for sparetime activities (Sucht- und Drogenkoordination Wien 2009b). At the As-
sociation of Psychosocial Centres (PSZ) in Lower Austria, the group of older clients falls into 
two categories. One group is in a relatively stable situation in opioid substitution treatment 
(partly on a low maintenance dose, frequently methadone is administered) and socially inte-
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grated to some extent (employed or having a family of their own) or suffering from a chronic 
disease (e.g., infectious disease), whereas members of the other group frequently show 
poly-drug use patterns (opioids, alcohol, benzodiazepines), have social contacts mainly 
within the drug scene, have been through several attempts of drug-free treatment and other 
forms of therapy and have experienced several periods of imprisonment and/or long years of 
prostitution (Werner, personal communication).  
Regarding drug-related health problems the situation in the group of clients older than 29 
is generally considered to be much worse than that of younger clients. By and large, the 
prevalence of infectious diseases rises with age, which is in line with expectations. In this 
context it has to be taken into account that the share of clients who inject drugs rises with 
age (GÖG/ÖBIG 2009a). Based on the reports of clients of BADO Vienna it becomes appar-
ent that nearly all drug users over 40 are confronted with a number of serious health prob-
lems. In the order of frequency, the diseases indicated were chronic hepatitis C, dental prob-
lems, gastrointestinal problems, psychiatric conditions, skin problems and vascular problems, 
convulsions or epileptic attacks (ÖBIG 2005). The B.I.T. counselling unit (Tyrol) reports to 
have diagnosed manifest depression or other comorbid disorders in a majority of clients aged 
over 40 (GÖG/ÖBIG 2008c). Older clients of PSZ (Lower Austria) often show psychiatric dual 
diagnoses (personality disorders, depression, panic attacks; Werner, personal communica-
tion). 
There is some evidence that older drug users are underrepresented in the services that 
communicate data to DOKLI. This may be concluded especially from comparisons with other 
EU countries and with data relating to opioid substitution treatment. The reasons for this dis-
crepancy are a matter of speculation. On the one hand, older clients undergoing opioid sub-
stitution treatment may be stable and integrated enough as not to require other drug help 
services. On the other hand, the results could be interpreted in the sense that there are no 
adequate interventions available for the target group. According to another assumption, the 
specific needs of older OST clients are covered by services outside the drug help system. On 
the basis of routine monitoring data it is impossible to decide which of the three views actu-
ally applies. To provide conclusive evidence in this respect is a task for further research 
(GÖG/ÖBIG 2008a). 
12.3 Treatment, management and care of older drug users 
A number of regulations at federal and provincial levels are relevant for the treatment and 
care of older drug users in Austria (see Chapter 1). In principle, the same legal provisions 
apply to drug users of all ages. In existing regulations and services, drug users are men-
tioned as being excluded (e.g., non-eligibility for unemployment benefits, restrictions in the 
house rules of care homes etc.) (Spirig et al. 2009).  
Many benefits of the social system are hard to obtain for most older drug users. All appli-
cants encounter administrative obstacles when trying to gain access to benefits, but older 
drug users are especially disadvantaged in this situation. In addition to suffering from health 
impairments (e.g., limited mobility) this age group is confronted by obstacles which often re-
sult from social deprivation (Spirig et al. 2009). (Re-)integration into the job market is espe-
cially hard for older drug users (see Chapter 8.2).  
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Older drug users are rarely mentioned in addiction plans (see Chapter 1). As an example, 
in its current binding framework plan for the further expansion of the Carinthian addiction 
help system the Province of Carinthia pursues the aim to build up a medium-term care pro-
gramme for older citizens in danger of addiction who show problem use of illicit drugs and/or 
alcohol. In this context it is interesting to note that the target group of older drug users was 
not defined according to a fixed age limit (Preshlauer, personal communication). The drug 
strategy of Vorarlberg (Amt der Vorarlberger Landesregierung 2002) mentions the need for a 
specific treatment programme for users between 30 and 50 years of age who have started 
using drugs as mature adults. This need should not be covered by a separate unit, but rather 
by specific services in existing institutions; at Maria Ebene hospital, a corresponding treat-
ment programme has already been created for this target group. The addiction plans of the 
other provinces make no specific mention of older drug users.  
Spirig et al. (2009) state that currently no specific treatment programmes for older drug 
users exist. Individual drug help centres have reported an increased use of their services by 
this group, e.g., B.I.T. (Tyrol; GÖG/ÖBIG 2008c) and VWS in Vienna (2009a). The specific 
care needs of older drug users (see Chapter 12.2) pose a great challenge to the drug help 
system. According to reports from Carinthia, there are no adequate care services available 
for older drug users suffering from a psychiatric primary disease and showing problem drug 
use patterns. As a result, clients move back and forth between emergency departments and 
rehabilitation facilities, which entails substantial costs; in this sense, care is insufficient (Land 
Kärnten 2006).  
Especially in the area of care for older citizens, specific strategies should be designed to 
meet the needs of older drug users (GÖG/ÖBIG 2009a). According to the drug strategy of 
Vorarlberg (Amt der Vorarlberger Landesregierung 2002) the situation of older drug users 
requires specific interventions in which members of all care professions dealing with older 
citizens as well as friends and relatives of those concerned should be included. Experience 
from Vorarlberg has shown that the state of health of addiction patients can be raised to a 
satisfying level of stability in care facilities (Neubacher, personal communication). By con-
trast, Musalek and Preinsperger report that the massive additional substance use by part of 
the target group is hardly tolerated in geriatric facilities. Moreover, there are problems of ac-
ceptance of the target group by non-users in such facilities. Programmes providing a daily 
structure for older drug users are considered useful, as they are often unemployed and have 
few social contacts. In addition, assisted housing and specific care is required. The treatment 
of older drug users calls for a consideration of the specific aspects of aging, especially co-
morbidities45.  
Regarding the development of policies for assistance and care for older drug users, the 
EU project SDD-Care is of key significance for Austria46. As part of this project, currently ba-
sic information on the social situation and health status of older drug users (women and men) 
and their objective and subjective care needs is collected. In addition, it is planned to draw 
up strategies and guidelines for practical implementation of outpatient and inpatient depart-
                                                
45 www.geriatrie-online.at/dynasite.cfm?dsmid=96679&dspaid=744846 (15 April 2009) 
46 www.sddcare.eu (7 August 2009) 
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ments for the target group of persons over 35 with drug problems. At provincial level, under 
the drug plan in Carinthia (see above) currently a strategy for assisting older drug users is 
designed by the OIKOS association for drug patients, which is soon to be completed and im-
plemented (Land Kärnten 2006). 
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Personal communications, alphabetical order 
 
Name and page Organisation or function 
Anderwald, DGKS Christine (p. 43) Caritas Marienambulanz outpatient clinic, Graz 
Bauer, Prim. Dr. Bernhard (p. 43) Caritas Marienambulanz outpatient clinic, Graz 
Duspara, Vinko (p. 43) Lukasfeld therapy department, Maria Ebene foundation, 
Vorarlberg 
Ederer, DSA Klaus Peter (pp. 27, 30) Addiction Coordinator of Styria 
Frossard, OA Dr. Martin (p.71) 
Haltmayer, Dr. Hans (p. 43) 
emergency medicine clinic, General Hospital Vienna 
VWS (Vienna Social Projects Association) 
Hörhan, Mag. Dr. Ursula (pp. 8, 30, 31, 52, 
57) Addiction Coordinator of Lower Austria 
Kahl, DSA Walter (p. 66) Federal Ministry of Justice, Dept. V/1 
Kern, Harald (pp. 8, 31, 64) Addiction Coordinator of the Tyrol 
Mader, ADir. Christian (p. 79) Federal Ministry of the Interior / Federal Criminal 
Agency 
Mahnert, OA Dr. Franz Alfons (p. 30) Walkabout therapy department 
Mellish, Sadiya Petra (pp. 17, 19) Addiction Prevention, Coordination and Counselling 
Unit of Lower Austria 
Nagy, Mag.a Constanze (p. 71) ChEck iT!, Vienna Social Projects Association 
Neubacher, Thomas (pp. 29, 90) Drug Coordinator Vorarlberg 
Prehslauer, Dr. Brigitte (pp. 26, 30) Drug Coordinator Carinthia 
Rögl, Nicole (pp. 16, 19) Akzente Addiction Prevention Unit in the Province of 
Salzburg 
Schäfer, Mag. Silke (p. 45) Komfüdro, Tyrol 
Springer, Univ.-Prof. Dr. Alfred (p. 75) Ludwig Boltzmann Institute for Addiction Research 
Stolz-Gombocz, OA Dr. Ingrid (p. 43) Anton Proksch Institute, long-term therapy department 
for drug addicts with personality disorders, Mödling, 
Lower Austria 
Werner, Dr. Wolfgang (p. 89) Association of Psychosocial Centres (PSZ) 
Zeder, Dr. Ulf (p. 52) Addiction Coordinator Graz  
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DATABASES 
 
Best practice portal –Examples for evaluated measures: EDDRA = Exchange on Drug 
Demand Reduction Action 47 
 
Internet database of the EMCDDA: http://eddra.emcdda.europa.eu/html.cfm/index45497EN.html 
Austrian projects in the EDDRA database respectively Best practice portal of 
the EMCDDA (as of August 2008): 
abrakadabra – (Re-)socialisation of drug addicts by integration in the labour market 
(Caritas der Diözese Innsbruck, Tyrol) 
Addiction information in schools supported by experts 
(kontakt+co - Suchtpräventionsstelle, Tyrol) 
Addiction prevention within the apprenticeship of the Austrian Federal Railways 
(Institut für Suchtprävention, Vienna) 
Addiction prevention within the Styrian Soccer Association 
(VIVID – Fachstelle für Suchtprävention, Styria) 
Ambulance for addiction diseases at the University Hospital of Innsbruck, Department for 
Psychiatry 
(Universitätsklinik für Psychiatrie - Innsbruck, Tyrol) 
Become Independent: education programme for prevention in schools  
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
Being a parent can be beautifully difficult sometimes 
(Fachstelle für Suchtvorbeugung, Koordination und Beratung, Lower Austria) 
Caritas Marienambulanz. Drug related street work, an outreach service in the field of 
medical care and treatment. 
(Caritas der Diözese Graz Seckau, Styria) 
CONTACT: Liaison service for hospitals 
(Sucht- und Drogenkoordination Wien, Vienna) 
DAPHNE project: Addiction as chance of survival? For women with experience of violence. 
(Verein Dialog und Verein Wiener Sozialprojekte, Vienna) 
DP drugaddicts@work. Equal ESF community initiative programme for reintegrating people 
with problematic drug use into the labour market. 
(Sucht- und Drogenkoordination Wien, Vienna) 
                                                
47 In the course of establishing an internet portal on best practices, the EDDRA database of EMCDDA was revised in a move to 
improve the quality of entries and facilitate integrated use within the online portal. In this process the existing entries were se-
lected according to certain criteria, reclassified and validated. Major improvements to the search function have been made; 
project descriptions are now available for download. During the revision a few Austrian projects were cancelled, which had 
been entered before 2001 and are no longer running. 
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Drug free zone Hirtenberg prison 
(Justizanstalt Hirtenberg, Lower Austria) 
Drug Out: Innsbruck prison’s therapy unit 
(Justizanstalt Innsbruck, Tyrol) 
Drug treatment at the Drug Outpatient Clinic Klagenfurt 
(Magistrat Klagenfurt, Carynthia) 
Early detection and intervention with regard to problematic drug use and addic-
tion 
(kontakt+co – Suchtpräventionsstelle, Tyrol) 
Employment Programme WALD (Forest) 
(H.I.O.B. - Anlauf- und Beratungsstelle für Drogenabhängige, Vorarlberg) 
Erlenhof: An inpatient treatment centre for addicts 
(Pro mente Upper Austria) 
Generation E: Workshop for creative parents work 
(Institut für Suchtprävention, Fonds Soziales, Vienna) 
Grüner Kreis: A treatment facility for adolescents 
(Verein Grüner Kreis, Lower Austria) 
“Guat beinand’!”: Addiction prevention in communities and city districts 
(Akzente Salzburg – Suchtprävention, Salzburg) 
Health Promotion and Addiction Prevention in the Workplace  
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
High enough? – Practical kit for addiction prevention in the field of youth social work 
(VIVID Fachstelle für Suchtprävention, Styria) 
H.I.O.B.: Help, information, orientation and counselling for drug addicts  
(H.I.O.B. - Anlauf- und Beratungsstelle für Drogenabhängige, Vorarlberg) 
In motion: A multiplier project for addiction prevention at schools  
(Institut Suchtprävention - eine Einrichtung von pro mente, Upper Austria) 
Job assistance - subproject of the Vienna Job Exchange in the context of the Equal devel-
opment partnership 
(Wiener Berufsbörse, Vienna) 
Living together in the 2nd district. Program for the prevention of addiction in schools, 
children and youth social work in urban areas. 
(Institut für Suchtprävention, Vienna) 
Local Capital for Social Purposes (a pilot action of the DG V of the EU) Programme: 
“Socially Innovative 2000” (EU regional management Eastern Styria) 
(Volkshilfe Steiermark, VIVID Fachstelle für Suchtprävention, Regionalbüro Oststeiermark, 
Styria) 
Log In: Measures for the integration and health promotion of former drug users 
(Anton Proksch Institute, Lower Austria) 
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Long-term therapy, Anton Proksch-Institute, Mödling  
(Anton Proksch Institute, Lower Austria) 
Long-term therapy facility CARINA 
(Stiftung Maria Ebene, Vorarlberg) 
Long-term treatment of drug dependence Senobio, Schnifis, Vorarlberg 
(Senobio, Vorarlberg)  
Low threshold service Ganslwirt 
(Verein Wiener Sozialprojekte, Vienna) 
Lukasfeld: A short term therapy for young illegal drug addicts 
(Stiftung Maria Ebene hospital, Vorarlberg) 
Making kids strong through Sports 
(SUPRO - Werkstatt für Suchtprophylaxe, Vorarlberg) 
MDA basecamp – mobile drug work in recreational settings 
(Jugendzentrum Z6, Tyrol) 
Medico-psycho-social Sanatorium „Schweizer Haus Hadersdorf“ 
(Evangelisches Haus Hadersdorf - WOBES, Vienna) 
Needles or Pins: Vienna: A European Project to develop innovative projects for the social 
and labour integration of people with drug related problems. 
(Beratungsstelle DIALOG, Vienna) 
Needles or Pins: Occupational reintegration of (former) drug addicts. 
(Beratungsstelle DIALOG, Vienna) 
Peer education project 
(Fachstelle für Suchtvorbeugung, Koordination und Beratung, Lower Austria) 
Pib – prevention in companies 
(kontakt+co - Suchtpräventionsstelle, Tyrol) 
Pilot projekt: Addiction prevention in Trofaiach 
(b.a.s. (betrifft alkohol und sucht) – steirischer Verein für Suchtkrankenhilfe, Styria) 
Probation assistance for prisoners at Vienna Favoriten prison provided by 
voluntary staff 
(Verein für Bewährungshilfe und soziale Arbeit – Bewährungshilfe, Vienna) 
Scientific project: ChEckiT! 
(Verein Wiener Sozialprojekte, Vienna) 
Social medicine counselling centre Ganslwirt 
(Verein Wiener Sozialprojekte, Vienna) 
Socio economical company: Fix und Fertig (“All ready”) 
(Verein Wiener Sozialprojekte, Vienna) 
Stationenmodell: Primary addiction prevention in schools 
(Fachstelle für Suchtvorbeugung, Koordination und Beratung, Lower Austria) 
Step by Step: A programme for early detection and crisis intervention at schools 
(VIVID – Fachstelle für Suchtprävention, Styria) 
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Streetwork mobile youth work: “Rumtrieb” Wiener Neustadt 
(Verein für Jugend und Kultur Wr. Neustadt, Lower Austria) 
Substitution treatment in the Outpatient Clinic for Addictions in Innsbruck 
(Outpatient Clinic for Addictions Innsbruck, Tyrol) 
Supervised housing 
(Verein Wiener Sozialprojekte, Vienna) 
Supromobil: Secondary prevention of the Foundation Maria Ebene 
(Stiftung Maria Ebene, Vorarlberg) 
The Umbrella Network Programme: Analysis of border issues with regard to HIV, 
AIDS and STD problems and the development of cooperative border crossing pre-
ventative measures. 
(Institut für Sozialdienste, Vorarlberg) 
Therapy for parents and children at Grüner Kreis 
(Verein Grüner Kreis, Lower Austria) 
Travelling exhibition with the aim of addiction prevention: “Have you got the hang of 
everything?“ 
(Fachstelle für Suchtprävention, Lower Austria) 
Treatment and care of addicted offenders in Vienna Favoriten prison 
(Justizanstalt Wien-Favoriten, Vienna) 
Vaccination project Hepatitis B of the Social Medicine Counselling Centre Ganslwirt 
(Verein Wiener Sozialprojekte, Vienna) 
Vienna Job Exchange 
(Wiener Berufsbörse, Vienna) 
Viennese pilot project “Pregnancy and Addiction”: Aftercare of the children. 
Comprehensive care project for substance abusing mothers and their children 
(Neuropsychiatrische Abteilung für Kinder und Jugendliche am KH Rosenhügel, Vienna) 
Viennese pilot project “Pregnancy and Addiction”: Comprehensive care for substance 
dependent mothers and their children 
(AKH, Vienna) 
Viktoria’s birthday: Primary addiction prevention for primary school pupils. 
(Fachstelle für Suchtprävention, Lower Austria) 
Way Out: Early intervention for young drug-using first offenders.  
(Kooperation der Landesstelle Suchtprävention und Neustart, Carinthia) 
Youth and addiction counselling centre “Auftrieb” 
(Verein für Jugend und Kultur Wr. Neustadt, Lower Austria)  
Youth counselling centre „Waggon” 
(TENDER – Verein für Jugendarbeit, Lower Austria) 
Youth without borders?! Mladi brez meja?! – Addiction prevention in the district of 
Radkersburg 
(blue|monday gesundheitsmanagement, Styria) 
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Websites  
Please find below websites of relevant institutions and associations in the field of drugs and 
addiction in Austria.  
For a comprehensive list of European and international websites on drugs and addic-
tion please consult http://www.oebig.at under Activities/ Prevention/ Illegal drugs/ 
Links 
Provincial Drug or Addiction Coordinators: 
Addiction Coordinators for the Province of Burgenland 
http://www.psd-bgld.at/suchtkoordination/index.html 
Drug Coordinators for the Province of Carinthia 
http://www.gesundheit-kaernten.at/gesundheitsserverhtml/page.asp?MEN_ID=42 
Addiction Coordinators of the Province of Lower Austria 
http://www.suchtvorbeugung.at/suchtkoordination/ 
Drug and Addiction Coordinators of the Province of Upper Austria 
http://www.land-oberoesterreich.gv.at/cps/rde/xchg/SID-3DCFCFC3-
8C8F5206/ooe/hs.xsl/554_DEU_HTML.htm  
Drug Coordinators of the Province of Salzburg 
http://www.salzburg.gv.at/themen/gs/soziales/leistungen_und_angebote/abhaengigkeit/a
bhaengigkeit_drogenkoordination.htm 
Addiction Coordinators of the Province of Styria 
http://www.drogenberatung-stmk.at/ 
Addiction Coordinators of the Province of the Tyrol 
http://www.tirol.gv.at/themen/gesellschaft-und-soziales/soziales/suchtkoordination/ 
Addiction Coordinators of the Province of Vorarlberg 
http://www.vorarlberg.at/vorarlberg/gesellschaft_soziales/gesellschaft/suchtkoordination/
start.htm  
Addiction and Drug Coordinators Vienna (SDW), 
http://www.drogenhilfe.at 
Provincial Addiction Prevention Units: 
Burgenland: Fachstelle für Suchtprävention Burgenland 
http://www.psd-bgld.at/suchtpraevention/index.html 
Carinthia: Landesstelle für Suchtprävention Kärnten 
http://www.gesundheit-kaernten.at/gesundheitsserverhtml/page.asp?MEN_ID=77  
Lower Austria: Fachstelle für Suchtvorbeugung, Koordination und Beratung, NÖ 
http://www.suchtvorbeugung.at 
Upper Austria: Institut Suchtprävention, OÖ 
http://www.praevention.at  
Salzburg: AKZENTE Suchtprävention – Fachstelle für Suchtvorbeugung Salzburg 
http://www.akzente.net/Suchtpraevention.7.0.html  
Styria: VIVID – Fachstelle für Suchtprävention, Steiermark 
http://www.vivid.at/http://www.vivid.at  
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Tyrol: Kontakt&co – Suchtprävention. Jugendrotkreuz, Tirol 
http://www.kontaktco.at 
Vorarlberg: SUPRO – Werkstatt für Suchtprophylaxe, Vorarlberg 
http://www.supro.at 
Vienna: Institut für Suchtprävention 
http://www.drogenhilfe.at 
Federal Ministries: 
Federal Ministry for Health 
http://www.bmg.gv.at  
Federal Ministry of the Interior 
http://www.bmi.gv.at   
Federal Ministry of Justice 
http://www.bmj.gv.at 
Federal Ministry for Education, the Arts and Culture 
http://www.bmukk.gv.at  
Federal Ministry of Science and Research 
http://www.bmwf.gv.at  
Federal Ministry for Labour, Social Affairs and Consumer Protection 
http://www.bmsk.gv.at 
Federal Ministry for Transport, Innovation and Technology 
http://www.bmvit.gv.at  
Federal Ministry of Economy, Family and Youth 
http://www.bmwfj.gv.at 
Monitoring and research: 
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) 
http://www.emcdda.europa.eu 
Institut für Suchtforschung der Universität Innsbruck mit Sitz am Krankenhaus Maria Ebene 
(Addiction Research Institute of the University of Innsbruck, based at the hospital Maria 
Ebene) 
http://www.suchtforschung.at 
Ludwig Boltzmann Institute of Addiction Research at Anton Proksch Institute 
http://www.api.or.at/lbi/index.htm 
ÖBIG – Österreichischer Suchthilfekompass (Austrian Addiction Help Compass) 
http://suchthilfekompass.oebig.at  
ÖBIG – Einheitliches Dokumentationssystem der Klienten und Klientinnen der Drogenhilfe  
(Uniform documentation and reporting system of clients of Austrian drug help centres) 
http://tdi.oebig.at  
Suchtforschung und Suchttherapie an der Medizinischen Universität Wien 
(Addiction Research at the Medical University of Vienna) 
http://www.sucht-addiction.info 
European Centre for Social Welfare Policy and Research 
http://www.euro.centre.org/ 
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Other websites: 
AIDS assistance 
http://www.aidshilfen.at 
Allgemeines Krankenhaus in Wien (General Hospital Vienna) 
http://www.meduniwien.ac.at 
ARGE Suchtvorbeugung (Working Group for Addiction Prevention) 
http://www.suchtvorbeugung.net 
Anton Proksch Institute 
http://www.api.or.at  
Auftrieb – youth and addiction counselling 
http://jugendundkultur.at 
b.a.s. – Styrian society for addiction issues 
http://www.bas.at 
Blue Monday Gesundheitsmanagement (health management) 
http://www.bluemonday.at 
Bundesarbeitsgemeinschaft Streetwork – Mobile Jugendarbeit Österreich (federal associa-
tion of mobile youth street work in Austria) 
http://www.bast.at 
Carina – Therapiestation (treatment centre) 
http://www.mariaebene.at/carina/  
Caritas Innsbruck 
http://www.caritas-innsbruck.at  
Caritas Graz – Kontaktladen (contact point) 
http://caritas-steiermark.at  
ChEck iT! – Vienna Social Projects Association (VWS) 
http://checkyourdrugs.com 
CONTACT – hospital connection service 
http://www.drogenhilfe.at/rathilfe/skh/r-s-contact.htm 
dialog – counselling and care centre 
http://www.dialog-on.at  
Do it yourself – low-threshold centre for drug users 
http://www.doit.at  
Drogenberatung des Landes Steiermark (Drug Counselling Centre of the Province of Styria) 
http://www.drogenberatung-stmk.at 
ENCARE Austria 
http://www.encare.at  
Ex und Hopp – drug counselling 
http://www.exundhopp.at 
Fachzeitschrift für Online-Beratung und computervermittelte Kommunikation (Magazine for 
online counselling and computer-aided communication) 
http://www.e-beratungsjournal.net 
Fonds Gesundes Österreich 
http://www.fgoe.org/startseite 
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Ganslwirt – Verein Wiener Sozialprojekte (low-threshold centre; Vienna Social Projects As-
sociation) 
http://www.vws.or.at/ganslwirt  
Grüner Kreis – Society for the rehabilitation and integration of addicted persons 
http://www.gruenerkreis.at 
Haus am Seespitz (short-term therapy centre for drug patients) 
http://sogis.i-med.ac.at/ich-brauche-hilfe/einrichtungsdaten.cfm?eid=47 
H.I.O.B. – (drug counselling centre) 
http://www.caritas-vorarlberg.at 
Jugendstreetwork Graz (youth street work) 
http://caritas-
graz.at/home.php?cakt=einr&id=2&einrakt=&narchiv=&armonat=&arjahr=&suche=&einri
d=&ibhid=&mitid 
Klinische Abteilung für Allgemeine Psychiatrie; Universitätsklinik für Psychiatrie in Wien  
(Clinical department of general psychiatry, Vienna University Hospital of Psychiatry) 
http://www.medizin-medien.info/dynasite.cfm?dssid=4263 
Komfüdro – communication centre for drug users 
http://www.caritas-innsbruck.at/einrichtungen.cfm?mode=showseite1&e_id=15 
Kontaktstelle in Suchtfragen – contact and information centre for addiction prevention in 
schools, Salzburg 
http://www.landesschulrat.salzburg.at//service/kis/index.php 
Krankenhaus Rosenhügel (hospital) 
http://www.wienkav.at/kav/nkr/ 
Verein LOG IN Association 
http://www.login-info.at  
Lukasfeld – (therapy centre) 
http://www.mariaebene.at  
Marienambulanz (outpatient centre) 
http://www.caritas-graz.at/home.php?cakt=einr&id=68 
MDA basecamp – (mobile drug prevention in the Tyrol) 
http://www.mdabasecamp.com  
MDA basecamp – (online counselling) 
http://www.onlinedrogenberatung.at 
Needles or Pins – dialog 
http://www.dialog-on.at/article_69.html 
Neustart – Bewährungshilfe, Konfliktregelung, Soziale Arbeit (probation assistance, conflict 
management, social work) 
 http://www.neustart.at/ 
Oikos – Association for drug addicts 
http://www.oikos-klagenfurt.at 
Otto-Wagner-Spital – drug institute 
http://www.wienkav.at/kav/ows/medstellen_anzeigen.asp?suchstring=912 
Österreichische Caritaszentrale – (Caritas social integration enterprise) 
http://www.esf.at/projekte/arbeitslose/projekte_ida.html 
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Österreichischer Verein für arzneimittelgestützte Behandlung von Suchtkranken (Austrian 
Association for pharmacologically assisted treatment of drug addicts 
http://www.oegabs.at/index.php 
Österreichischer Verein für Drogenfachleute (Austrian Association of Experts in the Field 
of Drugs) 
http://www.oevdf.at  
Österreichisches Netzwerk Gesundheitsfördernde Schulen (Austrian Network of 
Health-Promoting Schools) 
http://www.schule.at/gesundheit  
Plattform Drogentherapien – information on opiate addiction 
http://www.drogensubstitution.at  
pro mente Oberösterreich (psychosocial care association) 
http://www.promenteooe.at 
Schulpsychologie Bildungsberatung (school psychology, education counselling) 
http://www.schulpsychologie.at 
Schultüte (FSW/ISP Vienna; school project)  
http://schultuete.at  
Schweizer Haus Hadersdorf (counselling and treatment centre) 
http://www.shh.at  
Stadt Wien - City of Vienna 
http://www.magwien.gv.at 
Stiftung Maria Ebene (foundation, hospital) 
http://www.mariaebene.at  
Streetwork Graz (street social work) 
http://caritas-steiermark.at  
Substanz – Verein für suchtbegleitende Hilfe (association for accepting drug assistance) 
http://www.substanz.at 
Supromobil (secondary prevention) 
http://www.supromobil.at 
Therapiestation Erlenhof (treatment centre) 
http://www.therapiestation-erlenhof.at  
Therapiestation Walk about (treatment centre) 
http://www.barmherzige-brueder.at/walkabout/ 
Tiroler JugendWeb – Drogen, Sucht, Hilfe (Tyrolean youth network for drug assistance) 
http://www.startblatt.net/at/jugend/jugend-tirol/tiroler-jugendweb 
Verein für eine Legalisierung von Cannabis (legalise cannabis association) 
http://www.legalisieren.at  
Verein PASS (prevention and drug counselling) 
http://www.pass.at/start.htm 
VIVA (drug counselling centre) 
http://www.gesundheit-
kaernten.at/gesundheitsserverhtml/page.asp?MEN_ID=109&SEI_ID=99&LST_ID=48  
Vorarlberger Drogenhilfe (drug help services) 
www.suchthaufen.at  
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VWS (Vienna Social Projects Association) 
http://www.vws.or.at  
Verein Jugend & Kultur Wiener Neustadt (youth and culture association) 
http://www.jugendundkultur.at  
Wiener BerufsBörse (Vienna Job Exchange)  
http://www.berufsboerse.at  
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Table A1: Overview of selected general population surveys on drug experience among the Austrian 
population from 2004 to 2008  
Study 
(author(s), 
year of publication) 
Area covered 
year of data 
collection 
(period covered) 
Target group 
(sample) 
Drug types surveyed Percentage of re-
spondents with 
drug experience 
   Age group        % 
Bevölkerungsbefragung 
Österreich / 
general population 
survey, Austria 
(Uhl et al. 2005a) 
Austria 
2004 
(lifetime) 
General population 
aged 14 and older
(n = 4 547) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opioids 
Biogenic drugs 
LSD 
Solvents and inhalants 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
20.1 
3.0 
2.4 
2.3  
0.7 
2.7 
1.7 
2.4 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(IFES 2005) 
Vienna 
2005 
(lifetime) 
General population 
aged 15 and older
(n = 600) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opioids 
Biogenic drugs 
Other illicit drugs (e.g., LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
17 
2 
2 
2  
2 
3 
2 
Bevölkerungsbefragung OÖ 
/ general population survey, 
Upper Austria 
(Seyer et al. 2007) 
Upper Austria 
2006 
(lifetime) 
General population
aged 15 to 59  
(n = 1 125) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Heroin 
Morphine  
LSD 
Solvents and inhalants 
Biogenic drugs 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
15–59 
27.6 
7.3 
7.6 
5.8 
4.2 
4.4 
4.6 
8.0 
7.4 
Gesundheitsbefragung 
Österreich (ATHIS) / 
Austrian Health Interview 
Survey (ATHIS) 
(Klimont et al. 2007) 
Austria 
2006/7 
(lifetime) 
General population
aged 15 to 64  
(n = 11 822) 
Cannabis  
Cannabis 
Cannabis  
Cannabis  
Cannabis 
Cannabis 
15 + 
15–24 
25–34 
35–44 
45–54 
55–64 
9.7 
13.0 
15.0 
10.1  
6.7 
2.8 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(IFES 2008) 
Vienna 
2007 
(lifetime) 
General population
aged 15 and older
(n = 624) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opioids 
Biogenic drugs 
Other illicit drugs (e.g., LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
19 
4 
4 
4  
2 
7 
4 
Bevölkerungsbefragung 
Österreich / genera 
population survey, 
Austria 
(Uhl et al. 2009 
in preparation) 
Austria 
2008 
(lifetime) 
General population
aged 14 and older
(n = 4 196) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opioids 
Biogenic drugs 
LSD 
Solvents and inhalants 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
14 + 
12 
2 
2 
2 
1 
2 
2 
2 
Wiener Suchtmittelstudie / 
drug survey, Vienna 
(IFES 2009) 
Vienna 
2009 
(lifetime) 
General population
aged 15 and older
(n = 600) 
Cannabis 
Ecstasy 
Amphetamines 
Cocaine 
Opioids 
Biogenic drugs 
Other illicit drugs (e.g., LSD) 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
15 + 
16 
3 
3 
4 
3 
4 
3 
Summarised by GÖG/ÖBIG 
 118 
Table A2: Overview of selected youth surveys on drug experience among young people in Austria 
from 2001 to 2008  
Study 
(author(s), 
year of publication) 
Area covered 
year of data 
collection 
(period covered) 
Target group 
(sample) 
Drug types surveyed Percentage of re-
spondents with drug 
experience 
    Age group        % 
Schulstudie Burgenland / 
school survey, Burgenland 
(Schönfeldinger 2002) 
Burgenland 
2001 
(lifetime) 
Students in their  
7th to 13th school years
(n = 1 899) 
Cannabis 
Ecstasy 
Cocaine 
Heroin 
Speed 
Hallucinogenic drugs 
Solvents and inhalants 
Biogenic drugs 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
20 
  4 
  2 
   1 
  3 
  3  
20 
  8  
HBSC-Studie / 
HBSC-study 
(Dür und Mravlag 2002) 
Austria 
2001 
(lifetime) 
Students aged 15 
(n = 1 292) 
Cannabis 15 14 
ESPAD Österreich / 
ESPAD Austria 
(Uhl et al. 2005b) 
 
Austria 
2003 
(lifetime) 
Students aged 14 to 17 
(n = 5 281) 
Cannabis 
Ecstasy  
Cocaine 
Crack 
Heroin 
Amphetamines 
GHB 
LSD 
Solvents and inhalants 
Magic Mushrooms 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
14–17 
22 
3 
2 
2 
1 
5 
1 
2 
15 
4  
Berufsschulstudie 
Steiermark / 
vocational school survey, 
Styria 
(Hutsteiner, Seebauer, 
Auferbauer 2005) 
Styria 
2005 
(lifetime) 
Trainees at vocational 
school aged  15 to 19 
(n = 3 919) 
Cannabis 
Party drugs 
Cocaine 
Crack 
Opioids 
Amphetamines 
Hallucinogenic drugs 
Solvents and inhalants 
Magic Mushrooms 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
15–20 
27.1 
4.8 
2.0 
1.1 
1.4 
3.1 
1.8 
11.4 
8.9 
HBSC-Studie  / 
HBSC study 
(Dür und Griebler 2007) 
Austria 
2005/6 
(lifetime) 
Students aged 15  
(n = 1 239) 
Cannabis 15 14 
Bevölkerungsbefragung 
OÖ / 
general population survey, 
Upper Austria 
(Seyer et al. 2007) 
Upper Austria 
2006 
(lifetime) 
Adolescents and young 
adults aged 15 to 24  
(n = 669) 
Cannabis 
Ecstasy 
Heroin 
Morphine 
Amphetamines 
Cocaine 
LSD 
Solvents and inhalants 
Biogenic drugs 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
15–24 
36.9 
12.3 
7.7 
8.5 
12.3 
10.0 
9.0 
16.5 
13.0 
Schulstudie Burgenland / 
school study Burgenland 
(Falbesoner und Lehner 
2008) 
Burgenland 
2007 
(lifetime) 
Students in their 
7th to 13th school years 
(n = 1 213) 
Cannabis 
Ecstasy 
Cocaine 
Heroin 
Speed 
Solvents and inhalants 
Biogenic drugs 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
12–19 
 11 
  2 
  2 
   2 
  3 
 15 
  4  
ESPAD Österreich / 
ESPAD Austria 
(ESPAD-Austria 2007) 
 
Austria 
2007 
(lifetime) 
Students aged 15 to 16 
(n = 4 574) 
Cannabis 
Ecstasy  
Cocaine 
Crack 
Heroin 
Amphetamines 
GHB 
LSD 
Solvents and inhalants 
Magic Mushrooms 
15–16   
15–16   
15–16   
15–16   
15–16   
15–16   
15–16   
15–16   
15–16   
15–16   
18.0 
3.4 
3.2 
2.3 
1.8 
7.7 
2.3 
2.8 
14.1 
4.1 
Summarised by GÖG/ÖBIG 
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Table A3: Development of AIDS cases in Austria by risk situation from 1999 to 2008 
Risk situation 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Homo-/bisexual contact 27 13 21 19 7 16 14 16 19 12 
Injecting drug use 28 24 28 22 14 13 14 6 14 16 
Heterosexual contact 31 28 33 41 21 32 17 30 22 25 
Other cause/unknown 16 23 11 15 10 10 14 11 17 12 
Total 102 88 93 97 52 71 59 63 72 65 
Source: BMG, calculations by GÖG/ÖBIG  
 
Table A4: Distribution of reports of violations of the Narcotic Substances Act in Austria by first 
offenders and repeat offenders, development from 1990 to 2008 
Reports 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Total numbers of reports 17 597 18 125 21 862 22 422 22 245 25 215 25 892 24 008 24 166 20 043
First offenders 9 868 9 343 11.033 11.269 12.117 14 346 15 569 15 808 16 053 13 634
Repeat offenders 7 463 8 296 10 052 10 380 9 288 9 990 9 520 7 636 7 569 5 990
Difference between sum of individual figures and total figure = unknown 
Note: all reports, not only narcotic substances, but also psychotropic substances 
Source: BMI/.BK 
Table A5: Distribution of reports of violations of the Narcotic Substances Act (narcotic substances 
only) in Austria from 1999 to 2008 
Province 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Burgenland 603 843 712 805 984 967 923 1 033 1 008 871 
Carinthia 1 208 1 088 1 758 1 676 1 659 1 464 1 529 1 190 1 408 1 153 
Lower Austria 2 389 2 624 2 975 3 319 3 017 3 531 3 632 3 050 3 464 2 583 
Upper Austria 1 946 1 887 2 677 3 054 2 782 3 521 3 769 3 209 3 786 3 245 
Salzburg 840 718 1 471 1 384 868 1 077 1 092 1 001 1 116 1 015 
Styria 1 367 1 305 1 601 1 910 1 570 1 705 1 516 1 435 1 929 1 372 
Tyrol 2 152 2 687 2 449 2 229 2 102 2 695 2 775 2 607 2 454 1 982 
Vorarlberg 1 848 1 183 1 447 1 265 1 146 1 044 1 008 1 240 1 153 976 
Vienna 4 858 5 233 6 212 6 210 7 652 8 524 8 797 7 925 6 611 5 883 
Total 17 211 17 568 21 302 21 852 21 780 24 528 25 041 22 690 22 929 19 080 
Difference between sum of individual figures and total figure = reports not attributable 
Source: BMI/.BK 
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Table A6: Distribution of reports of violations of the Narcotic Substances Act in Austria by drug type 
from 1999 to 2008 
Drug type 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Cannabis 17 236 17 001 19 760 19 939 17 706 20 252 20 900 19 021 19 063 15 063 
Heroin and opioids 2 524 2 413 3 802 3 954 4 717 4 770 4 720 3 516 3 294 2 865 
Cocaine +Crack 2 608 2 494 3 416 3 762 4 785 5 365 5 491 4 252 4 263 3 551 
LSD 532 477 506 327 214 196 160 164 196 101 
Ecstasy 1 517 2 337 2 940 2 998 2 473 2 362 2 106 1 763 1 889 1 127 
Amphetamines – 1 041 1 215 1 357 1 619 1 741 1 664 1 503 1 914 1 296 
Psychotropic substances 750 780 822 736 603 903 1 085 1 701 1 555 1 198 
Other drugs – – 1 288 1 524 1 311 1 826 2 471 3 299 3 237 2 678 
– = not evaluated separately or not specified 
Note: because of data broken down by type of drug, one report may have been listed under several headings, therefore the 
added figures may differ from the total number of reports.  
Source: BMI/.BK 
Table A7: Distribution of reports of violations of the Narcotic Substances Act in Austria by drug type 
and province in 2008 
Drug type B C LA UA S ST T VB V Total 
Cannabis 819 1 233 2 109 2 662 976 1 323 1 912 976 3 053 15 063 
Heroin and opioids 90 58 429 508 39 105 70 237 1 329 2 865 
Cocaine + Crack 151 194 400 572 89 129 313 164 1 539 3 551 
LSD 13 1 24 26 3 8 12 6 8 101 
Ecstasy 68 87 313 291 74 96 82 37 79 1 127 
Amphetamines 80 34 298 434 96 118 47 51 138 1 296 
Psychotropic substances 24 3 94 66 23 36 67 17 868 1 198 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, ST = Styria, T = Tyrol, VB = Vorarlberg, 
V = Vienna 
Note: because of data broken down by type of drug, one report may have been listed under several headings, therefore the 
added figures may differ from the total number of reports.  
Source: BMI/.BK 
Table A8: Convictions under the Narcotic Substances Act (SMG) and total number of convictions 
in Austria from 1999 to 2008 
Year Total number 
of convictions 
under the SMG 
Convictions under 
Section 28 SMG resp.
Section 28 a SMG 
Convictions under 
Section 27 SMG 
Convictions in Austria 
Total number Under the SMG 
(percentages) 
1999 3 359 1 022 2 230 61 954 5.4 
2000 3 240 933 2 245 41 624 7.8 
2001 3 862 1 141 2 671 38 763 10.0 
2002 4 394 1 108 3 243 41 078 10.7 
2003 4 532 1 161 3 318 41 749 10.9 
2004 5 706 1 441 4 229 45 185 12.6 
2005 6 128 1 357 4 702 45 691 13.4 
2006 5 795 1 464 4 246 43 414 13.3 
2007 5 437 1 387 3 956 43 158 12.6 
2008 4 291 1 332 2 899 38 226 11.2 
Until 2007: Section 28 SMG   =  trafficking, possession etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 27 SMG   =  trafficking, possession etc. of small quantities of narcotic drugs 
As of 2008: Section 27 SMG   =  illicit handling of narcotic substances 
Section 28 SMG   =  preparation of trafficking of narcotic substances 
Section 28a SMG =  trafficking of narcotic substances 
Note: these figures only refer to the leading offence, i.e., the offence with the highest range of punishment, therefore not all 
convictions under the SMG are covered.  
Source: Statistics Austria (criminal court statistics) 
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Table A9: Final convictions under the Narcotic Substances Act (SMG) in Austria by age, gender and 
basis of conviction in 2008 
Basis of conviction  14–19 years 20–24 
years 
25–29 
years 
30–34 years > 34 years Total 
SMG total Men 585 1 365 727 432 731 3 840 Women 71 171 73 43 93 451 
Section 28 SMG / Section 28 a SMG Men 108 366 216 158 347 1 195 Women 13 41 23 17 43 137 
Section 27 SMG Men 476 994 501 269 354 2 594 Women 57 128 48 26 46 305 
Until 2007: Section 28 SMG   =  trafficking, possession etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 27 SMG   =  trafficking, possession etc. of small quantities of narcotic drugs 
As of 2008: Section 27 SMG   =  illicit handling of narcotic substances 
Section 28 SMG   =  preparation of trafficking of narcotic substances 
Section 28a SMG =  trafficking of narcotic substances 
Note: these figures only refer to the leading offence, i.e., the offence with the highest range of punishment, therefore not all 
convictions under the SMG are covered.  
Source: Statistics Austria (criminal court statistics) 
Table A10: Final convictions under the Narcotic Substances Act (SMG), young people and adults, 
basis of conviction and type of punishment in 2008 
Basis of conviction  Fine Prison sentence Other 
punishment1
Total 
Probation No probation Partial probation 
SMG total Young people 76 92 28 14 20 230Adults 997 1.272 1.219 414 159 4 061
Section 28 SMG /  
Section 28 a SMG (felonies) 
Young people 2 13 10 3 2 30
Adults 38 344 635 236 49 1 302
Section 27 SMG (misdemeanours) Young people 74 79 18 11 18 200Adults 949 907 560 174 109 2 699
Young people = person younger than 18 at the time of the offence 
Until 2007: Section 28 SMG   =  trafficking, possession etc. of large quantities of narcotic drugs (commercial trafficking) 
Section 27 SMG   =  trafficking, possession etc. of small quantities of narcotic drugs 
As of 2008: Section 27 SMG   =  illicit handling of narcotic substances 
Section 28 SMG   =  preparation of trafficking of narcotic substances 
Section 28a SMG =  trafficking of narcotic substances 
1 Other punishment: partial probation (Section 43(2) StGB), referrals to institutions (Section 21(1), 21(2), 22 and 23 StGB), 
no additional punishment (Section 40 StGB) and, only in the case of young people, conviction with 
punishment reserved (Section 13 JGG) and conviction without punishment (Section 12 JGG). 
Note: these figures only refer to the leading offence, i.e., the offence with the highest range of punishment, therefore not all 
convictions under the SMG are covered. 
Source: Statistics Austria (criminal court statistics) 
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Table A11: Development of alternatives to punishment applied in Austria from 1999 to 2008  
Waiving of reports/ 
suspension of proceedings 
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Total 6 989 8 049 8 145 8 974 9 023 9 666 11 660 10 379 10 175 9 384
Section 35 SMG (waiving of reports) 5 979 6 924 7 346 7 817 7 902 8 599 10 668 9 173 9 008 8 399
Of these: Section 35 (4) SMG (cannabis) 1 330 1 410 1 570 1 876 1 499 2 016 2 697 1 895 1 841 2 249
Section 37 SMG (dismissal of proceedings) 1 010 1 125 799 1 157 1 121 1 067 992 1 206 1 167 985
Until 2007: Section 35 SMG = temporary waiving of reports by the public prosecutor  
Section 35 (4) SMG = waiving of reports in the case of small quantities of cannabis for personal use 
Section 37 SMG = temporary dismissal of proceedings by the court 
As of 2008: § 35 SMG = temporary deferment of charge by the public prosecutor’s office  
Section 35 (4) SMG = waiving of reports in the case of small quantities of cannabis for personal use 
Section 37 SMG = temporary dismissal of proceedings by the court 
 
Note: data on Section 39 of the SMG (suspension of sentence – therapy instead of punishment) are not available at present. 
Source: BMG, calculations by GÖG/ÖBIG 
Table A12: Number of seizures of narcotic drugs/substances in Austria from 1999 to 2008 
Narcotic drug/substances 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Cannabis 5 079 4 833 5 249 5 294 5 422 6 202 6 012 5 770 5 732 5 050 
Heroin 452 478 895 836 1 263 1 383 1 371 883 765 673 
Cocaine 519 554 768 863 1 271 1 475 1 507 1 044 1 087 936 
Amphetamines – 141 161 202 294 324 312 299 319 262 
LSD 56 42 32 20 33 29 20 20 39 20 
Ecstasy 215 330 352 308 276 286 295 248 250 181 
Psychotropic substances 74 65 1 0 6 5 2 2 10 1 
Psychotropic medicines 517 501 566 515 432 678 823 1 300 1 019 843 
– = not evaluated separately or not specified 
Source: BMI/.BK 
Table A13: Seizures of narcotic drugs/substances in Austria by quantity from 1999 to 2008 
Narcotic drug/substances 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Cannabis (kg) 451 1 806 456 743.1 925.9 1 680.9 819.9 1 880.4 1 276.0 873.6
Heroin (kg) 78 230 288 59.5 42.8 235.0 282.2 34.3 117.0 104.0
Cocaine (kg) 63 20 108 36.9 58.3 75.5 244.9 61.8 78.1 78.38
Amphetamines (kg) – 1 3 9.4 54.2 25.7 8.9 38.17 17.5 13.00
LSD (trips) 2 811 865 572 851 298 2 227.5 2 108.5 10 831.5 1 058 225.50
Ecstasy (number of pills) 31 129 162 093 256 299 383 451 422 103 122 663 114 104 30 855 66 167 45 335
Psychotropic substances (kg) 4.00 1.29 0.00 0.00 0.20 0.10 0.00 0.03 0.21 0.00003
Psychotropic medicines (units) 36 437 38 507 31 377 20 081 15 649 21 119 27 104 44 416 26 289 24 675
– = not evaluated separately or not specified 
Source: BMI/.BK 
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Table A14: Ingredients of samples bought as ecstasy and analysed by the ChEck iT! Project 
at parties and clubbing from 1999 to 2008 
Ingredients 
Samples bought as ecstasy 
(percentages) 
1999 
(n=152
) 
2000 
(n=319) 
2001 
(n=268)
2002
(n=269
) 
2003 
(n=143) 
2004
(n=93) 
2005 
(n=53) 
2006 
(n=134
) 
2007 
(n=117
) 
2008 
(n=146)
MDMA 86.2 83.4 77.2 68.0 83.2 72.0 67.9 74.6 60.7 61.6 
MDMA + MDE  3.1 2.2 14.1 7.7 9.7  1.5   
MDMA + MDA  0.9 1.5 6.7    0.7   
MDE and/or MDA 0.7 1.3 7.1 0.4  7.5    1.4 
MDMA + caffeine 1.3 1.6  0.7 0.7 1.1 5.7 5.2 0.9 0.7 
MDMA + amphetamines 0.7 0.6 0.4  0.7  1.9 1.5   
MDMA + various combinations* 3.9 2.2 0.4  3.5 1.1 13.2  6.0 7.5 
PMA/PMMA  1.3 0.4  0.7      
Amphetamines 3.3   1.9 1.4  1.9 4.5  0.7 
Methamphetamine  0.6 2.6 1.5    0.7   
Caffeine  0.9  1.5  1.1  0.7 1.7  
Chinine/chinidine  0.6 1.1        
mCPP/mCPP + various combinations**        1.5 16.2 17.8 
Various combinations* 3.9 3.4 7.1 5.2 2.1 7.5 9.4 9.0 14.5 10.3 
* Various combinations: combinations of more than two amphetamine derivates and/or other substances and/or unknown sub-
stances 
** mCPP/and various combinations: mCPP and one or more additional substances 
Source: Vienna Social Projects Association (VWS) 
Table A15: Ingredients of samples bought as speed and analysed by the ChEck iT! Project 
at parties and clubbing from 1999 to 2008 
Ingredients 
Samples bought as speed 
(percentages) 
1999 
(n=67) 
2000
(n=93)
2001
(n=51)
2002
(n=87)
2003
(n=57)
2004
(n=41)
2005 
(n=33) 
2006 
(n=75) 
2007 
(n=129) 
2008
(n=99)
Amphetamines 53.7 57.0 60.8 46.0 35.1 22.0 33.3 24.0 22.5 15.2 
Amphetamines + caffeine 4.5 9.7 9.8 8.0 15.8 19.5 6.1 29.3 10.1 27.3 
Amphetamines + methamphetamine 1.5         2.0 
Amphetamines + various combinations* 20.9 7.5 3.9 17.2 29.8 39.0 24.2 24.0 31.8 34.3 
Methamphetamine 7.5 3.2 2.0 3.4 1.8 2.4 3.0  10.1 1.0 
Caffeine 1.5 3.2 11.8 8.0  4.9 9.1 1.3 1.6 3.0 
MDMA 3.0 3.2  1.1   6.1 4.0  1.0 
Ephedrine total           
Various combinations* 7.5 16.1 11.8 16.1 17.5 12.2 18.2 17 23.3 14.1 
mCPP/mCPP + various combinations**         0.8 2.0 
* Various combinations: combinations of more than two amphetamine derivates and/or other substances and/or unknown sub-
stances 
** mCPP/and various combinations: mCPP and one or more additional substances 
Source: Vienna Social Projects Association (VWS) 
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Table A16: Number of persons currently registered for substitution treatment in Austria in the BMGFJ 
monitoring system by treatment/continued treatment and province in 2008 
Treatment B C LA UA S St T VB V 
Continued treatment 155 306 1.175 716 401 963 453 458 4.883
First Treatment 36 90 228 261 71 123 53 93 592
Total 191 396 1 403 977 472 1.086 506 551 5 475
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg, St = Styria, T = Tyrol, VB = Vorarlberg, V 
= Vienna 
Note: Continued treatment means treatment started before the respective year, or repeated treatment of persons who have al-
ready undergone substitution treatment before. First treatment means treatment of persons who have never undergone 
substitution treatment before. The figures relate to treatments reported to the BMGFJ and in part differ considerably from 
the figures collected at provincial level. 
The total number of substitution treatments in Austria is higher than the sum of substitution treatments by province since 
records of the provinces are incomplete in some cases. 
Source: BMG, calculations by ÖG/ÖBIG  
Table A17: Persons starting drug-specific treatment or assistance in 2008, by age and gender; 
percentages  
Age 
Short-term 
contacts 
Low-threshold 
assistance 
Long-term out-
patient treatment 
Long-term in-
patient treatment 
Gender 
Total
Gender 
Total
Gender 
Total 
Gender 
Total M F M F M F M F 
0 to 4 0 0 0 0 0 0 0 0 0 0 0 0
5 to 9 0 0 0 0 0 0 0 0 0 0 0 0
10 to 14 1 2 1 4 6 5 1 1 1 0 0 0
15 to 19 18 25 20 15 18 16 14 25 16 8 17 11
20 to 24 29 28 29 23 27 24 32 33 32 36 34 35
25 to 29 19 17 18 26 25 26 22 20 21 24 27 25
30 to 34 12 9 11 15 12 14 12 9 11 13 10 12
35 to 39 8 7 8 9 5 8 8 5 8 9 5 8
40 to 44 7 6 7 5 4 4 6 4 5 6 4 6
45 to 49  4 4 4 3 2 3 3 2 3 3 1 3
50 to 54 2 1 2 1 0 1 2 1 1 1 1 1
55 to 59 1 1 1 0 0 0 1 0 0 0 1 0
60 to 64 0 0 0 0 1 0 0 0 0 0 0 0
65 to 69 0 0 0 0 0 0 0 0 0 0 0 0
70 to 74 0 0 0 0 0 0 0 0 0 0 0 0
75 to 79 0 0 0 0 0 0 0 0 0 0 0 0
80 or older 0 0 0 0 0 0 0 0 0 0 0 0
Valid indications 4 022 1 107 5 129 477 214 691 2 946 1 013 3 959 1 002 350 1 352
Unknown 0 0 0 0 0 0 0 0 0 0 0 0
Missing – – – – – – – – – – – –
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field ‘unknown’ was indicated and Missing means that no indication was made. 
Sampled population: all clients 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
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Table A18: Persons starting drug-specific treatment or assistance in 2008, by gender and livelihood; 
percentages  
Livelihood/employment 
Short-term 
contacts 
Low-threshold 
assistance 
Long-term out- 
patient treatment 
Long-term in-
patient treatment 
Age Age Age Age 
< 20 20–29 > 29 < 20 20–29 > 29 < 20 20–29 > 29 < 20 20–29 > 29 
Gainful employment – – – 22 19 6 40 35 27 15 12 13
Registered as unemployed – – – 10 29 34 23 36 36 20 50 42
Welfare assistance – – – 2 10 11 4 11 15 11 12 13
Child, school student, university student – – – 43 1 0 16 4 2 14 3 3
Military service, alternative military service, 
parenthood leave, retired 
– – – 1 2 9 3 3 9 1 7 14
Housework, (re)training, other – – – 1 2 1 6 3 3 4 2 2
No gainful employment,  no other form of 
livelihood 
– – – 6 9 7 5 3 3 5 2 2
No gainful employment, other form of 
livelihood unknown 
– – – 15 28 32 3 4 5 30 12 11
Valid indications – – – 136 282 171 653 2 043 1 098 138 777 377
Unknown – – – 3 56 28 20 60 49 3 18 18
Missing – – – 2 7 6 6 21 9 1 17 3
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field ‘unknown’ was indicated and Missing means that no indication was made. 
Sampled population: all clients 
The corresponding data are not collected for short-term contacts 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Table A19: Persons starting drug-specific treatment or assistance in 2008, by place of residence and 
gender; percentages  
Place of residence 
Short-term 
contacts 
Low-threshold 
assistance 
Long-term out-
patient treatment 
Long-term in-
patient treatment 
Age Age Age Age 
< 20 20-29 > 29 < 20 20-29 > 29 < 20 20-29 > 29 < 20 20-29 > 29 
Burgenland – – – – – – 2 2 2 3 2 2
Carinthia – – – – – – 12 8 6 6 3 0
Lower Austria – – – – – – 13 9 5 18 9 2
Upper Austria – – – – – – 10 9 6 13 12 5
Salzburg – – – – – – 3 5 6 6 2 4
Styria – – – – – – 7 5 4 15 12 9
Tyrol – – – – – – 12 11 9 6 9 15
Vorarlberg – – – – – – 19 12 9 14 9 10
Vienna – – – – – – 22 38 52 20 42 53
Foreign country – – – – – – 0 1 1 0 0 1
Valid indications – – – – – – 661 2 048 1 117 140 777 379
Unknown – – – – – – 13 50 32 2 31 16
Missing – – – – – – 5 26 7 0 4 3
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field ‘unknown’ was indicated and Missing means that no indication was made. 
Sampled population: all clients 
The corresponding data are not collected for short-term contacts and low-threshold assistance. 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
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Table A20: Persons starting drug-specific treatment or assistance in 2008, by present housing 
situation and gender; Percentage  
Present housing situation 
Short-term 
contacts 
Low-threshold 
assistance 
Long-term care 
outpatient 
Long-term care 
inpatient 
Age Age Age Age 
< 20 20–29 > 29 < 20 20–29 > 29 < 20 20–29 > 29 < 20 20–29 > 29 
Stable (e.g., flat of one’s own) – – – 71 27 35 90 87 83 83 79 80
Unstable (e.g., homeless) – – – 19 54 43 5 8 8 11 13 10
In institution, plus stable housing situation – – – 5 7 15 3 4 7 3 6 10
In institution, plus unstable housing situation – – – 5 12 8 2 1 2 3 3 1
Valid indications – – – 132 296 172 646 2 043 1 106 138 779 376
Unknown – – – 8 42 27 29 61 46 1 31 20
Missing – – – 1 7 6 4 20 4 3 2 2
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field ‘unknown’ was indicated and Missing means that no indication was made. 
Sampled population: all clients 
The variable „present housing situation“ is not surveyed for short-term contacts. 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
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Table A21: Persons starting drug-specific treatment or assistance in 2008, by primary drug and 
gender; percentages 
Primary drug 
(multiple indications admissible) 
Short-term 
contacts 
Low-threshold 
assistance 
Long-term out- 
Patient treatment 
Long-term in- 
patient treatment 
Gender 
Total
Gender 
Total
Gender 
Total 
Gender 
Total M F M F M F M F 
Opioids 35 41 36 55 61 57 54 67 58 78 86 80
Heroin 28 29 28 35 35 35 36 43 38 54 52 54
Methadone 3 3 3 2 0 1 6 6 6 14 18 15
Other substitution substances 11 14 12 27 31 28 26 34 28 51 58 53
Other opioids, or opioids not specified 1 1 1 2 1 2 3 3 3 4 3 4
Cocaine group 9 8 9 10 10 10 12 9 11 25 21 24
Cocaine 9 8 9 10 10 10 12 9 11 25 21 24
Crack 0 0 0 0 0 0 0 0 0 0 1 0
Cocaine not specified 0 0 0 0 0 0 0 0 0 0 0 0
Stimulants 3 4 3 1 1 1 4 5 4 8 8 8
Amphetamines (e.g., speed) 2 3 3 0 1 0 3 3 3 7 6 7
MDMA (ecstasy), other derivatives 1 2 2 1 1 1 2 3 2 4 6 5
Stimulants not specified 0 0 0 0 0 0 0 0 0 0 0 0
Tranquillisers/hypnotics 10 14 11 14 18 15 10 14 11 19 24 20
Benzodiazepines 9 14 10 14 18 15 10 14 11 19 24 20
Barbiturates 0 0 0 0 0 0 0 0 0 0 0 0
Other hypnotics/tranquillisers 0 1 0 0 2 0 0 0 0 0 0 0
Hallucinogenic 0 1 0 0 0 0 1 1 1 2 3 3
LSD 0 1 0 0 0 0 1 1 1 2 3 2
Hallucinogenic drugs not specified  0 0 0 0 0 0 0 0 0 1 0 0
Cannabis 28 22 27 19 14 17 35 22 32 30 21 27
Solvents and inhalants 0 0 0 0 0 0 0 0 0 0 0 0
Alcohol 5 6 5 7 5 6 7 5 6 10 9 9
Biogenic drugs 0 0 0 0 0 0 0 0 0 1 0 0
Other drugs 0 0 0 0 0 0 0 0 0 0 1 0
Only use not relevant for treatment 35 31 34 9 8 9 4 5 4 0 0 0
Additional drug only 3 2 3 12 10 11 9 7 8 4 4 4
Valid indications 4 937 1 317 6 254 586 263 849 3 953 1 355 5 308 2 067 696 2 763
Number of persons with valid indications 3 618 957 4 575 424 196 620 2 537 865 3 402 909 306 1 215
Unknown 340 122 462 45 16 61 202 77 279 36 23 59
Missing 64 28 92 8 2 10 207 71 278 57 21 78
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field ‘unknown’ was indicated and Missing means that no indication was made.  
Bold type indicates main categories 
Sampled population: all clients 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
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Table A22: Persons starting drug-specific treatment or assistance in 2008, by injecting drug use and 
age; percentages 
Injecting drug use 
Short-term 
contacts 
Low-threshold 
assistance 
Long-term out- 
patient treatment 
Long-term in- 
patient treatment 
Gender 
Total
Gender 
Total
Gender 
Total 
Gender 
Total M F M F M F M F 
No 70 62 68 28 23 26 57 49 55 24 21 23
Yes 30 38 32 72 77 74 43 51 45 76 79 77
Valid indications 3 502 923 4 425 352 175 527 2 718 925 3 643 949 319 1 268
Unknown 444 161 605 89 29 118 178 72 250 43 24 67
Missing 76 23 99 36 10 46 50 16 66 10 7 17
Note: all lines except Valid indications, Unknown and Missing give percentages that relate to the number of valid indications. 
Unknown means that the field ‘unknown’ was indicated and Missing means that no indication was made.  
Sampled population: all clients 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
 
  
Table A23: Nationwide standardised interventions for addiction prevention implemented in schools, 2008 
Programme: Eigenständig werden (Become independent)  
Direct target group: children aged 6 to 10 
Indirect target group: teachers in elementary schools 
Province Number of  
implemented 
workshops/ 
events, 2008 
Number of lessons/ 
hours of training for 
multipliers, 2008 
Number of  
accredited 
teachers, 2008 
Percentage of 
teachers 
reached in 2008
Number of  
elementary 
schools 
reached in 2008
Percentage of 
elementary 
schools 
reached in 
2008 
Total number of 
teachers reached 
by end of 2008 
Percentage of  
total number of 
teachers reached by 
end of 2008 
Total number of 
elementary 
schools reached 
by end of 2008 
Percentage of total 
number of  
elementary schools 
reached by end of 
2008 
B 0 0 0 0 0 0 101 12.62 55 27.23 
C 1 24 12 0.6 9 0.4 143 6.43 61 24.01 
LA 6 24 105 1.80 21 3.19 328 5.61 105 15.93 
UA 12 n. v. 239 n. a. 46 n. a. n. a. n. a. n. a. n. a. 
S 5 24 68 3.2 34 18 200 9.4 71 37.76 
St 3 24 55 1.14 13 2.51 187 4.61 111 21.43 
T 3 24 42 1.62 31 8.01 270 10.71 139 35.9 
VB 6 24 110 6.76 15 9.03 155 9.53 28 16.86 
V 7 24 171 3.19 18 2.97 836 15.61 200 74.35 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg; St = Styria, T = Tyrol, VB = Vorarlberg, V = Vienna, n. a. = not available 
Note: the programmes „Step by Step“ and „feel.ok” are also implemented on a nationwide level, but only few trainings are currently organised. Therefore the corresponding numbers are not inc-
luded here. 
Sources: Akzente Suchtprävention - Fachstelle für Suchtvorbeugung Salzburg; Fachstelle für Suchtprävention Burgenland; Fachstelle für Suchtvorbeu-
gung, Koordination und Beratung, Lower Austria; VIVID – Fachstelle für Suchtprävention, Styria; Institut Suchtprävention, Upper Austria; Kon-
takt+co – Suchtprävention Jugendrotkreuz, Tyrol; SUPRO – Werkstatt für Suchtprophylaxe, Vorarlberg; ISP Vienna; Landesstelle für Suchtprä-
vention, Carinthia 
 
  
Table A24: Selected, approved and continuously implemented interventions for addiction prevention 
Setting Name of the project/ 
programme 
(province) 
Direct target 
group (age) 
Indirect 
target group 
(multipliers) 
Short description 
Kindergarten Spielzeugfreier Kindergarten 
(B);  
Toy-free kindergarten 
Children aged 
3 to 6 
Kindergarten 
teachers 
Over a period of around 3 months all prefabricated toys are removed from the groups. This is a period of intensive learning, in 
which children can make self-determined experience, develop social competence and find collective solutions to problems in the 
group. Children, parents and kindergarten teachers are carefully prepared for this period. The role of the kindergarten teachers 
changes from giving instructions for games to watching and supporting the group process. 
Family Elternvorträge (LA); 
Lectures for parents 
Children and 
adolescents 
Parents Especially children, but also adolescents, are oriented towards the role models of adults and learn from their behaviour. 
If addiction prevention starts early in life, better protection factors can be developed against the emergence of addiction and the 
related risk factors can be reduced. The lectures for parents focus on ways to promote life skills in the family and on other issues 
of addiction prevention that matter in education.  
Elementary school Kinder stark machen – 
erlebnispädagogischer Work-
shop (VB); 
Strengthening our children - 
experience-based workshop 
Children Teachers This intervention highlights joint group action in an exciting and challenging way in order to expand the children’s own action 
competence, . Teachers jointly try out experience-based games and exercises that they can use as activities for the children 
without a lot of work input and special knowledge. They are shown how they can strengthen the personalities of the children, 
who learn how to observe boundaries and rules, how to handle success, disappointment and conflicts, to help someone and be 
helped by someone, and also to express feelings and needs. It is demonstrated how attractive activities will enhance the creativ-
ity and imagination of the children.  
School 
(lower level) 
plus (T) School students 
aged 10 to 14 
Teachers The programme is aimed at the development of cognitive, social and emotional skills in order to facilitate coping with the tasks of 
adolescence, which reduces the probability of developing socially maladjusted and harmful behaviour, and especially of addic-
tion risks and problems. 
School 
(advanced level) 
Suchtvorbeugung in der 
Schule als Entwicklungs-
aufgabe (C); 
Addiction prevention in school 
as development task 
School students 
aged 15 to 19 
Teachers, 
educators, par-
ents 
Since 2007 the Carinthian Tourism College has worked with a team of teachers and educators, in cooperation with the Lan-
desstelle Suchtprävention (provincial agency for addiction prevention). In addition to strengthening the life skills of students, the 
aim is to critically examine organisational structures in schools that influence the daily work of teachers and students. The result 
is a package of interventions oriented towards various target groups. All activities are continually evaluated and improved upon 
suggestion. In the parallel working group, new themes can be discussed and adapted to current demands. 
Vocational schools LIZ – Lehrlinge im Zentrum (S); 
Apprentices in the centre 
Apprentices Teachers, trainers This programme includes interventions for trainees as well as trainers and vocational schools. Its aim is early detection and in-
tervention as well as distribution of knowledge regarding substances and addiction, and also the reflection about one’s personal 
handling of substances (alcohol, cannabis etc.). 
Youth social work in 
associations 
Suchtprävention in Vereinen 
(St); 
Addiction prevention in associa-
tions 
Youth Youth commis-
sioners, coaches 
… 
In rural areas, fire brigades and football clubs are important partners in youth social work and thus also in addiction prevention. 
The programme Brennpunkt Suchtprävention (Addiction Prevention In Focus) addresses local youth commissioners, interested 
fire-fighters and football trainers as multipliers. In addition to the causes and development of addiction, the functions of role 
models and specific ways to achieve prevention are discussed within the association in question. In 2008 the district of Liezen 
(Styria) was included in the project as the 12th fire brigade district. Also in 2008, evaluation of the feedback on the project for 
addiction prevention in football associations yielded the best results since the start of the project in 2003.  
Youth social work in 
recreational settings 
Lehrgang Suchtprävention in 
der Jugendarbeit (V); 
Training programme: Preven-
tion of addiction in youth social 
work 
Youth Youth workers in 
recreational set-
tings 
The programme is aimed at promoting professional attitude towards young drug users, developing skills and initiating addiction 
prevention projects as well as communicating practical approaches and methods of addiction prevention. 
Federal Armed 
Forces 
Lehrgang für Schlüsselper-
sonen im österreichischen 
Bundesheer (UA); 
Training courses for key 
actors in the Austrian army 
Conscripts Key actors in the 
Austrian army 
During one week of special training, addiction and drug-related information is communicated, which includes causes, sub-
stances and their effects, prevention, early detection and drug help system. 
B = Burgenland, C = Carinthia, LA = Lower Austria, UA = Upper Austria, S = Salzburg; St = Styria, T = Tyrol, VB = Vorarlberg, V = Vienna,  
Note: Only such projects/programmes have been selected, which meet the criteria of this report (see chapter 3), have continuously been implemented for more than one year and can serve as an ex-
ample for different settings. 
Sources: Akzente Suchtprävention - Fachstelle für Suchtvorbeugung Salzburg; Fachstelle für Suchtprävention Burgenland; Fachstelle für Suchtvorbeugung, Ko-
ordination und Beratung, Lower Austria; VIVID – Fachstelle für Suchtprävention, Styria; Institut Suchtprävention, Upper Austria; Kontakt+co – Suchtprä-
vention Jugendrotkreuz, Tyrol; SUPRO – Werkstatt für Suchtprophylaxe, Vorarlberg; ISP Vienna; Landesstelle für Suchtprävention, Carinthia 
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Table A25: Duration of treatment of clients with opioids as primary drugs, who were in long-term 
inpatient or outpatient treatment in 2008, by age group 
 Age (years)  
Duration of treatment 19 or younger 
(n = 145) 
between 20 
and 29 
(n = 1 093) 
between 30 
and 39 
(n = 406) 
between 40 
and 49 
(n = 172) 
between 50 
and 59 
(n = 24) 
60+ 
(n = 0) 
Up to 1 month 27.6% 20.8% 20.0% 16.3% 12.5% 0.0% 
1 to 3 months 32.4% 27.7% 24.6% 23.8% 8.3% 0.0% 
4 to 6 months 12.4% 14.9% 11.8% 12.8% 33.3% 0.0% 
7 to 12 months 17.9% 16.0% 13.7% 15.7% 8.3% 0.0% 
13 to 24 months 6.9% 13.1% 15.8% 14.0% 16.7% 0.0% 
25 to 36 months 2.1% 4.5% 4.2% 7.0% 12.5% 0.0% 
37 to 48 months 0.7% 0.9% 2.0% 1.7% 4.2% 0.0% 
more than 48 months 0.0% 2.1% 4.9% 8.7% 4.2% 0.0% 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Table A26: Main impulse for contacting a drug help unit among clients with opioids as primary drugs, 
who were in long-term inpatient or outpatient treatment in 2008, by age group 
 Age (years) 
Source of main impulse 19 or younger 
(n = 422) 
between 20 
and 29 
 (n = 3 163)
between 30 
and 39 
 (n = 1 362) 
between 40 
and 49 (n = 
683) 
between 50 
and 59 
 (n = 141) 
60+ 
(n = 4) 
Client’s own initiative 38.9% 41.1% 48.6% 51.7% 55.3% 75.0% 
Family 15.4% 10.4% 5.5% 3.8% 1.4% 0.0% 
Drug help centre 9.3% 9.4% 9.7% 8.3% 12.1% 0.0% 
General practitioner 3.4% 3.4% 4.5% 7.5% 7.8% 0.0% 
Hospital 4.3% 4.1% 2.6% 4.2% 4.3% 0.0% 
Social welfare office 5.2% 4.4% 4.9% 5.4% 5.7% 0.0% 
Public Employment Service 0.7% 1.5% 1.7% 0.9% 0.0% 0.0% 
Court order or obligation 11.5% 15.4% 11.5% 11.7% 9.9% 25.0% 
School 0.7% 0.2% 0.0% 0.0% 0.0% 0.0% 
Other 10.6% 10.1% 10.9% 6.4% 3.5% 0.0% 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
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Table A27: Main impulse for contacting a drug help unit among clients who were in long-term inpatient 
or outpatient treatment in 2008, by age group 
 Age (years)  
Source of main impulse 19 or younger 
 (n = 1196) 
between 20 
and 29 
 (n = 5 640)
between 30 
and 39 
 (n = 2 297) 
between 40 
and 49 (n = 
1 107) 
between 50 
and 59 
 (n = 257) 
60+ 
(n = 14) 
Client’s own initiative 21.3% 32.7% 42.7% 43.9% 44.4% 42.9% 
Family 14.9% 8.8% 5.7% 4.1% 3.1% 7.1% 
Drug help centre 4.7% 8.1% 9.1% 10.2% 12.5% 7.1% 
General practitioner 2.0% 3.2% 4.1% 6.0% 5.4% 7.1% 
Hospital 3.6% 3.7% 3.0% 4.3% 3.1% 0.0% 
Social welfare office 18.8% 9.6% 5.7% 6.0% 7.4% 0.0% 
Public Employment Service 0.8% 1.1% 1.8% 1.4% 0.4% 0.0% 
Court  22.7% 23.8% 17.2% 17.1% 16.3% 35.7% 
School 3.8% 0.3% 0.0% 0.1% 0.0% 0.0% 
Other 7.3% 8.7% 10.6% 7.0% 7.4% 0.0% 
Source: GÖG/ÖBIG 2009a. DOKLI analysis of client year 2008 
Table A28: Predominant form of heroin use among clients with opioids as primary drugs, who were in 
long-term inpatient or outpatient treatment in 2008, by age group 
 Age (years)  
Form of use 19 or younger 
 (n = 402) 
between 20 
and 29 
 (n = 2 924)
between 30 
and 39 
 (n = 1 223) 
between 40 
and 49 (n = 
622) 
between 50 
and 59 
 (n = 126) 
60+ 
(n = 2) 
Unknown 1.5% 2.7% 3.8% 4.5% 6.3% 0.0% 
Injecting 31.8% 43.2% 61.4% 68.0% 69.8% 100% 
Smoking 9.5% 7.1% 5.0% 3.2% 4.8% 0.0% 
Oral 0.7% 0.9% 0.7% 1.9% 2.4% 0.0% 
Snorting 56.5% 46.1% 28.9% 22.3% 16.7% 0.0% 
Other 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Table A29: Predominant form of heroin use among clients who were in long-term inpatient or 
outpatient treatment in 2008, by age group 
 Age (years) 
Form of use 19 or younger 
 (n = 507) 
between 20 
and 29 
 (n = 3 606)
between 30 
and 39 
 (n = 1 520) 
between 40 
and 49 (n = 
749) 
between 50 
and 59 
 (n = 153) 
60+ 
(n = 5) 
Unknown 1.6% 2.7% 4.3% 4.5% 5.9% 0.0% 
Injecting 28.2% 39.5% 56.8% 64.9% 66.7% 40.0% 
Smoking 9.3% 7.8% 5.9% 4.7% 6.5% 20.0% 
Oral 1.0% 1.1% 1.1% 1.6% 2.0% 20.0% 
Snorting 60.0% 48.7% 31.9% 24.3% 19.0% 20.0% 
Other 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 
Source: GÖG/ÖBIG 2009a. DOKLI analysis of client year 2008 
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Table A30: Predominant form of cocaine use among clients with opioids as primary drugs, who were in 
long-term inpatient or outpatient treatment in 2008, by age group 
 Age (years)  
Form of use 19 or younger 
 (n = 358) 
between 20 
and 29 
 (n = 2 576)
between 30 
and 39 
 (n = 1 024) 
between 40 
and 49 (n = 
503) 
between 50 
and 59 
 (n = 92) 
60+ 
(n = 2) 
Unknown 0.8% 2.9% 5.5% 5.2% 6.5% 0.0% 
Injecting 20.4% 27.4% 36.2% 36.8% 30.4% 0.0% 
Smoking 0.6% 1.6% 1.7% 1.2% 3.3% 0.0% 
Oral 2.2% 1.6% 2.3% 2.6% 5.4% 0.0% 
Snorting 76.0% 66.5% 54.3% 54.3% 54.3% 100% 
Other 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Table A31: Predominant form of cocaine use among clients who were in long-term inpatient or 
outpatient treatment in 2008, by age group 
 Age (years) 
Form of use 19 or younger 
 (n = 566) 
between 20 
and 29 
 (n = 3 629)
between 30 
and 39 
 (n = 1 485) 
between 40 
and 49 (n = 
689) 
between 50 
and 59 
 (n = 129) 
60+ 
(n = 8) 
Unknown 1.6% 2.9% 5.3% 4.4% 6.2% 0.0% 
Injecting 14.7% 23.3% 29.9% 32.2% 29.5% 0.0% 
Smoking 1.4% 1.6% 2.1% 1.6% 2.3% 12.5% 
Oral 2.8% 1.8% 2.4% 2.2% 4.7% 0.0% 
Snorting 79.5% 70.4% 60.3% 59.4% 57.4% 87.5% 
Other 0.0% 0.1% 0.1% 0.3% 0.0% 0.0% 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Table A32: (Median) age at first use of clients with opioids as primary drugs, who were in long-term 
inpatient or outpatient treatment in 2008, by age group 
 (Median) age at first use 
Age group Heroin Cocaine Cannabis 
19 or younger 16 16 14 
between 20 and 29 18 17 15 
between 30 and 39 20 20 16 
between 40 and 49 20 24 16 
between 50 and 59 20 23 16 
60+ 42 42 30 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
 134 
Table A33: (Median) age at first use of clients who were in long-term inpatient or outpatient treatment 
in 2008, by age group 
 (Median) age at first use 
Age group Heroin Cocaine Cannabis 
19 or younger 16 16 14 
between 20 and 29 18 18 15 
between 30 and 39 20 20 16 
between 40 and 49 20 24 16 
between 50 and 59 20 24,5 16 
60+ 42 40 30 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
Table A34: Clients in long-term inpatient or outpatient assistance in 2008 and selected 
sociodemographic and social indicators, by age 
Variables Age (years) 
 19 or younger
(n = 1 232) 
between 20 
and 29 
(n = 5 804) 
between 30 
and 39 
(n = 2 389) 
between 40 
and 49 
(n = 1 149) 
between 
50 and 59
(n = 264) 
Women 39% 26% 23% 21% 21% 
Treatment based on court order 42% 35% 24% 20% 23% 
Living in Vienna 19% 32% 40% 37% 32% 
Gainfully employed 39% 35% 30% 28% 22% 
Unemployed 20% 36% 36% 29% 18% 
Receiving welfare assistance 3% 9% 12% 12% 19% 
Doing military service / alternative service / on 
parents leave / retired 2% 4% 8% 19% 29% 
No compulsory school degree 14% 6% 5% 4% 4% 
No higher degree of education except compulsory 
school leaving certificate 75% 56% 53% 56% 52% 
Stable housing situation 94% 91% 90% 92% 94% 
Living alone 11% 25% 35% 46% 54% 
Note: As only 15 persons were 60 years and older, this age group is not represented here. 
Source: GÖG/ÖBIG 2009a, DOKLI analysis of client year 2008 
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Table A35: Austrian population statistics by age group and gender in 2008 
Age group Men Women Total 
  0  to under 4 years 202 913 193 570 396 483 
  5  to under 9 years 210 277 199 475 409 752 
10  to under 14 years 237 190 226 131 463 321 
15  to under 19 years 256 937 244 180 501 117 
20  to under 24 years 262 561 257 038 519 599 
25  to under 29 years 274 626 271 012 545 638 
30  to under 34 years 269 210 269 924 539 134 
35  to under 39 years 320 249 320 497 640 746 
40  to under 44 years 362 237 353 097 715 334 
45  to under 49 years 339 206 332 301 671 507 
50  to under 54 years 278 545 282 967 561 512 
55  to under 59 years 241 273 250 651 491 924 
60  to under 64 years 213 163 229 435 442 598 
65  to under 69 years 224 524 251 910 476 434 
70  to under 74 years 134 313 164 898 299 211 
75  to under 79 years 114 675 161 503 276 178 
80  to under 84 years 73 463 144 501 217 964 
85 years or older 43 273 124 824 168 097 
Total 4 058 635 4 277 914 8 336 549 
  0 to 14 years 650 380 619 176 1 269 556 
15 to 29 years 794 124 772 230 1 566 354 
30 to 44 years 951 696 943 518 1 895 214 
45 to 59 years 859 024 865 919 1 724 943 
60 to 74 years 572 000 646 243 1 218 243 
75 years or older 231 411 430 828 662 239 
Total 4 058 635 4 277 914 8 336 549 
 
Source: Statistics Austria, 30th of June 2009, calculations by GÖG/ÖBIG 
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ADHD attention deficit hyperactive disorder 
Aids Acquired Immune Deficiency Syndrome 
AKH Vienna General Hospital 
AMS Public Employment Service 
API Anton-Proksch-Institut 
ASK drug outpatient clinic 
BADO (Vienna) Basic Documentation 
BBRZ Labour Training and Rehabilitation Centre 
BDF Federal Drug Forum 
BGBl Federal Collection of Statutes 
BMASK Federal Ministry of Labour, Social Affairs and Consumer Protection 
BMeiA Federal Ministry for European and International Affairs 
BMF Federal Ministry of Finance 
BMG Federal Ministry for Health 
BMGFJ Federal Ministry for Health, Family and Youth 
BMI Federal Ministry of the Interior 
BMI/.BK Federal Ministry of the Interior / Federal Criminal Agency 
BMJ Federal Ministry of Justice 
BMLFUW Federal Ministry of Agriculture, Forestry Environment and Water Management 
BMLV Federal Ministry of Defence 
BMUKK Federal Ministry for Education, the Arts and Culture 
BMVIT Federal Ministry for Transport, Innovation and Technology 
BMWF Federal Ministry for Science and Research 
BZP Benzylpiperazine 
COFOG Classification of Functions of Government 
CRC capture-recapture 
CSR Corporate Social Responsibility 
DC Drug Coordinator 
DR Drug Representative 
DRD drug-related deaths 
DOKLI nationwide documentation system of clients of drug help units in Austria 
DTA low threshold therapeutic centre for drug addicts 
EDDRA Exchange on Drug Demand Reduction Action 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EMS Epidemiological detection system 
ENCARE European Network for Children Affected by Risky Environments 
within the Family 
ESPAD European School Survey Project on Alcohol and other Drugs 
EU European Union 
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FGÖ Health Austria Fund 
g gramme 
GBL gamma butyrolacetone  
GHB gamma hydroxybutyric acid 
GÖG Health Austria 
GÖG/ÖBIG Health Austria / Austrian Health Institute 
GÖG/FGÖ Health Austria / Healthy Austria Fund  
HAV hepatitis A virus 
HBV hepatitis B virus 
HBVcAb hepatitis B core antibody (= HBc-Ab) 
HBVeAg hepatitis B e antigen (= HBc-Ab) 
HBVsAb hepatitis B surface antibody (= HBs-Ab) 
HBVsAg hepatitis B surface antigen 
HCV hepatitis C virus 
HCV-Ab HCV antibody 
HCV-RNA RNA (ribonucleic acid) of the hepatitis C virus 
HIV human Immunodeficiency Virus 
ICD-10 International Classification of Diseases and Related Health Problems 
IFES Institute for Empirical Research 
ISD Institute for Addiction Diagnostics  
ISP Addiction Prevention Institute 
ITM International College of Tourism and Management 
i. v. intravenous 
JGG Juvenile Court Act 
JWH-018 Naphthalene-1-yl-(1-pentylindol-3-yl)-methanone 
kg kilogramme 
l litre 
LSD d-lysergic acid diethylamide 
MA Municipal Department 
mCPP meta-chlorophenyl piperazine 
MDA 3,4-methylenedioxyamphetamine 
MDE 3,4-methylenedioxy-N-ethylamphetamine 
MDMA 3,4-methylenedioxy-methylamphetamine 
mg milligramme 
NÖ Lower Austria 
ÖBIG Austrian Health Institute 
ÖGABS Austrian Society of Pharmacologically Assisted Treatment of Addiction 
OÖ Upper Austria 
OST opioid substitution treatment 
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PCR polymerase chain reaction 
PMA Paramethoxyamphetamine 
ppm parts per million 
PSD Psychosocial Services 
PTBS posttraumatic stress disorders 
REITOX European Information Network on Drugs and Drug Addiction 
(Réseau Européen d’Information sur les Drogues et les Toxicomanies) 
SAM Social, Safe, Active and Mobile 
SDW Addiction and Drug Coordination Vienna 
SMG Narcotic Drugs Act 
SMZ Centre of social medicine 
SQ Structured Questionnaire 
ST Standard Table 
StGB  Criminal Code  
TB tuberculosis 
THC Tetrahydrocannabinol (main psychoactive ingredient of cannabis) 
TILAK Association of Tyrolean community hospitals 
UNODC United Nations Office on Drugs and Crime 
VWS Verein Wiener Sozialprojekte (Vienna Social Projects Association) 
WBB Wiener BerufsBörse 
WGKK Wiener Gebietskrankenkasse 
WHO World Health Organization 
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List of Austrian Standard Tables and Structured Questionnaires of 2009 
 
The following list gives an overview of all Standard Tables and Structured Questionnaires drawn up for 
Austria in 2009 and submitted to the EMCDDA. Here, all Structured Questionnaires referred to in the 
text are mentioned, also those that were updated in previous years. If you are interested in obtaining 
any table or questionnaire please contact Ms Monika Löbau: monika.loebau@goeg.at 
STANDARD TABLES 01: BASIC RESULTS AND METHODOLOGY OF POPULATION SURVEYS 
ON DRUG USE (Vienna) 
STANDARD TABLE 02: METHODOLOGY AND RESULTS OF SCHOOL SURVEYS ON DRUG USE 
(ESPAD)  
STANDARD TABLES 03: CHARACTERISTICS OF PERSONS STARTING TREATMENT FOR DRUGS 
(DOKLI) 
STANDARD TABLES 03: CHARACTERISTICS OF PERSONS STARTING TREATMENT FOR DRUGS 
(Substitution treatments) 
STANDARD TABLE 05: ACUTE/DIRECT DRUG-RELATED DEATHS 
STANDARD TABLE 06: EVOLUTION OF ACUTE/DIRECT DRUG-RELATED DEATHS  
STANDARD TABLE 07: NATIONAL PREVALENCE ESTIMATES ON PROBLEM DRUG USE 
STANDARD TABLE 08: LOCAL PREVALE4NCE ESTIMATES ON PROBLEM DRUG USE 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Anton Proksch Institute: HBV, HCV, HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Lukasfeld short-term therapy department: HBV, HCV, HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Marienambulanz drug outpatient department, Graz: HBV, HCV, HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (Vienna Social Projects Association (VWS) – Ganslwirt: HBV, HCV, 
HIV) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (drug outpatient department of General Hospital Vienna: HCV, HIV) 
(latest update: 2008) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (drug-related deaths: HCV, HIV) (latest update: 2008) 
STANDARD TABLE 09: PREVALENCE OF HEPATITIS B/C AND HIV INFECTION AMONG INJECTING 
DRUG USERS (DOKLI: HBV, HCV, HIV)  
STANDARD TABLE 10: SYRINGE AVAILABILITY (latest update: 2008) 
STANDARD TABLE 11: ARRESTS/REPORTS FOR DRUG LAW OFFENCES 
STANDARD TABLE 12: DRUG USE AMONG PRISONERS 
STANDARD TABLE 13: NUMBER AND QUANTITY OF SEIZURES OF ILLICIT DRUGS 
STANDARD TABLE 14: PURITY AT STREET LEVEL OF ILLICIT DRUGS 
STANDARD TABLE 15: COMPOSITION OF ILLICIT DRUG TABLETS 
STANDARD TABLE 16: PRICE AT STREET LEVEL OF ILLICIT DRUGS 
STANDARD TABLE 18: OVERALL MORTALITY AND CAUSES OF DEATHS AMONG DRUG USERS 
STANDARD TABLE 24: ACCESS TO TREATMENT (latest update: 2008) 
STANDARD TABLE 34: TREATMENT DEMAND INDICATOR (TDI) DATA 
STRUCTURED QUESTIONNAIRE 22/25: UNIVERSAL PREVENTION (latest update: 2007) 
STRUCTURED QUESTIONNAIRE 23/29: PREVENTION AND REDUCTION OF HEALTH-RELATED HARM 
ASSOCIATED WITH DRUG USE (latest update: 2008) 
STRUCTURED QUESTIONNAIRE 26: SELECTIVE PREVENTION (latest update: 2007) 
STRUCTURED QUESTIONNAIRE 27: Part 1: TREATMENT PROGRAMMES (latest update: 2008), 
Part 2: QUALITY ASSURANCE TREATMENT (latest update: 2008) 
STRUCTURED QUESTIONNAIRE 28: SOCIAL REINTEGRATION (latest update: 2006) 
STRUCTURED QUESTIONNAIRE 31: TREATMENT AS AN ALTERNATIVE TO IMPRISONMENT 
APPLICABLE FOR DRUG USING OFFENDERS IN THE 
EUROPEAN UNION (latest update: 2006)  
STRUCTURED QUESTIONNAIRE 32: POLICY AND INSTITUTIONAL FRAMEWORK 
(latest update: 2006) 
